{
    "Sponsor Confidentiality Statement": {
        "template": {
            "long_name": "Enter Sponsor Confidentiality Statement",
            "short_name": "Sponsor Confidentiality Statement",
            "original_name": "Sponsor Confidentiality Statement",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Insert the Sponsor\u2019s confidentiality statement, if applicable, otherwise delete."
            ]
        },
        "technical": {
            "name": "Sponsor Confidentiality Statement",
            "data_type": "Text",
            "definition": "C181236\nFor review purpose, see definition of the controlled terminology below:\nA written message within the study protocol that asserts a statement of non-disclosure, such that information contained within the protocol document may only be shared with authorized parties.",
            "guidance": "Insert the Sponsor\u2019s confidentiality statement, if applicable, otherwise delete.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: C181236",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Sponsor Confidentiality Statement",
            "notes": "We could this this via NarrativeContent but maybe a better mechanism could be provided"
        }
    },
    "Full Title": {
        "template": {
            "long_name": "Enter Full Title",
            "short_name": "Full Title",
            "original_name": "Full Title",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "The protocol should have a descriptive title that identifies the scientific aspects of the trial sufficiently to ensure it is immediately evident what the trial is investigating and on whom, and to allow retrieval from literature or internet searches."
            ]
        },
        "technical": {
            "name": "Full Title",
            "data_type": "Text",
            "definition": "C132346\nFor review purpose, see definition of the controlled terminology below:\nThe formal descriptive name for the protocol sufficient to describe key elements of the study, aimed at a scientific audience.",
            "guidance": "The protocol should have a descriptive title that identifies the scientific aspects of the trial sufficiently to ensure it is immediately evident what the trial is investigating and on whom, and to allow retrieval from literature or internet searches.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "Title page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: C132346",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "StudyTitle",
                    "notes": "There are many titles. Select the correct one via the 'type' attribute in StudyTitle",
                    "path": "StudyVersion/@studyTitles/StudyTitle/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Full Title",
            "notes": ""
        }
    },
    "Trial Acronym": {
        "template": {
            "long_name": "Enter Trial Acronym",
            "short_name": "Trial Acronym",
            "original_name": "Trial Acronym",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Acronym or abbreviation used publicly to identify the clinical trial. Delete this line from the table if not applicable."
            ]
        },
        "technical": {
            "name": "Trial Acronym",
            "data_type": "Text",
            "definition": "C94108\nFor review purpose, see definition of the controlled terminology below:\nAcronym or abbreviation used publicly to identify the clinical trial.",
            "guidance": "Acronym or abbreviation used publicly to identify the clinical trial. Delete this line from the table if not applicable.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier\nConcept: C94108",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "StudyTitle",
                    "notes": "There are many titles. Select the acronym via the 'type' attribute in StudyTitle",
                    "path": "StudyVersion/@studyTitles/StudyTitle/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial Acronym",
            "notes": ""
        }
    },
    "Sponsor Protocol Identifier": {
        "template": {
            "long_name": "Enter Sponsor Protocol Identifier",
            "short_name": "Sponsor Protocol Identifier",
            "original_name": "Sponsor Protocol Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "A unique alphanumeric identifier for the trial, designated by the Sponsor."
            ]
        },
        "technical": {
            "name": "Sponsor Protocol Identifier",
            "data_type": "Text",
            "definition": "C132351\nFor review purpose, see definition of the controlled terminology below: \nA unique code assigned by the Sponsor that identifies a specific protocol.",
            "guidance": "A unique alphanumeric identifier for the trial, designated by the Sponsor.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "Title page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: C132351\nNote: Must have at least One Character May not be space(null)",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "studyIdentifier",
                    "klass": "StudyIdentifier",
                    "notes": "Select the sponsor identifier. This can be identified via the 'studyIdentifierScope' attribute, teh resulting organization and its type",
                    "path": "StudyVersion/@studyIdentifiers/StudyIdentifier/@studyIdentifier"
                }
            ],
            "map_status": "Mapped",
            "name": "Sponsor Protocol Identifier",
            "notes": ""
        }
    },
    "Original Protocol Indicator": {
        "template": {
            "long_name": "Original Protocol Indicator",
            "short_name": "Original Protocol Indicator",
            "original_name": "Original Protocol Indicator",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Original Protocol Indicator",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the protocol document reflects the original version of the protocol.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title page",
            "value": "Yes (C49488), No(C49487)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66742",
                    "preferred_term": "NY",
                    "definition": "A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable."
                },
                {
                    "ncit_code": "C49487",
                    "preferred_term": "No",
                    "definition": "The non-affirmative response to a question."
                },
                {
                    "ncit_code": "C49488",
                    "preferred_term": "Yes",
                    "definition": "The affirmative response to a question."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "amendments",
                    "klass": "StudyVersion",
                    "notes": "Existance of any amendments tells us this is not an original protocol. Set to 'Yes' if no amendments exist, otherwise 'No'",
                    "path": "StudyVersion/@amendments"
                }
            ],
            "map_status": "Mapped",
            "name": "Original Protocol Indicator",
            "notes": ""
        }
    },
    "Version Number": {
        "template": {
            "long_name": "Enter Version Number",
            "short_name": "Version Number",
            "original_name": "Version Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "For use by the Sponsor at their discretion."
            ]
        },
        "technical": {
            "name": "Version Number",
            "data_type": "Text",
            "definition": "C181232\nFor review purpose, see definition of the controlled terminology below:\nA string of numerals that uniquely identifies a specific version of a study protocol.",
            "guidance": "For use by the Sponsor at their discretion.",
            "conformance": "Optional",
            "cardinality": "One to one, Protocol Identifier",
            "relationship": "Title Page",
            "value": "Number",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier\nConcept: C181232",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "versionIdentifier",
                    "klass": "StudyVersion",
                    "notes": "",
                    "path": "StudyVersion/@versionIdentifier"
                }
            ],
            "map_status": "Mapped",
            "name": "Version Number",
            "notes": ""
        }
    },
    "Version Date": {
        "template": {
            "long_name": "Enter Version Date",
            "short_name": "Version Date",
            "original_name": "Version Date",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "For use by the Sponsor at their discretion."
            ]
        },
        "technical": {
            "name": "Version Date",
            "data_type": "Date",
            "definition": "C93813\nFor review purpose, see definition of the controlled terminology below\nThe date on which the document is versioned.",
            "guidance": "For use by the Sponsor at their discretion.",
            "conformance": "Optional",
            "cardinality": "One to one; one to Version Number",
            "relationship": "Title page",
            "value": "Date Format",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Version number; Sponsor Protocol Identifier \nConcept: C93813",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "dateValue",
                    "klass": "GovernanceDate",
                    "notes": "The governamce data 'type' attribute should be examined and the type 'Protocol Effective Date' selected",
                    "path": "StudyProtocolDocumentVersion/@dateValues/GovernanceDate/@dateValue"
                }
            ],
            "map_status": "Mapped",
            "name": "Version Date",
            "notes": ""
        }
    },
    "Amendment Identifier": {
        "template": {
            "long_name": "Amendment Identifier",
            "short_name": "Amendment Identifier",
            "original_name": "Amendment Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Enter the amendment identifier (e.g., amendment number). If this is the original instance of the protocol, delete the row or enter \"Not applicable\"."
            ]
        },
        "technical": {
            "name": "Amendment Identifier",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below \nA sequence of characters used to uniquely identify a protocol amendment.",
            "guidance": "Enter the amendment identifier (e.g. amendment number). If this is the original instance of the protocol, delete the row or enter \u201cNot applicable\u201d",
            "conformance": "Conditional: when there is an amendment",
            "cardinality": "One to one; One to Protocol Identifier if not original",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes if Original Protocol = No; blank if Original Protocol = Yes   \nRelationship: Heading, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "Yes, repeatable for Table for Document History",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Amendment Identifier",
            "notes": ""
        }
    },
    "Amendment Scope": {
        "template": {
            "long_name": "Amendment Scope",
            "short_name": "Amendment Scope",
            "original_name": "Amendment Scope",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "If this is the original instance of the protocol, delete the row or enter \"Not applicable\". If an amendment applies to all sites in the trial, enter \u201cglobal\u201d and delete the Country, Region and Site Identifier fields. If amending a single-country study, enter \u201cglobal\u201d.",
                "If the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope."
            ]
        },
        "technical": {
            "name": "Amendment Scope",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description as to whether the amendment scope applies globally across the trial.",
            "guidance": "Leave blank for original protocol.\nIf this is the original instance of the protocol, delete the row or enter \"Not applicable\". If an amendment applies to all sites in the trial, enter \u201cglobal\u201d and delete the Country, Region and Site Identifier fields. If amending a single-country study, enter \u201cglobal\u201d.",
            "conformance": "Conditional: when there is an amendment",
            "cardinality": "One to one, One to Amendment Identifier",
            "relationship": "Title page",
            "value": "Blank; Global (C68846), Not Global (CNEW)",
            "business_rules": "Value Allowed: Yes; Blank if Original Protocol Indicator = Yes\nRelationship: Heading, Amendment Identifier, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Amendment Scope Response",
                    "definition": "A terminology value set relevant to the responses for the protocol amendment scope within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C68846",
                    "preferred_term": "Global",
                    "definition": "Covering or affecting the whole of a system."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not Global",
                    "definition": "Covering or affecting a portion of the system."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "type",
                    "klass": "GeographicScope",
                    "notes": "The type will give Global, Regional or Country scope. There may be several scopes but only be one global scope",
                    "path": "StudyVersion/@amendments/StudyAmendment/@enrollments/SubjectEnrollment/@code/AliasCode/@standardCode/Code/@decode"
                }
            ],
            "map_status": "Mapped",
            "name": "Amendment Scope",
            "notes": ""
        }
    },
    "Country Identifier": {
        "template": {
            "long_name": "Country Identifier",
            "short_name": "Country Identifier",
            "original_name": "Country Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "If this is the original instance of the protocol, delete the row or enter \"Not applicable\". If an amendment applies to all sites in the trial, enter \u201cglobal\u201d and delete the Country, Region and Site Identifier fields. If amending a single-country study, enter \u201cglobal\u201d.",
                "If the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope."
            ]
        },
        "technical": {
            "name": "Country Identifier",
            "data_type": "Valid Value",
            "definition": "C20108\nCNEW\nCNEW\n\nFor review purpose, see definition of the controlled terminology below\nC20108\nA sequence of characters used to identify and/or name the country.\nCNEW\nA sequence of characters used to identify and/or name the region\nCNEW\nA sequence of characters used to identify and/or name the study site.",
            "guidance": "Leave blank for original protocol.\nIf the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope.",
            "conformance": "Conditional: when not global",
            "cardinality": "One to one; Many to Amendment Scope; One to Amendment Identifier; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Country specific: [Country Identifier] (ISO 3166 Country Codes, Alpha 3; ISO 3166 \nCountry Codes, Alpha 2)\nor\nRegion Specific: [Region Identifier]\nor\nSite specific: [Site Identifier] (Text)\nSite Identifier Text\nCondition Blank for Original Protocol Indicator = yes",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Amendment Scope, Amendment Identifier, Sponsor Protocol Identifier\nConcept: C20108, CNEW, CNEW",
            "repeating": "Yes, repeatable in 12.2 country/region-specific differences",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "type",
                    "klass": "GeographicScope",
                    "notes": "The type will give Global, Regional or Country scope. There may be several scopes but only be one global scope",
                    "path": "StudyVersion/@amendments/StudyAmendment/@enrollments/SubjectEnrollment/@code/AliasCode/@standardCode/Code/@decode"
                }
            ],
            "map_status": "Mapped",
            "name": "Country Identifier",
            "notes": ""
        }
    },
    "Region Identifier": {
        "template": {
            "long_name": "Region Identifier",
            "short_name": "Region Identifier",
            "original_name": "Region Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "If this is the original instance of the protocol, delete the row or enter \"Not applicable\". If an amendment applies to all sites in the trial, enter \u201cglobal\u201d and delete the Country, Region and Site Identifier fields. If amending a single-country study, enter \u201cglobal\u201d.",
                "If the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope."
            ]
        },
        "technical": {
            "name": "Region Identifier",
            "data_type": "Valid Value",
            "definition": "C20108\nCNEW\nCNEW\n\nFor review purpose, see definition of the controlled terminology below\nC20108\nA sequence of characters used to identify and/or name the country.\nCNEW\nA sequence of characters used to identify and/or name the region\nCNEW\nA sequence of characters used to identify and/or name the study site.",
            "guidance": "Leave blank for original protocol.\nIf the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope.",
            "conformance": "Conditional: when not global",
            "cardinality": "One to one; Many to Amendment Scope; One to Amendment Identifier; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Country specific: [Country Identifier] (ISO 3166 Country Codes, Alpha 3; ISO 3166 \nCountry Codes, Alpha 2)\nor\nRegion Specific: [Region Identifier]\nor\nSite specific: [Site Identifier] (Text)\nSite Identifier Text\nCondition Blank for Original Protocol Indicator = yes",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Amendment Scope, Amendment Identifier, Sponsor Protocol Identifier\nConcept: C20108, CNEW, CNEW",
            "repeating": "Yes, repeatable in 12.2 country/region-specific differences",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "type",
                    "klass": "GeographicScope",
                    "notes": "The type will give Global, Regional or Country scope. There may be several scopes but only be one global scope",
                    "path": "StudyVersion/@amendments/StudyAmendment/@enrollments/SubjectEnrollment/@code/AliasCode/@standardCode/Code/@decode"
                }
            ],
            "map_status": "Mapped",
            "name": "Region Identifier",
            "notes": ""
        }
    },
    "Site Identifier": {
        "template": {
            "long_name": "Enter Site Identifier",
            "short_name": "Site Identifier",
            "original_name": "Site Identifier",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "If this is the original instance of the protocol, delete the row or enter \"Not applicable\". If an amendment applies to all sites in the trial, enter \u201cglobal\u201d and delete the Country, Region and Site Identifier fields. If amending a single-country study, enter \u201cglobal\u201d.",
                "If the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope."
            ]
        },
        "technical": {
            "name": "Site Identifier",
            "data_type": "Valid Value",
            "definition": "C20108\nCNEW\nCNEW\n\nFor review purpose, see definition of the controlled terminology below\nC20108\nA sequence of characters used to identify and/or name the country.\nCNEW\nA sequence of characters used to identify and/or name the region\nCNEW\nA sequence of characters used to identify and/or name the study site.",
            "guidance": "Leave blank for original protocol.\nIf the amendment does not apply to all sites in the trial, select \u201cNot Global\u201d and utilise one of the identifiers based on amendment scope.",
            "conformance": "Conditional: when not global",
            "cardinality": "One to one; Many to Amendment Scope; One to Amendment Identifier; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Country specific: [Country Identifier] (ISO 3166 Country Codes, Alpha 3; ISO 3166 \nCountry Codes, Alpha 2)\nor\nRegion Specific: [Region Identifier]\nor\nSite specific: [Site Identifier] (Text)\nSite Identifier Text\nCondition Blank for Original Protocol Indicator = yes",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Amendment Scope, Amendment Identifier, Sponsor Protocol Identifier\nConcept: C20108, CNEW, CNEW",
            "repeating": "Yes, repeatable in 12.2 country/region-specific differences",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "name",
                    "klass": "StudySite",
                    "notes": "Sites may need an address or similar mechanism",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@organizations/ResearchOrganization/@manages/StudySite/@name"
                }
            ],
            "map_status": "Mapped",
            "name": "Site Identifier",
            "notes": ""
        }
    },
    "Sponsors Investigational Product Codes": {
        "template": {
            "long_name": "Enter Sponsor\u2019s Investigational Product Code(s)",
            "short_name": "Sponsors Investigational Product Codes",
            "original_name": "Sponsor\u2019s Investigational Product Code(s)",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Enter the Sponsor\u2019s unique identifier for investigational compound(s) in the trial. Add fields as needed."
            ]
        },
        "technical": {
            "name": "Sponsors Investigational Product Codes",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below:\nA symbol or combination of symbols that are assigned by the Sponsor to uniquely identify an experimental intervention.",
            "guidance": "Enter the Sponsor\u2019s unique identifier for investigational compound(s) in the trial. Add fields as needed.",
            "conformance": "Optional: if there is Sponsor Investigational Product Code",
            "cardinality": "One to one, Many to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "Yes, repeatable for each Investigational compound\nYes, repeatable in 1.1.2 under Intervention",
            "ct": []
        }
    },
    "Nonproprietary Names": {
        "template": {
            "long_name": "Enter Nonproprietary Name(s)",
            "short_name": "Nonproprietary Names",
            "original_name": "Nonproprietary Name(s)",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Nonproprietary Names",
            "data_type": "Text",
            "definition": "C97054\nFor review purpose, see definition of the controlled terminology below\nDrug name that is not protected by a trademark, usually descriptive of its chemical structure.",
            "guidance": "Omit nonproprietary name fields if a nonproprietary name has not yet been assigned.",
            "conformance": "Optional; Blank",
            "cardinality": "One to many; Many to Sponsor Investigational Product Code(s); Many to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text for example WHO INN, USAN, JAN, XEVMPD",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier\nConcept: C97054",
            "repeating": "Yes, repeatable for each nonproprietary name \nYes, repeatable in 1.1,2 under intervention",
            "ct": []
        }
    },
    "Proprietary Names": {
        "template": {
            "long_name": "Enter Proprietary Name(s)",
            "short_name": "Proprietary Names",
            "original_name": "Proprietary Name(s)",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Omit nonproprietary name fields if a nonproprietary name has not yet been assigned. Omit proprietary name fields if not yet established."
            ]
        },
        "technical": {
            "name": "Proprietary Names",
            "data_type": "Text",
            "definition": "C71898\nFor review purpose, see definition of the controlled terminology below\nA commercial name granted by a naming authority for use in marketing an experimental intervention.",
            "guidance": "Omit proprietary name fields if not yet established.",
            "conformance": "Optional; Blank",
            "cardinality": "One to many; Many to Sponsor Investigational Product Code(s); Many to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier; Sponsor Investigational Product Code(s)\nConcept: C71898",
            "repeating": "Yes, repeatable for each proprietary name",
            "ct": []
        }
    },
    "Trial Phase": {
        "template": {
            "long_name": "Trial Phase",
            "short_name": "Trial Phase",
            "original_name": "Trial Phase",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "For trials combining investigational drugs or vaccines with devices, classify according to the phase of drug development."
            ]
        },
        "technical": {
            "name": "Trial Phase",
            "data_type": "Valid Value",
            "definition": "C48281\nFor review purpose, see definition of the controlled terminology below\nA step in the clinical research and development of a therapy from initial clinical trials to post-approval studies.",
            "guidance": "For trials combining investigational drugs or vaccines with devices, classify according to the phase of drug development.",
            "conformance": "Required",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Early Phase 1 (C54721); Phase 1(C15600); Phase 1/Phase 2 (C15693) Phase 1/Phase 2/Phase 3 (C198366); Phase 1/Phase 3(C198367); Phase 2(C15601); Phase 2/Phase 3(C15694); Phase2/Phase 3/Phase 4(CNEW); Phase 3(C15602); Phase 3/Phase 4 (CNEW); Phase 4 (C15603)))",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: C48281",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66737",
                    "preferred_term": "TPHASE",
                    "definition": "A terminology codelist relevant to the phase, or stage, of the clinical trial."
                },
                {
                    "ncit_code": "C54721",
                    "preferred_term": "Early Phase 1",
                    "definition": "First-in-human trials, in a small number of subjects, that are conducted before Phase 1 trials and are intended to assess new candidate therapeutic and imaging agents. The study agent is administered at a low dose for a limited time, and there is no therapeutic or diagnostic intent."
                },
                {
                    "ncit_code": "C15600",
                    "preferred_term": "Phase 1",
                    "definition": "The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects."
                },
                {
                    "ncit_code": "C15693",
                    "preferred_term": "Phase 1/Phase 2",
                    "definition": "A class of clinical study that combines elements characteristic of traditional Phase 1 and Phase 2 trials. See also Phase I, Phase II."
                },
                {
                    "ncit_code": "C198366",
                    "preferred_term": "Phase 1/Phase 2/Phase 3",
                    "definition": "A study that begins as a Phase 1 study and transitions into Phases 2 and 3 based upon successful completion of each previous portion."
                },
                {
                    "ncit_code": "C198367",
                    "preferred_term": "Phase 1/Phase 3",
                    "definition": "A study that begins as a Phase 1 study and transitions into a Phase 3 study upon successful completion of the Phase I portion."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Phase 2/Phase 3/Phase 4",
                    "definition": "A study that begins as a Phase 2 study and transitions into Phases 3 and 4 based upon successful completion of each previous portion."
                },
                {
                    "ncit_code": "C15601",
                    "preferred_term": "Phase 2",
                    "definition": "Phase that includes the controlled clinical trials conducted to evaluate the safety and efficacy of the drug in a limited number of patients with the disease or condition under study. Objectives can be dose-ranging (dose-response, frequency of dosing), type of patients, or numerous other characteristics of safety and efficacy."
                },
                {
                    "ncit_code": "C15694",
                    "preferred_term": "Phase 2/Phase 3",
                    "definition": "A class of clinical study that combines elements characteristic of traditional Phase 2 and Phase 3 trials."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Phase 3/Phase 4",
                    "definition": "A class of clinical study that combines elements characteristic of traditional Phase 3 and Phase 4 trials."
                },
                {
                    "ncit_code": "C15602",
                    "preferred_term": "Phase 3",
                    "definition": "Phase that includes the controlled clinical trials intended to confirm safety and effectiveness, evaluate the overall benefit-risk relationship, and to provide substantial evidence for regulatory approval and labeling."
                },
                {
                    "ncit_code": "C15603",
                    "preferred_term": "Phase 4",
                    "definition": "Post-approval studies to delineate additional information about the drug's risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "studyPhase",
                    "klass": "StudyVersion",
                    "notes": "",
                    "path": "StudyVersion/@studyPhase"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial Phase",
            "notes": ""
        }
    },
    "Trial Short Title": {
        "template": {
            "long_name": "Enter Trial Short Title",
            "short_name": "Trial Short Title",
            "original_name": "Trial Short Title",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Short title should convey in plain language what the trial is about and should be suitable for use as \u201cBrief Title\u201d or \u201cTitle in Plain Language\u201d in global clinical trial registries. It can also be suitable for use with informed consents and ethics committee submissions."
            ]
        },
        "technical": {
            "name": "Trial Short Title",
            "data_type": "Text",
            "definition": "C132345\nFor review purpose, see definition of the controlled terminology below\nThe short descriptive name for the protocol.",
            "guidance": "Short title should convey in plain language what the trial is about and should be suitable for use as \u201cBrief Title\u201d or \u201cTitle in Plain Language\u201d in global clinical trial registries. It can also be suitable for use with informed consents and ethics committee submissions.",
            "conformance": "Optional",
            "cardinality": "One to one, One to Sponsor Protocol identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier\nConcept: C132345",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "StudyTitle",
                    "notes": "There are many titles. Select the correct one via the 'type' attribute in StudyTitle",
                    "path": "StudyVersion/@studyTitles/StudyTitle/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial Short Title",
            "notes": ""
        }
    },
    "Sponsor Name": {
        "template": {
            "long_name": "Enter Sponsor Name",
            "short_name": "Sponsor Name",
            "original_name": "Sponsor Name",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Name",
            "data_type": "Text",
            "definition": "C70793\nFor review purpose, see definition of the controlled terminology below\nAn individual, company, institution, or organisation that takes responsibility for the initiation, management, and/or financing of a clinical study. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP]",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
            "conformance": "Required",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: C70793",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "name",
                    "klass": "Organization",
                    "notes": "Select the sponsor organization",
                    "path": "StudyIdentifier/@studyIdentifierScope/Organization/@name"
                }
            ],
            "map_status": "Mapped",
            "name": "Sponsor Name",
            "notes": ""
        }
    },
    "Sponsor Legal Address": {
        "template": {
            "long_name": "Enter Sponsor Legal Address",
            "short_name": "Sponsor Legal Address",
            "original_name": "Sponsor Legal Address",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Legal Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the trial Sponsor.",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
            "conformance": "Required",
            "cardinality": "One to one, One to Sponsor Name",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "Address",
                    "notes": "Select the sponsor organization",
                    "path": "StudyIdentifier/@studyIdentifierScope/Organization/@legalAddress/Address/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Sponsor Legal Address",
            "notes": ""
        }
    },
    "Co-Sponsor Name": {
        "template": {
            "long_name": "Enter Co-Sponsor Name",
            "short_name": "Co-Sponsor Name",
            "original_name": "Co-Sponsor Name",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Co-Sponsor Name",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) of the trial co-Sponsor.",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
            "conformance": "Optional",
            "cardinality": "One to one, One to Co-Sponsor Name, One to Sponsor Name; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Co-Sponsor Name, Sponsor Name, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "Address",
                    "notes": "Select the co-sponsor organization",
                    "path": "StudyIdentifier/@studyIdentifierScope/Organization/@legalAddress/Address/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Co-Sponsor Name",
            "notes": ""
        }
    },
    "Co-Sponsor Legal Address": {
        "template": {
            "long_name": "Enter Co-Sponsor Legal Address",
            "short_name": "Co-Sponsor Legal Address",
            "original_name": "Co-Sponsor Legal Address",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
                "Local Sponsor Name and Address:"
            ]
        },
        "technical": {
            "name": "Co-Sponsor Legal Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the trial co-sponsor.",
            "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Heading; One to Co-Sponsor Name",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Co- Sponsor Name\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "name",
                    "klass": "Organization",
                    "notes": "Select the co-sponsor organization",
                    "path": "StudyIdentifier/@studyIdentifierScope/Organization/@name"
                }
            ],
            "map_status": "Mapped",
            "name": "Co-Sponsor Legal Address",
            "notes": ""
        }
    },
    "Local Sponsor Name": {
        "template": {
            "long_name": "Enter Local Sponsor Name",
            "short_name": "Local Sponsor Name",
            "original_name": "Local Sponsor Name",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Local Sponsor Name",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.",
            "guidance": "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Local Sponsor Name and Address Field.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Name and Address; Many to Sponsor Name",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name and Address; Sponsor Name; Country\nConcept: CNEW",
            "repeating": "Yes, repeatable for each Local Sponsor Name",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "Address",
                    "notes": "Select the co-sponsor organization",
                    "path": "StudyIdentifier/@studyIdentifierScope/Organization/@legalAddress/Address/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Local Sponsor Name",
            "notes": ""
        }
    },
    "Local Sponsor Address": {
        "template": {
            "long_name": "Enter Local Sponsor Address",
            "short_name": "Local Sponsor Address",
            "original_name": "Local Sponsor Address",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Local Sponsor Name and Address Field."
            ]
        },
        "technical": {
            "name": "Local Sponsor Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.",
            "guidance": "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Sponsor Local Name and Address Field.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Local Sponsor; One to Country",
            "relationship": "Title page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Local Sponsor, Country\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "name",
                    "klass": "Organization",
                    "notes": "Select the co-sponsor organization",
                    "path": "StudyIdentifier/@studyIdentifierScope/Organization/@name"
                }
            ],
            "map_status": "Mapped",
            "name": "Local Sponsor Address",
            "notes": ""
        }
    },
    "Device Manufacturer Name": {
        "template": {
            "long_name": "Enter Device Manufacturer Name",
            "short_name": "Device Manufacturer Name",
            "original_name": "Device Manufacturer Name",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Device Manufacturer Name",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe organisation defined as being responsible for creating the device as stated on the package in which the product is supplied.",
            "guidance": "Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above.\nAdd additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier; One to Sponsor Name",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier; Sponsor Name\nConcept: CNEW",
            "repeating": "Yes, repeatable for each device manufacturers",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Device Manufacturer Name",
            "notes": "Currently USDM not handling device entities. Will be mapped in Phase 4 and use the Organization class"
        }
    },
    "Device Manufacturer Address": {
        "template": {
            "long_name": "Enter Device Manufacturer Address",
            "short_name": "Device Manufacturer Address",
            "original_name": "Device Manufacturer Address",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above.",
                "Add additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable."
            ]
        },
        "technical": {
            "name": "Device Manufacturer Address",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the device manufacturer.",
            "guidance": "Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above.\nAdd additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable.",
            "conformance": "Optional",
            "cardinality": "One to One; One to Device Manufacturer Name",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Device Manufacturing Name\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Device Manufacturer Address",
            "notes": "Currently USDM not handling device entities. Will be mapped in Phase 4 and use the Organization class"
        }
    },
    "EU CT Number": {
        "template": {
            "long_name": "EU CT Number",
            "short_name": "EU CT Number",
            "original_name": "EU CT Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "EU CT Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the Clinical Trials Information System (CTIS) of the European Medicines Agency.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes; EU CT number: yyyy-5xxxxx-xx with YYYY corresponding to a year i.e. 2024 and x being an integer\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "studyIdentifier",
                    "klass": "StudyIdentifier",
                    "notes": "Select where the organization is of type 'Regulatory Agency' and is the EU",
                    "path": "StudyVersion/@studyIdentifiers/StudyIdentifier/@studyIdentifier"
                }
            ],
            "map_status": "Mapped",
            "name": "EU CT Number",
            "notes": ""
        }
    },
    "FDA IND Number": {
        "template": {
            "long_name": "FDA IND Number",
            "short_name": "FDA IND Number",
            "original_name": "FDA IND Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "FDA IND Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the US Food and Drug Administration.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier;",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "studyIdentifier",
                    "klass": "StudyIdentifier",
                    "notes": "Select where the organization is of type 'Regulatory Agency' and is the FDA",
                    "path": "StudyVersion/@studyIdentifiers/StudyIdentifier/@studyIdentifier"
                }
            ],
            "map_status": "Mapped",
            "name": "FDA IND Number",
            "notes": ""
        }
    },
    "IDE Number": {
        "template": {
            "long_name": "IDE Number",
            "short_name": "IDE Number",
            "original_name": "IDE Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "IDE Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial under an Investigational Device Exemption (IDE) application, as assigned by the US Food and Drug Administration.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "studyIdentifier",
                    "klass": "StudyIdentifier",
                    "notes": "Select where the organization is of type 'Regulatory Agency' and is the FDA",
                    "path": "StudyVersion/@studyIdentifiers/StudyIdentifier/@studyIdentifier"
                }
            ],
            "map_status": "Mapped",
            "name": "IDE Number",
            "notes": ""
        }
    },
    "jRCT Number": {
        "template": {
            "long_name": "jRCT Number",
            "short_name": "jRCT Number",
            "original_name": "jRCT Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "jRCT Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the Japan Registry for Clinical Trials (JRCT) of the Ministry of Health, Labour and Welfare (MHLW) in Japan.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "NCT Number": {
        "template": {
            "long_name": "NCT Number",
            "short_name": "NCT Number",
            "original_name": "NCT Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "NCT Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the protocol registration and results (PRS) system of the US National Library of Medicine.",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "studyIdentifier",
                    "klass": "StudyIdentifier",
                    "notes": "Select where the organization is of type 'Clinical Study Registry' and is the ClinicalTrials.gov",
                    "path": "StudyVersion/@studyIdentifiers/StudyIdentifier/@studyIdentifier"
                }
            ],
            "map_status": "Mapped",
            "name": "NCT Number",
            "notes": ""
        }
    },
    "NMPA IND Number": {
        "template": {
            "long_name": "NMPA IND Number",
            "short_name": "NMPA IND Number",
            "original_name": "NMPA IND Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "NMPA IND Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the Chinese National Medicinal Products Administration (NMPA).",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "studyIdentifier",
                    "klass": "StudyIdentifier",
                    "notes": "Select where the organization is of type 'Regulatory Agency' and is the NMPA (China)",
                    "path": "StudyVersion/@studyIdentifiers/StudyIdentifier/@studyIdentifier"
                }
            ],
            "map_status": "Mapped",
            "name": "NMPA IND Number",
            "notes": ""
        }
    },
    "WHO-UTN Number": {
        "template": {
            "long_name": "WHO/UTN Number",
            "short_name": "WHO-UTN Number",
            "original_name": "WHO/UTN Number",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "WHO-UTN Number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the World Health Organisation's International Clinical Trial's Registry Platform (ICTRP).",
            "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "UTN/WHO: Uxxxx-xxxx-xxxx with X being an integer",
            "business_rules": "Value Allowed: Yes; \nRelationship: Heading; Sponsor Protocol Identifier; \nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Other Regulatory or Clinical Trial Identifier": {
        "template": {
            "long_name": "Other Regulatory or Clinical Trial Identifier",
            "short_name": "Other Regulatory or Clinical Trial Identifier",
            "original_name": "Other Regulatory or Clinical Trial Identifier",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Include all identifiers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for identifiers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed."
            ]
        },
        "technical": {
            "name": "Other Regulatory or Clinical Trial Identifier",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below \nA sequence of characters used to identify a clinical trial, that is different than the one(s) previously specified or mentioned.",
            "guidance": "Include allidentifiers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for identifiersnot available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol IdentifierConcept: CNEW",
            "repeating": "Yes, repeatable for each regulatory agency identifier",
            "ct": []
        }
    },
    "Approval Date": {
        "template": {
            "long_name": "Enter Approval Date",
            "short_name": "Approval Date",
            "original_name": "Approval Date",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "All versions should be uniquely identifiable. "
            ]
        },
        "technical": {
            "name": "Approval Date",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below \nThe date that the sponsor approved the current version of the protocol, or the physical or virtual location of the date on which the sponsor approved the current version of the protocol.",
            "guidance": "All versions should be uniquely identifiable.",
            "conformance": "Required",
            "cardinality": "One to one; One to Sponsor Protocol Identifier; One to Original Protocol One to Amendment Identifier",
            "relationship": "Title Page",
            "value": "Sponsor Approval Date (C132352)\nLocation of Sponsor Approval Date (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier, Protocol Amendment\nConcept: CNEW",
            "repeating": "Yes, reuse to approval date in Section 12.3",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Sponsor Approval Response",
                    "definition": "A terminology value set relevant to the sponsor approval responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C132352",
                    "preferred_term": "Sponsor Approval Date",
                    "definition": "The date that the sponsor approved the current version of the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Location of Sponsor Approval Date",
                    "definition": "The physical or virtual location of the date on which the sponsor approved the current version of the protocol."
                }
            ]
        }
    },
    "sponsor signature block name and title of sponsor signatory and signature date": {
        "template": {
            "long_name": "Enter sponsor signature block (name and title of sponsor signatory and signature date)",
            "short_name": "sponsor signature block name and title of sponsor signatory and signature date",
            "original_name": "sponsor signature block (name and title of sponsor signatory and signature date)",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "sponsor signature block name and title of sponsor signatory and signature date",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA block of text containing the name and signature of the sponsor's signatory, along with a signature date, or a statement on behalf of the sponsor that describes the method of protocol approval.",
            "guidance": "Include either the Sponsor signature or the statement below.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "Title Page",
            "value": "Sponsor Signature Block (CNEW)\n OR \nSponsor Protocol Approval Statement (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Sponsor Signatory Response",
                    "definition": "A terminology value set relevant to the sponsor signatory responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Sponsor Signature Block",
                    "definition": "A block of text containing the name and signature of the sponsor's signatory, along with the signature date."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Sponsor Protocol Approval Statement",
                    "definition": "A statement that the protocol was approved by a method as described. This protocol was approved via <describe method>"
                }
            ]
        }
    },
    "contact information for Medical Expert as designated by sponsor or state location where information can be found": {
        "template": {
            "long_name": "Enter contact information for Medical Expert (as designated by sponsor) or state location where information can be found",
            "short_name": "contact information for Medical Expert as designated by sponsor or state location where information can be found",
            "original_name": "contact information for Medical Expert (as designated by sponsor) or state location where information can be found",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "contact information for Medical Expert as designated by sponsor or state location where information can be found",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe contact information for the sponsor's representative who can advise on specific trial-related medical questions or problems.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one; One to Sponsor Protocol Identifier",
            "relationship": "Title Page",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Medical Expert Contact Response\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Globally-Locally-by Cohort": {
        "template": {
            "long_name": "Globally/Locally/by Cohort",
            "short_name": "Globally-Locally-by Cohort",
            "original_name": "Globally/Locally/by Cohort",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Enter the approximate number or percentage of participants enrolled as a percentage of the expected total. If the number of expected participants is changing as a result of the current amendment, use the updated number of expected participants to estimate the current percent of enrollment. Estimates are adequate, as precise enrollment figures will likely be changing while an amendment is being prepared.",
                "For a country/regional amendment, provide the estimated local or regional enrollment at the time the Sponsor approved the amendment."
            ]
        },
        "technical": {
            "name": "Globally-Locally-by Cohort",
            "data_type": "Text",
            "definition": "C68846\nCNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
            "guidance": "",
            "conformance": "Optional",
            "cardinality": "One to one; One to amendment number",
            "relationship": "Amendment Details",
            "value": "Approximate <#/%> enrolled <Globally/Locally/by Cohort>",
            "business_rules": "Value Allowed: Yes\nRelationship: Statement\nConcept: C68846, CNEW",
            "repeating": "Yes, reuse to Section 12.3",
            "ct": []
        }
    },
    "Primary Reason for Amendment": {
        "template": {
            "long_name": "Primary Reason for Amendment",
            "short_name": "Primary Reason for Amendment",
            "original_name": "Primary Reason for Amendment",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Primary Reason for Amendment",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe rationale of greatest importance for the protocol amendment.",
            "guidance": "Choose from the available categories as the primary reason and secondary reason(s) for the amendment. Select the closest match among the choices. Changes to primary estimand, endpoints, or related measures should be listed as a change of strategy. If none of the choices apply, choose \u201cother\u201d and provide a description. If no secondary reason, indicate \u201cnot applicable\u201d for the secondary reason.",
            "conformance": "Conditional : if the protocol is=No",
            "cardinality": "One to Amendment Details",
            "relationship": "Amendment Details",
            "value": "Regulatory agency request to amend (CNEW)\nNew regulatory guidance (CNEW)\nIRB/IEC feedback (CNEW)\nNew safety information available (CNEW)\nManufacturing change (NEW)\nIMP addition (CNEW)\nChange in strategy (CNEW)\nChange in standard of care (CNEW)\nNew data available (other than safety data) (CNEW)\nInvestigator/site feedback (CNEW)\nRecruitment difficulty (CNEW)\nInconsistency and/or error in the protocol (CNEW)\nProtocol design error (CNEW)\nOther(C17649)\nNot applicable(C48660)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier, Protocol Amendment\nConcept: CNEW",
            "repeating": "Yes, Multiple values can be selected except when it is Original Protocol",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Reason for Amendment Response",
                    "definition": "A terminology value set relevant to the primary reason for amendment responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Regulatory Agency Request To Amend",
                    "definition": "A regulatory agency has expressed a need for a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "New Regulatory Guidance",
                    "definition": "A regulatory agency has published a guidance document that necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "IRB/IEC Feedback",
                    "definition": "Feedback from the institutional review board or independent ethics committee necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "New Safety Information Available",
                    "definition": "Previously unavailable safety data becomes available, which necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Manufacturing Change",
                    "definition": "A change to manufacturing processes of the study agents necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "IMP Addition",
                    "definition": "The addition of an investigational medicinal product to a clinical trial design necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Change In Strategy",
                    "definition": "A change in the study purpose or intent of the scientific plan necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Change In Standard Of Care",
                    "definition": "A change in the standard of care necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "New Data Available (Other Than Safety Data)",
                    "definition": "Previously unavailable data (other than safety data) becomes available, which necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Investigator/Site Feedback",
                    "definition": "Feedback from the investigator or study site necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Recruitment Difficulty",
                    "definition": "Challenges with participant recruitment necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Inconsistency And/Or Error In The Protocol",
                    "definition": "An error or inconsistency in the protocol necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Protocol Design Error",
                    "definition": "A protocol design error necessitates a change(s) to, or formal clarification of, a document."
                },
                {
                    "ncit_code": "C17649",
                    "preferred_term": "Other",
                    "definition": "Different than the one(s) previously specified or mentioned."
                },
                {
                    "ncit_code": "C48660",
                    "preferred_term": "Not Applicable",
                    "definition": "Determination of a value is not relevant in the current context."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "code",
                    "klass": "StudyAmendmentReason",
                    "notes": "",
                    "path": "StudyVersion/@amendments/StudyAmendment/@primaryReason/StudyAmendmentReason/@code"
                },
                {
                    "attribute": "otherReason",
                    "klass": "StudyAmendmentReason",
                    "notes": "Allows for free text other reason",
                    "path": "StudyVersion/@amendments/StudyAmendment/@primaryReason/StudyAmendmentReason/@otherReason"
                }
            ],
            "map_status": "Mapped",
            "name": "Primary Reason for Amendment",
            "notes": ""
        }
    },
    "Secondary Reason for Amendment": {
        "template": {
            "long_name": "Secondary Reason for Amendment",
            "short_name": "Secondary Reason for Amendment",
            "original_name": "Secondary Reason for Amendment",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Secondary Reason for Amendment",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAdditional rationale for the protocol amendment that is not considered the primary rationale.",
            "guidance": "Choose from the available categories as the primary reason and secondary reason(s) for the amendment. Select the closest match among the choices. Changes to primary estimand, endpoints, or related measures should be listed as a change of strategy. If none of the choices apply, choose \u201cother\u201d and provide a description. If no secondary reason, indicate \u201cnot applicable\u201d for the secondary reason.",
            "conformance": "Conditional If Protocol Original = No",
            "cardinality": "One to one; One to Protocol Identifier; One to Amendment Identifier",
            "relationship": "Amendment Details",
            "value": "Regulatory agency request to amend (CNEW)\nNew regulatory guidance (CNEW)\nIRB/IEC feedback (CNEW)\nNew safety information available (CNEW)\nManufacturing change (CNEW)\nIMP addition (CNEW)\nChange in strategy (CNEW)\nChange in standard of care (CNEW)\nNew data available (other than safety data) (CNEW)\nInvestigator/site feedback (CNEW)\nRecruitment difficulty (CNEW)\nInconsistency and/or error in the protocol (CNEW)\nProtocol design error (CNEW)\nOther(C17649)\nNot applicable(C48660)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier, Protocol Amendment\nConcept: CNEW",
            "repeating": "Yes, Multiple accepted except for the Original",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Reason for Amendment Response",
                    "definition": "A terminology value set relevant to the secondary reason for amendment responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Regulatory Agency Request To Amend",
                    "definition": "A regulatory agency has expressed a need for a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "New Regulatory Guidance",
                    "definition": "A regulatory agency has published a guidance document that necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "IRB/IEC Feedback",
                    "definition": "Feedback from the institutional review board or independent ethics committee necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "New Safety Information Available",
                    "definition": "Previously unavailable safety data becomes available, which necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Manufacturing Change",
                    "definition": "A change to manufacturing processes of the study agents necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "IMP Addition",
                    "definition": "The addition of an investigational medicinal product to a clinical trial design necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Change In Strategy",
                    "definition": "A change in the study purpose or intent of the scientific plan necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Change In Standard Of Care",
                    "definition": "A change in the standard of care necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "New Data Available (Other Than Safety Data)",
                    "definition": "Previously unavailable data (other than safety data) becomes available, which necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Investigator/Site Feedback",
                    "definition": "Feedback from the investigator or study site necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Recruitment Difficulty",
                    "definition": "Challenges with participant recruitment necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Inconsistency And/Or Error In The Protocol",
                    "definition": "An error or inconsistency in the protocol necessitates a change(s) to, or formal clarification of, the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Protocol Design Error",
                    "definition": "A protocol design error necessitates a change(s) to, or formal clarification of, a document."
                },
                {
                    "ncit_code": "C17649",
                    "preferred_term": "Other",
                    "definition": "Different than the one(s) previously specified or mentioned."
                },
                {
                    "ncit_code": "C48660",
                    "preferred_term": "Not Applicable",
                    "definition": "Determination of a value is not relevant in the current context."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "code",
                    "klass": "StudyAmendmentReason",
                    "notes": "",
                    "path": "StudyVersion/@amendments/StudyAmendment/@secondaryReasons/StudyAmendmentReason/@code"
                },
                {
                    "attribute": "otherReason",
                    "klass": "StudyAmendmentReason",
                    "notes": "Allows for free text other reason",
                    "path": "StudyVersion/@amendments/StudyAmendment/@secondaryReasons/StudyAmendmentReason/@otherReason"
                }
            ],
            "map_status": "Mapped",
            "name": "Secondary Reason for Amendment",
            "notes": ""
        }
    },
    "Amendment Summary": {
        "template": {
            "long_name": "Amendment Summary",
            "short_name": "Amendment Summary",
            "original_name": "Amendment Summary",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Describe key changes briefly. Changes which are included in the amendment but unrelated to the key changes do not need to be described here."
            ]
        },
        "technical": {
            "name": "Amendment Summary",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short narrative representation describing the changes introduced in the current version of the protocol.",
            "guidance": "Describe key changes briefly. Changes which are included in the amendment but unrelated to the key changes do not need to be described here.",
            "conformance": "Conditional: if there is an amendment",
            "cardinality": "One to Amendment identifier",
            "relationship": "Amendment Details",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details; Amendment Identifier, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "summary",
                    "klass": "StudyAmendment",
                    "notes": "",
                    "path": "StudyVersion/@amendments/StudyAmendment/@summary"
                }
            ],
            "map_status": "Mapped",
            "name": "Amendment Summary",
            "notes": ""
        }
    },
    "Description of Change": {
        "template": {
            "long_name": "Enter Description of Change",
            "short_name": "Description of Change",
            "original_name": "Description of Change",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Description of Change",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology belowA narrative representation of the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: if there is an amendment",
            "cardinality": "One to many",
            "relationship": "Amendment Details",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading and Row; Amendment Details; Column Heading, Row Heading\nConcept: CNEW",
            "repeating": "Yes, repeatable for every description of change in the amendment",
            "ct": []
        }
    },
    "Brief Rationale for Change": {
        "template": {
            "long_name": "Enter Brief Rationale for Change",
            "short_name": "Brief Rationale for Change",
            "original_name": "Brief Rationale for Change",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Brief Rationale for Change",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe brief reason for the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: if there is an amendment",
            "cardinality": "One to many",
            "relationship": "Amendment Details",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details; Table Column Heading Row; Description of change; Section # and Name\nConcept: CNEW",
            "repeating": "Yes, repeatable for each description of change in the amendment",
            "ct": []
        }
    },
    "Section - and Name of Change": {
        "template": {
            "long_name": "Enter Section # and Name of Change",
            "short_name": "Section - and Name of Change",
            "original_name": "Section # and Name of Change",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "(Add lines as needed)"
            ]
        },
        "technical": {
            "name": "Section - and Name of Change",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe protocol section number and name containing the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: if there is an amendment",
            "cardinality": "One to many\nRow description of change \nDescription of Change, Rational for Amendment Change",
            "relationship": "Amendment Details; Description of Change; Brief Rationale for Change; Table Column Heading",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Brief Rational; Change description; table\nConcept: CNEW",
            "repeating": "Yes, repeatable for each description of change in the amendment",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Protocol Number and Name Response",
                    "definition": "A terminology value set relevant to the protocol number and name responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                },
                {
                    "ncit_code": "",
                    "preferred_term": "",
                    "definition": ""
                }
            ]
        }
    },
    "Primary and Secondary Objectives and Estimands": {
        "template": {
            "long_name": "Enter Primary and Secondary Objectives and Estimands",
            "short_name": "Primary and Secondary Objectives and Estimands",
            "original_name": "Primary and Secondary Objectives and Estimands",
            "optional": false,
            "section_number": "1.1.1",
            "section_title": "Primary and Secondary Objectives and Estimands",
            "instructions": []
        },
        "technical": {
            "name": "Primary and Secondary Objectives and Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA descriptive summary of the primary and secondary objectives and their associated estimands related to the trial.",
            "guidance": "Summarise the primary and secondary objectives and any associated estimands in natural, nontechnical (layperson) language. \nFor trials intended to estimate a treatment effect or test a hypothesis related to a treatment effect, include the primary and secondary objectives and any associated estimands using a nontechnical summary describing the objective and treatment effect of interest (estimand). \nFor other types of trials not intended to estimate a treatment effect or test a hypothesis related to a treatment effect, define trial objectives and describe additional information relevant to the clinical question(s) of interest (e.g., the endpoint(s) associated with each objective).\nFor trials with numerous objectives in which the description of objectives will exceed half a page, consider including the most important objectives and estimands in the synopsis and refer to Section 3 Trial Objectives and Associated Estimands, which covers the objectives and estimands in technical detail. For considerations on estimands, refer to ICH E9(R1).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.1.1 Primary and Secondary Objectives and Estimands\nConcept: CNEW",
            "repeating": "Yes, Reuse <Primary Objective> and <Endpoint> for each Primary Objective from section 3.1, reuse <Secondary Objective> and <Endpoint> for each Secondary Objective from section 3.2.",
            "ct": []
        }
    },
    "units of minimum age": {
        "template": {
            "long_name": "units of minimum age",
            "short_name": "units of minimum age",
            "original_name": "units of minimum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "units of minimum age",
            "data_type": "Valid Value",
            "definition": "C50400\nFor review purpose, see definition of the controlled terminology below\nThose units of time that are routinely used to express the age of a person.",
            "guidance": "Population age range - For trials in which multiple age ranges may be eligible (for example, a younger cohort and an older cohort), indicate the minimum and maximum ages for the trial overall, with an additional comment for any excluded age ranges.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "hour (C25529), day (C25301), weeks (C29844), months (C29846), years (C29848)",
            "business_rules": "Value Allowed: Yes\nRelationship: Population age; Minimum, Numeric Minimum\nConcept: C50400",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Units of Time",
                    "definition": "A terminology value set relevant to units of time within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25301",
                    "preferred_term": "DAYS",
                    "definition": "A unit of measurement of time equal to 24 hours."
                },
                {
                    "ncit_code": "C25529",
                    "preferred_term": "HOURS",
                    "definition": "A unit of measurement of time equal to 60 minutes."
                },
                {
                    "ncit_code": "C29846",
                    "preferred_term": "MONTHS",
                    "definition": "One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks."
                },
                {
                    "ncit_code": "C29844",
                    "preferred_term": "WEEKS",
                    "definition": "Any period of seven consecutive days."
                },
                {
                    "ncit_code": "C29848",
                    "preferred_term": "YEARS",
                    "definition": "The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period."
                }
            ]
        }
    },
    "maximum age": {
        "template": {
            "long_name": "maximum age",
            "short_name": "maximum age",
            "original_name": "maximum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "maximum age",
            "data_type": "Number",
            "definition": "C49694\nFor review purpose, see definition of the controlled terminology below\nThe anticipated maximum age of the participants to be entered in a clinical trial",
            "guidance": "Population age range - For trials in which multiple age ranges may be eligible (for example, a younger cohort and an older cohort), indicate the minimum and maximum ages for the trial overall, with an additional comment for any excluded age ranges.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Integer",
            "business_rules": "Value Allowed: Yes\nRelationship: population age, Maximum Age; Maximum unit of age\nConcept:C49694",
            "repeating": "No",
            "ct": []
        }
    },
    "units of maximum age": {
        "template": {
            "long_name": "units of maximum age",
            "short_name": "units of maximum age",
            "original_name": "units of maximum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "units of maximum age",
            "data_type": "Valid Value",
            "definition": "C50400\nFor review purpose, see definition of the controlled terminology below\nThose units of time that are routinely used to express the age of a person.",
            "guidance": "Population age range - For trials in which multiple age ranges may be eligible (for example, a younger cohort and an older cohort), indicate the minimum and maximum ages for the trial overall, with an additional comment for any excluded age ranges.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "hour (C25529), day (C25301), weeks (C29844), months (C29846), years (C29848)",
            "business_rules": "Value Allowed: Yes\nRelationship: Population Age; Maximum, Numeric Maximum\nConcept: C50400",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Units of Time",
                    "definition": "A terminology value set relevant to units of time within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25301",
                    "preferred_term": "DAYS",
                    "definition": "A unit of measurement of time equal to 24 hours."
                },
                {
                    "ncit_code": "C25529",
                    "preferred_term": "HOURS",
                    "definition": "A unit of measurement of time equal to 60 minutes."
                },
                {
                    "ncit_code": "C29846",
                    "preferred_term": "MONTHS",
                    "definition": "One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks."
                },
                {
                    "ncit_code": "C29844",
                    "preferred_term": "WEEKS",
                    "definition": "Any period of seven consecutive days."
                },
                {
                    "ncit_code": "C29848",
                    "preferred_term": "YEARS",
                    "definition": "The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period."
                }
            ]
        }
    },
    "Nonproprietary name": {
        "template": {
            "long_name": "Nonproprietary name",
            "short_name": "Nonproprietary name",
            "original_name": "Nonproprietary name",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Nonproprietary name",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the comparator against which the study intervention is evaluated.",
            "guidance": "",
            "conformance": "Conditional : if there is a nonproprietary name or INN or Not applicable",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "[Nonproprietary name] or [INN] or <Enter \u201cN/A\u201d>",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "image": "",
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Nonproprietary name",
            "notes": ""
        }
    },
    "INN": {
        "template": {
            "long_name": "INN",
            "short_name": "INN",
            "original_name": "INN",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "INN",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the comparator against which the study intervention is evaluated.",
            "guidance": "",
            "conformance": "Conditional : if there is a nonproprietary name or INN or Not applicable",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "[Nonproprietary name] or [INN] or <Enter \u201cN/A\u201d>",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "INN",
            "notes": ""
        }
    },
    "Not applicable": {
        "template": {
            "long_name": "Enter \u201cNot applicable\u201d",
            "short_name": "Not applicable",
            "original_name": "\u201cNot applicable\u201d",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Not applicable",
            "data_type": "Text",
            "definition": "Verbatim Text",
            "guidance": "",
            "conformance": "Conditional: if there is no nonproprietary name and INN",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "N/A",
            "business_rules": "Value Allowed: Yes, cannot have not applicable if Nonproprietary or INN are completed\nRelationship: Row title; Control Description; Protocol Identifier\nConcept: Verbatim Text",
            "repeating": "No",
            "ct": []
        }
    },
    "Site geographic scope": {
        "template": {
            "long_name": "Site geographic scope",
            "short_name": "Site geographic scope",
            "original_name": "Site geographic scope",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Site geographic scope",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the trial is taking place in one or more countries.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Single Country (CNEW), Multiple Countries (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title Heading, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Site Geographic Scope Response",
                    "definition": "A terminology value set relevant to the trial site geographic scope responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Single Country",
                    "definition": "Of, or pertaining to, an occurrence in one country."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Multiple Countries",
                    "definition": "Of, or pertaining to, an occurrence in more than one country."
                }
            ]
        }
    },
    "Master Protocol Indicator": {
        "template": {
            "long_name": "Master Protocol Indicator",
            "short_name": "Master Protocol Indicator",
            "original_name": "Master Protocol Indicator",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Master Protocol Indicator",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether this is a master protocol.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Yes (C49488), No(C49487)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading Master Protocol Indicator; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66742",
                    "preferred_term": "NY",
                    "definition": "A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable."
                },
                {
                    "ncit_code": "C49487",
                    "preferred_term": "No",
                    "definition": "The non-affirmative response to a question."
                },
                {
                    "ncit_code": "C49488",
                    "preferred_term": "Yes",
                    "definition": "The affirmative response to a question."
                }
            ]
        }
    },
    "Drug-Device Combination Product Indicator": {
        "template": {
            "long_name": "Drug/Device Combination Product Indicator",
            "short_name": "Drug-Device Combination Product Indicator",
            "original_name": "Drug/Device Combination Product Indicator",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Drug-Device Combination Product Indicator",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the clinical trial is testing a drug device combination product.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Yes (C49488), No(C49487)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading Drug/Device Combination Product; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66742",
                    "preferred_term": "NY",
                    "definition": "A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable."
                },
                {
                    "ncit_code": "C49487",
                    "preferred_term": "No",
                    "definition": "The non-affirmative response to a question."
                },
                {
                    "ncit_code": "C49488",
                    "preferred_term": "Yes",
                    "definition": "The affirmative response to a question."
                }
            ]
        }
    },
    "Adaptive Trial Design Indicator": {
        "template": {
            "long_name": "Adaptive Trial Design Indicator",
            "short_name": "Adaptive Trial Design Indicator",
            "original_name": "Adaptive Trial Design Indicator",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "Further clarification:"
            ]
        },
        "technical": {
            "name": "Adaptative Trial Design Indicator",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the clinical trial uses an adaptive kind of trial design, that is a clinical trial design that allows for prospectively planned modifications to one or more aspects of the design based on accumulating data from subjects in the trial.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Yes (C49488), No(C49487)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "Adaptive Trial Design Indicator"
        }
    },
    "Number of Arms": {
        "template": {
            "long_name": "Number of Arms",
            "short_name": "Number of Arms",
            "original_name": "Number of Arms",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Number of Arms",
            "data_type": "Number",
            "definition": "C98771\nFor review purpose, see definition of the controlled terminology below\nThe planned number of intervention groups.",
            "guidance": "Enter the numeric value for the number of arms in the trial. For trials with a different number of arms in different periods, populate this field based on the period with the greatest number of arms.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Integer",
            "business_rules": "Value Allowed: Yes\nRelationship: Number of Arms, Heading; Sponsor Protocol Identifier\nConcept: C98771",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "name",
                    "klass": "StudyArm",
                    "notes": "Count of the number of arms within the study design",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@arms/StudyArm/@name"
                }
            ],
            "map_status": "Mapped",
            "name": "Number of Arms",
            "notes": ""
        }
    },
    "Trial Blind Schema": {
        "template": {
            "long_name": "Trial Blind Schema",
            "short_name": "Trial Blind Schema",
            "original_name": "Trial Blind Schema",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Trial Blind Schema",
            "data_type": "Valid Value",
            "definition": "C49658\nFor review purpose, see definition of the controlled terminology below\nThe type of experimental design used to describe the level of awareness of the study subjects and/ or study personnel as it relates to the respective intervention(s) or assessments being observed, received or administered.",
            "guidance": "For designs in which these details may differ in one or more trial periods, answer according to the portion of the trial in which the highest number of blinded roles occurs. Additional details can be provided in Section 6.8.3 of the protocol.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Double Blind (C15228), Observer Blind (C187674), Open Label (C49659), Single Blind (C28233)",
            "business_rules": "Value Allowed: Yes\nRelationship: Trial Blind Schema, Heading; Protocol Sponsor Identifier\nConcept: C49658",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66735",
                    "preferred_term": "TBLIND",
                    "definition": "A terminology codelist relevant to the type of blinding for the trial."
                },
                {
                    "ncit_code": "C15228",
                    "preferred_term": "Double Blind",
                    "definition": "A study in which neither the subject nor the study personnel interacting with the subject or data during the study knows what intervention a subject is receiving."
                },
                {
                    "ncit_code": "C187674",
                    "preferred_term": "Observer Blind",
                    "definition": "A study in which the study personnel who measure, record, or assess the subject do not know which intervention the subject is receiving or, in the context of observational studies, do not know the external factors to which a subject has been exposed."
                },
                {
                    "ncit_code": "C49659",
                    "preferred_term": "Open Label",
                    "definition": "A study in which subjects and study personnel know which intervention each subject is receiving."
                },
                {
                    "ncit_code": "C28233",
                    "preferred_term": "Single Blind",
                    "definition": "A study in which one party, either the subject or study personnel, does not know which intervention is administered to the subject."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "blindingSchema",
                    "klass": "StudyDesign",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@blindingSchema"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial Blind Schema",
            "notes": ""
        }
    },
    "Target-Maximum": {
        "template": {
            "long_name": "Target/Maximum",
            "short_name": "Target-Maximum",
            "original_name": "Target/Maximum",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Target-Maximum",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA characterisation or classification of the trial participant numbers as to whether the numbers reflect a target or maximum.",
            "guidance": "State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "A (choose Target/Maximum) of",
            "business_rules": "Value Allowed: Universal Text and Yes\nRelationship: Heading; Sponsor Protocol Identifier  \nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Number of Participants": {
        "template": {
            "long_name": "Enter Number of Participants",
            "short_name": "Number of Participants",
            "original_name": "Number of Participants",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Number of Participants",
            "data_type": "Number",
            "definition": "C49692\nFor review purpose, see definition of the controlled terminology below\nThe planned number of participant be entered in a clinical trial.",
            "guidance": "State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Integer; <Number of Participants> participants will be",
            "business_rules": "Value Allowed: Yes and Universal Text\nRelationship: beheading; Sponsor Protocol Identifiers\nConcept: C49692",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "plannedEnrollmentNumber",
                    "klass": "StudyDesignPopulation",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@plannedEnrollmentNumber"
                },
                {
                    "attribute": "plannedCompletionNumber",
                    "klass": "StudyDesignPopulation",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@plannedCompletionNumber"
                },
                {
                    "attribute": "plannedEnrollmentNumber",
                    "klass": "StudyCohort",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@cohorts/StudyCohort/@plannedEnrollmentNumber"
                },
                {
                    "attribute": "plannedCompletionNumber",
                    "klass": "StudyCohort",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@cohorts/StudyCohort/@plannedCompletionNumber"
                }
            ],
            "map_status": "Mapped",
            "name": "Number of Participants",
            "notes": ""
        }
    },
    "randomly assigned to trial intervention-enrolled": {
        "template": {
            "long_name": "randomly assigned to trial intervention/enrolled",
            "short_name": "randomly assigned to trial intervention-enrolled",
            "original_name": "randomly assigned to trial intervention/enrolled",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "randomly assigned to trial intervention- enrolled",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe target or maximum number of participants who have been randomly assigned to the trial intervention or enrolled in the trial.",
            "guidance": "State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "randomly assigned to trial intervention/enrolled",
            "business_rules": "Value Allowed: Universal Text\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "randomly assigned to trial intervention-enrolled"
        }
    },
    "total planned duration of trial intervention": {
        "template": {
            "long_name": "Enter total planned duration of trial intervention",
            "short_name": "total planned duration of trial intervention",
            "original_name": "total planned duration of trial intervention",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "technical": {
            "name": "total planned duration of trial intervention",
            "data_type": "Integer, Valid value",
            "definition": "",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when Planned Duration of trial Intervention Number and unit of time",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "total planned duration of trial intervention Integer \ntotal planned duration of time unit of time days (C25301), hours (25529), months (C29846), weeks (C29844), years (C29848)",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of trial intervention for each participant:\nConcept: CNEW, CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Units of Time",
                    "definition": "A terminology value set relevant to units of time within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25301",
                    "preferred_term": "DAYS",
                    "definition": "A unit of measurement of time equal to 24 hours."
                },
                {
                    "ncit_code": "C25529",
                    "preferred_term": "HOURS",
                    "definition": "A unit of measurement of time equal to 60 minutes."
                },
                {
                    "ncit_code": "C29846",
                    "preferred_term": "MONTHS",
                    "definition": "One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks."
                },
                {
                    "ncit_code": "C29844",
                    "preferred_term": "WEEKS",
                    "definition": "Any period of seven consecutive days."
                },
                {
                    "ncit_code": "C29848",
                    "preferred_term": "YEARS",
                    "definition": "The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period."
                }
            ]
        }
    },
    "total planned duration of trial intervention unit of time": {
        "template": {
            "long_name": "total planned duration of trial intervention unit of time",
            "short_name": "total planned duration of trial intervention unit of time",
            "original_name": "total planned duration of trial intervention unit of time",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "technical": {
            "name": "total planned duration of trial unit of time",
            "data_type": "Integer, Valid value",
            "definition": "",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when Planned Duration of trial Intervention Number and unit of time",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "total planned duration of trial intervention Integer \ntotal planned duration of time unit of time days (C25301), hours (25529), months (C29846), weeks (C29844), years (C29848)",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of trial intervention for each participant:\nConcept: CNEW, CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Units of Time",
                    "definition": "A terminology value set relevant to units of time within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25301",
                    "preferred_term": "DAYS",
                    "definition": "A unit of measurement of time equal to 24 hours."
                },
                {
                    "ncit_code": "C25529",
                    "preferred_term": "HOURS",
                    "definition": "A unit of measurement of time equal to 60 minutes."
                },
                {
                    "ncit_code": "C29846",
                    "preferred_term": "MONTHS",
                    "definition": "One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks."
                },
                {
                    "ncit_code": "C29844",
                    "preferred_term": "WEEKS",
                    "definition": "Any period of seven consecutive days."
                },
                {
                    "ncit_code": "C29848",
                    "preferred_term": "YEARS",
                    "definition": "The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period."
                }
            ],
            "short_name": "total planned duration of trial intervention unit of time"
        }
    },
    "alternate description of planned duration of trial intervention if duration will vary": {
        "template": {
            "long_name": "Enter alternate description of planned duration of trial intervention if duration will vary",
            "short_name": "alternate description of planned duration of trial intervention if duration will vary",
            "original_name": "alternate description of planned duration of trial intervention if duration will vary",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "alternate description of planned duration of trial intervention if duration will vary",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn alternative textual narrative for the planned duration of trial intervention.",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when an alternate description for planned duration of trial Intervention if the duration varies",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "text",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of trial intervention for each participant:\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "total planned duration of trial participation": {
        "template": {
            "long_name": "Enter total planned duration of trial participation",
            "short_name": "total planned duration of trial participation",
            "original_name": "total planned duration of trial participation",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "technical": {
            "name": "total planned duration of trial participation",
            "data_type": "Integer, Valid value",
            "definition": "",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when planned duration of trial participation number and unit of time",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "total planned duration of trial participation : Integer \n total planned duration of trial participation unit of time: days (C25301), hours (25529), months (C29846), weeks (C29844), years (C29848)",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of trial participation for each participant:\nConcept: CNEW, CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Units of Time",
                    "definition": "A terminology value set relevant to units of time within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25301",
                    "preferred_term": "DAYS",
                    "definition": "A unit of measurement of time equal to 24 hours."
                },
                {
                    "ncit_code": "C25529",
                    "preferred_term": "HOURS",
                    "definition": "A unit of measurement of time equal to 60 minutes."
                },
                {
                    "ncit_code": "C29846",
                    "preferred_term": "MONTHS",
                    "definition": "One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks."
                },
                {
                    "ncit_code": "C29844",
                    "preferred_term": "WEEKS",
                    "definition": "Any period of seven consecutive days."
                },
                {
                    "ncit_code": "C29848",
                    "preferred_term": "YEARS",
                    "definition": "The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period."
                }
            ]
        }
    },
    "total planned duration of trial participation unit of time": {
        "template": {
            "long_name": "total planned duration of trial participation unit of time",
            "short_name": "total planned duration of trial participation unit of time",
            "original_name": "total planned duration of trial participation unit of time",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "or"
            ]
        },
        "technical": {
            "name": "Total planned duration of trial participation unit of time",
            "data_type": "Integer, Valid value",
            "definition": "",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when planned duration of trial participation number and unit of time",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "total planned duration of trial participation : Integer \n total planned duration of trial participation unit of time: days (C25301), hours (25529), months (C29846), weeks (C29844), years (C29848)",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of trial participation for each participant:\nConcept: CNEW, CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Units of Time",
                    "definition": "A terminology value set relevant to units of time within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25301",
                    "preferred_term": "DAYS",
                    "definition": "A unit of measurement of time equal to 24 hours."
                },
                {
                    "ncit_code": "C25529",
                    "preferred_term": "HOURS",
                    "definition": "A unit of measurement of time equal to 60 minutes."
                },
                {
                    "ncit_code": "C29846",
                    "preferred_term": "MONTHS",
                    "definition": "One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks."
                },
                {
                    "ncit_code": "C29844",
                    "preferred_term": "WEEKS",
                    "definition": "Any period of seven consecutive days."
                },
                {
                    "ncit_code": "C29848",
                    "preferred_term": "YEARS",
                    "definition": "The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period."
                }
            ],
            "short_name": "total planned duration of trial participation unit of time"
        }
    },
    "alternate description of planned duration of trial participation if duration will vary": {
        "template": {
            "long_name": "Enter alternate description of planned duration of trial participation if duration will vary",
            "short_name": "alternate description of planned duration of trial participation if duration will vary",
            "original_name": "alternate description of planned duration of trial participation if duration will vary",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "alternate description of planned duration of trial participation if duration will vary",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn alternative narrative for the planned duration of trial participation.",
            "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
            "conformance": "Conditional: when an alternate description for planned duration of trial participation if duration will vary",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Total duration of planned duration of trial participation if duration will vary:\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Additional Description of Duration": {
        "template": {
            "long_name": "Enter Additional Description of Duration",
            "short_name": "Additional Description of Duration",
            "original_name": "Additional Description of Duration",
            "optional": true,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Additional Description of Duration",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative clarifying information regarding the length of time an individual usage of trial intervention or planned time in a trial.",
            "guidance": "If necessary, include any clarifications or cross-references to details in the main body of the protocol in the optional field below.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Duration\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Independent Committees": {
        "template": {
            "long_name": "Enter Independent Committees",
            "short_name": "Independent Committees",
            "original_name": "Independent Committees",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Independent Committees",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn independent group of experts that has oversight over, and conducts periodic review of, specific trial activities.",
            "guidance": "Indicate whether any committee(s) will be reviewing data while the trial is ongoing, and the type of committee. Common examples include Data Monitoring Committee, Dose Escalation Committee, or Endpoint Adjudication Committee; describe others, if applicable. List independent committees in the space indicated. Other committees may be included in the separate space provided. Committees listed here should be fully described in Section 11.4.",
            "conformance": "Required",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "Independent Data Monitoring Committee(C142578), Dose Escalation Committee(C78726), Endpoint Adjudication Committee(C78726), other (C17649), none(C41132)",
            "business_rules": "Value Allowed: Yes, More than one committee can be selected\nRelationship: Independent Committees\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Independent Committee Name Response",
                    "definition": "A terminology value set relevant to the independent committee name responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C142578",
                    "preferred_term": "Independent Data Monitoring Committee",
                    "definition": "A committee established by the sponsor to assess at intervals the progress of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify, or terminate the trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Dose Escalation Committee",
                    "definition": "A type of safety monitoring committee that monitors dose escalation activities in first-in-human trials."
                },
                {
                    "ncit_code": "C78726",
                    "preferred_term": "Endpoint Adjudication Committee",
                    "definition": "An external committee whose purpose is to evaluate study data and decide whether a study endpoint or other criterion has been met."
                },
                {
                    "ncit_code": "C17649",
                    "preferred_term": "Other",
                    "definition": "Different than the one(s) previously specified or mentioned."
                },
                {
                    "ncit_code": "C41132",
                    "preferred_term": "None",
                    "definition": "No person or thing, nobody, not any."
                }
            ]
        }
    },
    "Other Committees": {
        "template": {
            "long_name": "Enter Other Committees",
            "short_name": "Other Committees",
            "original_name": "Other Committees",
            "optional": true,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": [
                "Delete \u201cOther Committees\u201d if not applicable."
            ]
        },
        "technical": {
            "name": "Other Committees",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA committee that is different than the one(s) previously specified or mentioned.",
            "guidance": "Delete \u201cOther Committees\u201d if not applicable.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Other Committees\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Schema": {
        "template": {
            "long_name": "Enter Trial Schema",
            "short_name": "Trial Schema",
            "original_name": "Trial Schema",
            "optional": false,
            "section_number": "1.2",
            "section_title": "Trial Schema",
            "instructions": []
        },
        "technical": {
            "name": "Trial Schema",
            "data_type": "Image; Text",
            "definition": "C93682\nFor review purpose, see definition of the controlled terminology below\nA diagram that outlines the decision points (e.g. randomisation, response evaluation) that define the different paths a participant could take through the trial.",
            "guidance": "The purpose of this section is to provide a visual depiction of the trial design, orienting users of the protocol to the key features of the design. The schema depicts the trial arms, the flow of individual participants through the progression of trial period(s)/epochs (such as screening, washout/run-in, intervention, and key milestones [e.g., randomisation, cross-over, end of treatment, end of study, post-treatment follow-up]). For complex trials, additional schemas may be added to describe activities or trial periods in greater detail.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.2",
            "value": "Image; Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.2 Trial Schema\nConcept: C93682",
            "repeating": "Yes, repeatable within Section",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Trial Schema",
            "notes": ""
        }
    },
    "Schema Notes": {
        "template": {
            "long_name": "Enter Schema Notes",
            "short_name": "Schema Notes",
            "original_name": "Schema Notes",
            "optional": true,
            "section_number": "1.2",
            "section_title": "Trial Schema",
            "instructions": []
        },
        "technical": {
            "name": "Schema Notes",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA brief written record describing the trial schematic.",
            "guidance": "The purpose of this section is to provide a visual depiction of the trial design, orienting users of the protocol to the key features of the design. The schema depicts the trial arms, the flow of individual participants through the progression of trial period(s)/epochs (such as screening, washout/run-in, intervention, and key milestones [e.g., randomisation, cross-over, end of treatment, end of study, post-treatment follow-up]). For complex trials, additional schemas may be added to describe activities or trial periods in greater detail.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.2 Trial Schema\nConcept: CNEW",
            "repeating": "Yes, repeatable and aligned with appropriate schema",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Schema Notes",
            "notes": ""
        }
    },
    "Schedule of Activities": {
        "template": {
            "long_name": "Enter Schedule of Activities",
            "short_name": "Schedule of Activities",
            "original_name": "Schedule of Activities",
            "optional": false,
            "section_number": "1.3",
            "section_title": "Schedule of Activities",
            "instructions": []
        },
        "technical": {
            "name": "Schedule of Activities",
            "data_type": "Table; Text; Image",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA standardised representation of planned clinical trial activities including interventions (e.g. administering drug, surgery) and study administrative activities (e.g. obtaining informed consent, distributing clinical trial material and diaries, randomisation) as well as assessments.",
            "guidance": "The schedule of activities must capture the procedures that will be accomplished at each trial visit, and all contact with participants, e.g., telephone contacts. This includes any tests that are used for eligibility, participant randomisation or stratification, or decisions on trial intervention discontinuation. Allowable windows should be stated for all visits and procedures. A tabular format is recommended.\nWhen applicable for studies with extensive sampling, e.g., serial PK sampling, a separate table may be added",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.3",
            "value": "Table; text; Image",
            "business_rules": "Value Allowed: Yes\nRelationship: 1.3 Schedule of Activities\nConcept: CNEW",
            "repeating": "Yes, repeatable for each Schedule of Activity if needed",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Schedule of Activities",
            "notes": ""
        }
    },
    "Purpose of Trial": {
        "template": {
            "long_name": "Enter Purpose of Trial",
            "short_name": "Purpose of Trial",
            "original_name": "Purpose of Trial",
            "optional": false,
            "section_number": "2.1",
            "section_title": "Purpose of Trial",
            "instructions": []
        },
        "technical": {
            "name": "Purpose of Trial",
            "data_type": "Text",
            "definition": "C146997\nFor review purpose, see definition of the controlled terminology below\nThe overall rationale, reason, or intention of the clinical trial.",
            "guidance": "Explain why the trial is needed, and why the research questions being asked are important. Do not restate the objectives or estimands. Do not restate the IB; rather, cross reference to the IB as applicable to the description.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.1 Purpose of Trial\nConcept: C146997",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial-specific Intervention Risks and Mitigations": {
        "template": {
            "long_name": "Enter Trial-specific Intervention Risks and Mitigations",
            "short_name": "Trial-specific Intervention Risks and Mitigations",
            "original_name": "Trial-specific Intervention Risks and Mitigations",
            "optional": true,
            "section_number": "2.2.1",
            "section_title": "Risk Summary and Mitigation Strategy",
            "instructions": []
        },
        "technical": {
            "name": "Trial-specific Intervention Risks and Mitigations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with the trial interventions and mitigation strategies to be employed within the trial.",
            "guidance": "Trial Intervention \u2013 Describe risks related to trial-specific treatments and interventions. For the protocol, focus on the relevant key risks for THIS trial. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "2.2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2.1 Risk Summary and Mitigation Strategy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial-specific Intervention Risks and Mitigations",
            "notes": ""
        }
    },
    "Trial-specific Procedure Risks and Mitigations": {
        "template": {
            "long_name": "Enter Trial-specific Procedure Risks and Mitigations",
            "short_name": "Trial-specific Procedure Risks and Mitigations",
            "original_name": "Trial-specific Procedure Risks and Mitigations",
            "optional": true,
            "section_number": "2.2.1",
            "section_title": "Risk Summary and Mitigation Strategy",
            "instructions": []
        },
        "technical": {
            "name": "Trial-specific Procedure Risks and Mitigations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with the trial procedures and mitigation strategies to be employed within the trial.",
            "guidance": "Trial Procedures \u2013 Describe risks associated with the design (e.g., placebo arm) and procedures specific to this trial (e.g., biopsies), and any measures to control or mitigate the risks. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section. This is not intended to be an exhaustive list of all possible risks associated with trial procedures but should focus on the unique risks inherent in the design or less common or high-risk procedures. As above, provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "2.2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2.1 Risk Summary and Mitigation Strategy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial-specific Procedure Risks and Mitigations",
            "notes": ""
        }
    },
    "Trial-specific Other Risks and Mitigations": {
        "template": {
            "long_name": "Enter Trial-specific Other Risks and Mitigations",
            "short_name": "Trial-specific Other Risks and Mitigations",
            "original_name": "Trial-specific Other Risks and Mitigations",
            "optional": true,
            "section_number": "2.2.1",
            "section_title": "Risk Summary and Mitigation Strategy",
            "instructions": []
        },
        "technical": {
            "name": "Trial-specific Other Risks and Mitigations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with other trial-related agents and mitigation strategies to be employed within the trial.",
            "guidance": "Other \u2013 Consider risks associated with other items (e.g., challenge agents, imaging agents, medical devices). This could include discussion of risk mitigation for special populations, if not described elsewhere. Insert a line for each, as needed.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "2.2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2.1 Risk Summary and Mitigation Strategy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial-specific Other Risks and Mitigations",
            "notes": ""
        }
    },
    "Benefit Summary": {
        "template": {
            "long_name": "Enter Benefit Summary",
            "short_name": "Benefit Summary",
            "original_name": "Benefit Summary",
            "optional": true,
            "section_number": "2.2.2",
            "section_title": "Benefit Summary",
            "instructions": []
        },
        "technical": {
            "name": "Benefit Summary",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short textual description containing the potential physical, psychological, social, legal, and other benefits to the trial participant.",
            "guidance": "The benefit summary should describe any physical, psychological, social, or any other potential benefits to individual participants as a result of participating in the trial, addressing immediate potential benefits and/or long-range potential benefits. Clearly state if no benefits to an individual participant can be anticipated, or if potential benefits are unknown. For early clinical trials such as Phase 1 or trials in healthy participants, benefits for an individual participant (other than those of altruism) are expected to be minimal. \nBenefits to society in general may also be included but should be described separately from the individual participant perspective.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "2.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2.2 Benefit Summary\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Benefit Summary",
            "notes": ""
        }
    },
    "Overall Risk-Benefit Assessment": {
        "template": {
            "long_name": "Enter Overall Risk-Benefit Assessment",
            "short_name": "Overall Risk-Benefit Assessment",
            "original_name": "Overall Risk-Benefit Assessment",
            "optional": false,
            "section_number": "2.2.3",
            "section_title": "Overall Risk-Benefit Assessment",
            "instructions": []
        },
        "technical": {
            "name": "Overall Risk-Benefit Assessment",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short textual description containing the risks and benefits associated with participation in the trial.",
            "guidance": "Provide a succinct, concluding statement on the perceived balance between risks that have been identified from cumulative safety data, protocol procedures, and anticipated efficacy/benefits within the context of the proposed trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "2.2.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 2.2.3 Overall Risk-Benefit Assessment OR 2.2 Assessment of Risks and Benefits (when the Optional Level 3 subheading (2.2.3) is not used)\nIf the Optional Level 3 subheadings (2.2.1, 2.2.2, 2.2.3) are not used, the user guidance below Section 2.2 applies.\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Primary Objective": {
        "template": {
            "long_name": "Enter Primary Objective",
            "short_name": "Primary Objective",
            "original_name": "Primary Objective",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Primary Objective",
            "data_type": "Text",
            "definition": "C85826\nFor review purpose, see definition of the controlled terminology below\nThe principle reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to One, One to Table of Contents Number 3.1.X, One to Estimand Characteristics Table, Primary Objective X, Protocol Identifier",
            "relationship": "3.1.X: X is a unique number for each primary objective.",
            "value": "Text and unique integer which is same as Level 3 number for the section.",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.1.X Primary Objective \nConcept: C85826",
            "repeating": "Yes, repeatable for each numbered primary objective.\nYes, reuse to the table in Section 1.1.1.for each primary objective",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "Objective",
                    "notes": "Where the objective level is 'primary'",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@objectives/Objective/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Primary Objective",
            "notes": ""
        }
    },
    "Table of Estimand Characteristics including Endpoint at a minimum": {
        "template": {
            "long_name": "Enter Table of Estimand Characteristics including Endpoint at a minimum",
            "short_name": "Table of Estimand Characteristics including Endpoint at a minimum",
            "original_name": "Table of Estimand Characteristics including Endpoint at a minimum",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Table of Estimand Characteristics including Endpoint at a minimum",
            "data_type": "Text",
            "definition": "N/A",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "3.1.X: X is a unique number for each primary objective",
            "value": "Estimand Characteristics",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.1.1 Primary Objective\nConcept: Heading",
            "repeating": "Yes, repeatable for each numbered primary objective.\nYes, reuse to the table in Section 1.1.1.for each primary objective",
            "ct": []
        }
    },
    "Population": {
        "template": {
            "long_name": "Enter Population",
            "short_name": "Population",
            "original_name": "Population",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Population",
            "data_type": "Text",
            "definition": "C70833\nFor review purpose, see definition of the controlled terminology below\nThe population of patients targeted by the clinical question. This will be represented by the entire trial population, a subgroup defined by a particular characteristic measured at baseline, or a principal stratum defined by the occurrence (or non-occurrence, depending on context) of a specific intercurrent event.",
            "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status)",
            "conformance": "Conditional: If there is a population as estimand characteristic",
            "cardinality": "One to Row Heading, One to Primary Objective Table, Primary Objective X, Protocol Identifier",
            "relationship": "3.1.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description\nConcept: C70833",
            "repeating": "Yes, repeatable for each numbered primary objective",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Population",
            "notes": ""
        }
    },
    "Treatment": {
        "template": {
            "long_name": "Enter Treatment",
            "short_name": "Treatment",
            "original_name": "Treatment",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Treatment",
            "data_type": "Text",
            "definition": "C49236\nFor review purpose, see definition of the controlled terminology below\nThe treatment condition of interest and, as appropriate, the alternative treatment condition to which comparison will be made (referred to as \u201ctreatment\u201d through the remainder of this document). These might be individual interventions, combinations of interventions administered concurrently, e.g. as add-on to standard of care, or might consist of an overall regimen involving a complex sequence of interventions.",
            "guidance": "List of key aspects of treatment regimens in each study group, including at least investigational agents, dosage, and administration route",
            "conformance": "Conditional: If there is a treatment as estimand characteristic",
            "cardinality": "One to Row Heading, One to Primary Objective Table, Project Identifier",
            "relationship": "3.1.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description\nConcept: C49236",
            "repeating": "Yes, repeatable for each numbered primary objective",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Treatment",
            "notes": ""
        }
    },
    "Endpoint": {
        "template": {
            "long_name": "Enter Endpoint",
            "short_name": "Endpoint",
            "original_name": "Endpoint",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Endpoint",
            "data_type": "Text",
            "definition": "C25212\nFor review purpose, see definition of the controlled terminology below\nThe variable to be obtained for each patient that is required to address the clinical question. The specification of the variable might include whether the patient experiences an intercurrent event",
            "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status))",
            "conformance": "Required",
            "cardinality": "One to Row Heading, One to Primary Objective Table, Project Identifier",
            "relationship": "3.1.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description\nConcept: C25212",
            "repeating": "Yes, repeatable for each numbered primary objective",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Endpoint",
            "notes": ""
        }
    },
    "Description of Intercurrent Event": {
        "template": {
            "long_name": "Enter Description of Intercurrent Event",
            "short_name": "Description of Intercurrent Event",
            "original_name": "Description of Intercurrent Event",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Description of Intercurrent Event",
            "data_type": "Text",
            "definition": "C188853\nFor review purpose, see definition of the controlled terminology below\nA textual description of the planned strategy to address intercurrent events.",
            "guidance": "Enter Description of Intercurrent Event",
            "conformance": "Conditional: If there is one or more other intercurrent events as estimand characteristic.",
            "cardinality": "One to one",
            "relationship": "3.1.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Estimand Characteristics \nConcept: C188853",
            "repeating": "Yes, repeatable for each intercurrent event",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Description of Intercurrent Event",
            "notes": ""
        }
    },
    "Intercurrent Event 1 Strategy": {
        "template": {
            "long_name": "Enter Intercurrent Event 1 Strategy",
            "short_name": "Intercurrent Event 1 Strategy",
            "original_name": "Intercurrent Event 1 Strategy",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Intercurrent Event 1 Strategy",
            "data_type": "Text",
            "definition": "C188857\nFor review purpose, see definition of the controlled terminology below\nA textual description of the planned strategy to address intercurrent events.",
            "guidance": "Description of the strategy to address the intercurrent event (e.g. a treatment policy strategy); cross-reference the justification in Section 4. If there is >1 intercurrent event for an objective, add additional intercurrent event rows",
            "conformance": "Conditional: If there is one or more other intercurrent events as estimand characteristic.",
            "cardinality": "One to one",
            "relationship": "3.1.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Strategy, Description\nConcept: C188857",
            "repeating": "Yes, repeatable for each intercurrent event",
            "ct": []
        }
    },
    "Secondary Objective": {
        "template": {
            "long_name": "Enter Secondary Objective",
            "short_name": "Secondary Objective",
            "original_name": "Secondary Objective",
            "optional": false,
            "section_number": "3.2.1",
            "section_title": "{Secondary Objective}",
            "instructions": []
        },
        "technical": {
            "name": "Secondary Objective Number",
            "data_type": "Number",
            "definition": "N/A",
            "guidance": "",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "3.2.X",
            "value": "an integer, unique number",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.2.X Secondary Objective\nConcept: Sequential number",
            "repeating": "Yes, repeatable for each numbered secondary objective.",
            "ct": [],
            "short_name": "Secondary Objective"
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "Objective",
                    "notes": "Where the objective level is 'secondary'",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@objectives/Objective/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Secondary Objective",
            "notes": ""
        }
    },
    "Exploratory Objective": {
        "template": {
            "long_name": "Enter Exploratory Objective",
            "short_name": "Exploratory Objective",
            "original_name": "Exploratory Objective",
            "optional": false,
            "section_number": "3.3.1",
            "section_title": "{Exploratory Objective}",
            "instructions": []
        },
        "technical": {
            "name": "Exploratory Objective",
            "data_type": "Text",
            "definition": "C163559\nFor review purpose, see definition of the controlled terminology below\nThe exploratory reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
            "guidance": "State each exploratory objective. This should generally include documentation of associated exploratory endpoints. It may be helpful in some cases to describe precise estimands to provide clarity on what is being estimated.",
            "conformance": "Conditional: if an exploratory objective is part of the trial",
            "cardinality": "One to Table of Contents Number 3.3.X, One to Estimand Characteristic Table, Exploratory Objective X, Protocol Identifier",
            "relationship": "3.3.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 3.3.X Exploratory Objective(s)\nConcept: C163559",
            "repeating": "Yes, repeatable for each numbered exploratory objective.",
            "ct": []
        }
    },
    "Overall Description of Trial Design and Description of Intervention Model": {
        "template": {
            "long_name": "Enter Overall Description of Trial Design and Description of Intervention Model",
            "short_name": "Overall Description of Trial Design and Description of Intervention Model",
            "original_name": "Overall Description of Trial Design and Description of Intervention Model",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": []
        },
        "technical": {
            "name": "Overall Description of Trial Design and Description of Intervention Model",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the trial duration.",
            "guidance": "Describe the overall trial design and intervention model (e.g., single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (e.g., placebo, active comparator, low dose, external, standard of care, sham procedure, or none [uncontrolled]). If there are any key aspects of the investigational trial intervention that inform the selection of the intervention model, this should be described.\nIf applicable, indicate other design characteristics (e.g., superiority, noninferiority, dose escalation, or equivalence).\nIf the trial will have an adaptive or novel design (e.g., the trial will be conducted under a master protocol), provide a summary of these design aspects.\nIf applicable, describe within-trial transition rules, e.g., transitions involving cohorts or trial parts. Dose escalation or dose-ranging details should also be described.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Description of Trial Duration": {
        "template": {
            "long_name": "Enter Description of Trial Duration",
            "short_name": "Description of Trial Duration",
            "original_name": "Description of Trial Duration",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": []
        },
        "technical": {
            "name": "Description of Trial Duration",
            "data_type": "Text",
            "definition": "",
            "guidance": "Describe the trial duration with reference to Section 1.2 Trial Schema. Explain what the overall duration for an individual participant is anticipated to be and why, including the sequence and duration of trial periods (e.g., screening, run-in, randomisation, treatment [fixed dose/titration], follow-up/washout periods). Where applicable, include discussion of sentinel dosing (or lack thereof), dose escalation, and cohort expansion. If dose modification decisions are dependent upon review by a committee, include details in Section 11.4 Committees.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Description of Trial Duration",
            "notes": ""
        }
    },
    "Method of Assignment to Trial Intervention": {
        "template": {
            "long_name": "Enter Method of Assignment to Trial Intervention",
            "short_name": "Method of Assignment to Trial Intervention",
            "original_name": "Method of Assignment to Trial Intervention",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": []
        },
        "technical": {
            "name": "Method of Assignment to Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe technique used to assign trial participants to a trial intervention or trial arm.",
            "guidance": "State the method of assignment to trial intervention the level and method of blinding that will be used with reference to Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Method of Assignment to Trial Intervention",
            "notes": ""
        }
    },
    "Description of Level and Method of Blinding": {
        "template": {
            "long_name": "Enter Description of Level and Method of Blinding",
            "short_name": "Description of Level and Method of Blinding",
            "original_name": "Description of Level and Method of Blinding",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": [
                "Describe any other important aspects of the design, e.g.:"
            ]
        },
        "technical": {
            "name": "Description of Level and Method of Blinding",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the level of awareness of the study participants and/or personnel to the respective intervention(s) or assessments being observed, received or administered",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Additional Description of Trial Design": {
        "template": {
            "long_name": "Enter Additional Description of Trial Design",
            "short_name": "Additional Description of Trial Design",
            "original_name": "Additional Description of Trial Design",
            "optional": true,
            "section_number": "4.1",
            "section_title": "Description of Trial Design",
            "instructions": []
        },
        "technical": {
            "name": "Additional Description of Trial Design",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn extra or further textual representation of the trial design.",
            "guidance": "",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Additional Description of Trial Design",
            "notes": ""
        }
    },
    "Stakeholder Input into Design": {
        "template": {
            "long_name": "Enter Stakeholder Input into Design",
            "short_name": "Stakeholder Input into Design",
            "original_name": "Stakeholder Input into Design",
            "optional": false,
            "section_number": "4.1.1",
            "section_title": "Stakeholder Input into Design",
            "instructions": []
        },
        "technical": {
            "name": "Stakeholder Input into Design",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe textual representation of the way in which trial stakeholders were consulted when determining the trial design.",
            "guidance": "If applicable, describe any stakeholder (e.g., patient, healthcare professional and patient advocacy groups) involvement in the design of the trial and any suggestions implemented.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "4.1.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.1.1 Stakeholder Input into Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Overall Rationale for Trial Design": {
        "template": {
            "long_name": "Enter Overall Rationale for Trial Design",
            "short_name": "Overall Rationale for Trial Design",
            "original_name": "Overall Rationale for Trial Design",
            "optional": true,
            "section_number": "4.2",
            "section_title": "Rationale for Trial Design",
            "instructions": [
                "OR"
            ]
        },
        "technical": {
            "name": "Overall Rationale for Trial Design",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial design considerations that are different than the one(s) previously specified or mentioned.",
            "guidance": "N/A",
            "conformance": "Conditional: If Level 3 subheadings are not used",
            "cardinality": "One to one",
            "relationship": "4.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2 Rationale for Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rationale for Estimands": {
        "template": {
            "long_name": "Enter Rationale for Estimand(s)",
            "short_name": "Rationale for Estimands",
            "original_name": "Rationale for Estimand(s)",
            "optional": false,
            "section_number": "4.2.1",
            "section_title": "Rationale for Estimand(s)",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the trial estimand features.",
            "guidance": "When estimands are associated with the Primary and Secondary Objectives described in Section 3 Trial Objectives and Associated Estimands, provide a rationale for the estimand not described elsewhere in the document. This should include a rationale that the selected endpoint(s) are clinically relevant and provide a reliable and valid measurement of the intended intervention effect. It should also include a rationale for the selected strategies for handling intercurrent events.",
            "conformance": "Conditional: when<Overall Rationale for Trial Design> is not used",
            "cardinality": "One to one",
            "relationship": "4.2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.1 Rationale for Estimand(s)\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Rationale for Estimands",
            "notes": ""
        }
    },
    "Rationale for Intervention Model": {
        "template": {
            "long_name": "Enter Rationale for Intervention Model",
            "short_name": "Rationale for Intervention Model",
            "original_name": "Rationale for Intervention Model",
            "optional": false,
            "section_number": "4.2.2",
            "section_title": "Rationale for Intervention Model",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Trial Intervention Model",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for why the intervention model was chosen for the trial.",
            "guidance": "Provide a rationale for the trial intervention model described in Section 4.1 Description of Trial Design with a cross-reference to Section 6.2 Rationale for Investigational Intervention Dose and Regimen. Rationale for choice of comparator, if applicable, should be described separately in Section 4.2.5 Rationale for Control Type. A rationale for the choice of trial population should be described separately in Section 5.1 Description of Trial Population and Rationale.",
            "conformance": "Conditional: when <Overall Rationale for Trial Design> is not used",
            "cardinality": "One to one",
            "relationship": "4.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.2 Rational for Intervention Model\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "Rationale for Intervention Model"
        }
    },
    "Rationale for Control Type": {
        "template": {
            "long_name": "Enter Rationale for Control Type",
            "short_name": "Rationale for Control Type",
            "original_name": "Rationale for Control Type",
            "optional": false,
            "section_number": "4.2.3",
            "section_title": "Rationale for Control Type",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Control Type",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the control types used in the trial.",
            "guidance": "If applicable, provide a rationale for the type and choice of control selected for the trial (e.g., placebo, active drug, combination, external). Describe any known or potential problems associated with the control group selected in light of the specific disease and intervention(s) being studied. If comparators will differ by region, describe. The rationale for dose/dose regimen is explained in Section 6.2 Rationale for Investigational Trial Intervention Dose and Regimen.",
            "conformance": "Conditional: when <Overall Rationale for Trial Design> is not used",
            "cardinality": "One to one",
            "relationship": "4.2.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.3 Rational for Control Type\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Rationale for Control Type",
            "notes": ""
        }
    },
    "Rationale for Duration": {
        "template": {
            "long_name": "Enter Rationale for Duration",
            "short_name": "Rationale for Duration",
            "original_name": "Rationale for Duration",
            "optional": false,
            "section_number": "4.2.4",
            "section_title": "Rationale for Trial Duration",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Duration",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the trial duration.",
            "guidance": "Provide a rationale that the trial duration is appropriate for a reliable and relevant evaluation of the trial intervention per the trial objective(s).",
            "conformance": "Conditional: when <Overall Rationale for Trial Design> is not used",
            "cardinality": "One to one",
            "relationship": "4.2.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.4 Rationale for Duration\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rationale for Adaptive or Novel Trial Design": {
        "template": {
            "long_name": "Enter Rationale for Adaptive or Novel Trial Design",
            "short_name": "Rationale for Adaptive or Novel Trial Design",
            "original_name": "Rationale for Adaptive or Novel Trial Design",
            "optional": false,
            "section_number": "4.2.5",
            "section_title": "Rationale for Adaptive or Novel Trial Design",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Adaptive or Novel Trial Design",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for why an adaptive or novel trial design was chosen for the trial.",
            "guidance": "If applicable, provide a rationale for the use of an adaptive or novel design.",
            "conformance": "Conditional: when <Overall Rationale for Trial Design> is not used",
            "cardinality": "One to one",
            "relationship": "4.2.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.5 Rational for Adoptive or Novel Trial Design\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rationale for Interim Analysis": {
        "template": {
            "long_name": "Enter Rationale for Interim Analysis",
            "short_name": "Rationale for Interim Analysis",
            "original_name": "Rationale for Interim Analysis",
            "optional": false,
            "section_number": "4.2.6",
            "section_title": "Rationale for Interim Analysis",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Interim Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation for the analysis comparing intervention groups at any time before the formal completion of the trial, usually before recruitment is complete.",
            "guidance": "If applicable, provide a rationale for any interim analysis planned with respect to its purpose (e.g., stopping the trial early for efficacy or futility) and timing.",
            "conformance": "Conditional: when<Overall Rationale for Trial Design> is not used",
            "cardinality": "One to one",
            "relationship": "4.2.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.6 Rational for Interim Analysis\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Rationale for Interim Analysis",
            "notes": ""
        }
    },
    "Rationale for Other Trial Design Aspects": {
        "template": {
            "long_name": "Enter Rationale for Other Trial Design Aspects",
            "short_name": "Rationale for Other Trial Design Aspects",
            "original_name": "Rationale for Other Trial Design Aspects",
            "optional": false,
            "section_number": "4.2.7",
            "section_title": "Rationale for Other Trial Design Aspects",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Other Trial Design Aspects",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for additional trial design considerations that are different than the one(s) previously specified or mentioned.",
            "guidance": "Discuss rationale for any additional aspects of the design not addressed above.",
            "conformance": "Conditional: when <Overall Rationale for Trial Design> is not used",
            "cardinality": "One to one",
            "relationship": "4.2.7",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.2.7 Rational for Other Trial Design Aspects\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Stopping Rules": {
        "template": {
            "long_name": "Enter Trial Stopping Rules",
            "short_name": "Trial Stopping Rules",
            "original_name": "Trial Stopping Rules",
            "optional": false,
            "section_number": "4.3",
            "section_title": "Trial Stopping Rules",
            "instructions": []
        },
        "technical": {
            "name": "Trial Stopping Rules",
            "data_type": "Text",
            "definition": "C142698\nFor review purpose, see definition of the controlled terminology below \nA criterion that, when met by the accumulating data, indicates that the trial can or should be stopped early to avoid putting participants at risk unnecessarily or because the intervention effect is so great that further data collection is unnecessary.",
            "guidance": "If applicable, describe any trial-specific stopping rules, including guidance on when the trial should be stopped for efficacy or safety reasons, when a cohort or dose escalation should be terminated, and/or when a given treatment arm should be terminated. If applicable, describe any rules that may result in a temporary pause of dosing and/or enrollment into the trial and criteria for restarting enrollment. Ensure that the trial stopping rules are aligned with the specifications that are described in Section 10.9 for Interim Analyses.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "4.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.3 Trial Stopping Rules\nConcept: C142698",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial Stopping Rules",
            "notes": ""
        }
    },
    "Start of Trial": {
        "template": {
            "long_name": "Enter Start of Trial",
            "short_name": "Start of Trial",
            "original_name": "Start of Trial",
            "optional": false,
            "section_number": "4.4",
            "section_title": "Start of Trial and End of Trial",
            "instructions": []
        },
        "technical": {
            "name": "Start of Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description containing a concise explanation, any local regulatory requirements and considerations, extensions, follow-up, and analysis for the trial start.",
            "guidance": "Define key timepoints in the trial, including trial start and end definitions. (e.g., a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant\u2019s last trial assessment has occurred). Consider local regulatory requirements for these and other definitions (e.g., the first act of recruitment).\nIf appropriate, provide a cross-reference to Section 11.11 Early Site Closure.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "4.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.4 Start of Trial and End of Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Start of Trial",
            "notes": ""
        }
    },
    "End of Trial": {
        "template": {
            "long_name": "Enter End of Trial",
            "short_name": "End of Trial",
            "original_name": "End of Trial",
            "optional": false,
            "section_number": "4.4",
            "section_title": "Start of Trial and End of Trial",
            "instructions": []
        },
        "technical": {
            "name": "End of Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description containing a concise explanation, any local regulatory requirements and considerations, extensions, follow-up, and analysis for the trial end.",
            "guidance": "Define key timepoints in the trial, including trial start and end definitions. (e.g., a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant\u2019s last trial assessment has occurred). If applicable, consider local regulatory requirements for these and other definitions (e.g., the first act of recruitment).\nIf appropriate, provide a cross-reference to Section 11.10 Early Site Closure.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "4.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.4 Start of Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "End of Trial",
            "notes": ""
        }
    },
    "Access to Trial Intervention after End of Trial": {
        "template": {
            "long_name": "Enter Access to Trial Intervention after End of Trial",
            "short_name": "Access to Trial Intervention after End of Trial",
            "original_name": "Access to Trial Intervention after End of Trial",
            "optional": false,
            "section_number": "4.5",
            "section_title": "Access to Trial Intervention After End of Trial",
            "instructions": []
        },
        "technical": {
            "name": "Access to Trial Intervention after End of Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual representation containing information about whether and how trial participants have access to the trial interventions after the trial ends.",
            "guidance": "If applicable, describe any possibilities for access to trial intervention, if any, beyond completion of the trial. Planned extension trials, if described in Section 4.1 Description of Trial Design do not need to be repeated in this section.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "4.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 4.5 Access to Trial Intervention After End of Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Access to Trial Intervention after End of Trial",
            "notes": ""
        }
    },
    "Description of Trial Population and Rationale": {
        "template": {
            "long_name": "Enter Description of Trial Population and Rationale",
            "short_name": "Description of Trial Population and Rationale",
            "original_name": "Description of Trial Population and Rationale",
            "optional": false,
            "section_number": "5.1",
            "section_title": "Description of Trial Population and Rationale",
            "instructions": []
        },
        "technical": {
            "name": "Description of Trial Population and Rationale",
            "data_type": "Text",
            "definition": "CNEW\nA narrative representation of the rationale for selection of trial population describing how the selected population can meet the trial objectives and how the enrolment criteria reflect the targeted populations.",
            "guidance": "Describe the population selected (e.g., healthy participants, adult participants, paediatric participants) and how the enrollment criteria reflect the populations that are likely to use the drug if approved. Specify the population age range (e.g., \u22643 months, \u226518 to \u226480 years old) including the time point at which qualification for age criteria is determined (e.g., at time of screening vs randomisation for paediatric trials). Specify any key diagnostic criteria for the population (e.g., \u201cacute lung injury\u201d, or a specific biomarker profile). If applicable, describe similar conditions or diseases and their differential diagnosis. \nProvide a rationale for the trial population ensuring that the population selected is well defined and clinically recognisable. Describe how the selected population can meet the trial objectives and how the enrollment criteria reflect the population of interest.\nIf the population targeted by a clinical question is based on a subset of the entire trial population, e.g., defined by a particular characteristic measured at baseline (e.g. a specific biomarker), this subset should be justified in this section.\nJustify whether the trial intervention is to be evaluated in paediatric participants, in adults unable to consent for themselves, other vulnerable participant populations, or those that may respond to the trial intervention differently (e.g., elderly, hepatic or renally impaired, or immunocompromised participants).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.1 Description of Trial Population and Rationale\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Description of Trial Population and Rationale",
            "notes": ""
        }
    },
    "Definitions Related to Childbearing Potential": {
        "template": {
            "long_name": "Enter Definitions Related to Childbearing Potential ",
            "short_name": "Definitions Related to Childbearing Potential",
            "original_name": "Definitions Related to Childbearing Potential ",
            "optional": false,
            "section_number": "5.4.1",
            "section_title": "Definitions Related to Childbearing Potential",
            "instructions": [
                "<",
                "Enter Definitions Related to Childbearing Potential ",
                ">"
            ]
        },
        "technical": {
            "name": "Definitions Related to Childbearing Potential",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of participants of childbearing potential and non-childbearing potential within the context of a trial, or state not applicable.",
            "guidance": "Specify the definitions of:\nparticipant of childbearing potential\nparticipant of nonchildbearing potential",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.4.1 Definitions Related to Childbearing Potential\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Definitions Related to Childbearing Potential",
            "notes": ""
        }
    },
    "Contraception Requirements": {
        "template": {
            "long_name": "Enter Contraception Requirements.",
            "short_name": "Contraception Requirements",
            "original_name": "Contraception Requirements.",
            "optional": false,
            "section_number": "5.4.2",
            "section_title": "Contraception Requirements",
            "instructions": [
                "<",
                "Enter Contraception Requirements.",
                ">"
            ]
        },
        "technical": {
            "name": "Contraception Requirements",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the requirements for the prevention of conception or impregnation by the use of devices or drugs or surgery within a context of a trial l, or state not applicable.",
            "guidance": "Specify the: \ncontraceptive methods required \nduration of use",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.4.2 Contraception requirements\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Contraception Requirements",
            "notes": ""
        }
    },
    "Lifestyle Restrictions": {
        "template": {
            "long_name": "Enter Lifestyle Restrictions",
            "short_name": "Lifestyle Restrictions",
            "original_name": "Lifestyle Restrictions",
            "optional": false,
            "section_number": "5.5",
            "section_title": "Lifestyle Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Lifestyle Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the restrictions related to trial participant lifestyle such as diet, substance intake, and physical or other daily activities.",
            "guidance": "In the following subsections, describe any restrictions during the trial pertaining to lifestyle and/or diet, intake of caffeine, alcohol, or tobacco, or physical and other activities. If not applicable, include a statement that no restrictions are required.",
            "conformance": "Conditional: If Level 3 subheadings are not used",
            "cardinality": "One to one",
            "relationship": "5.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5\t Lifestyle Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Lifestyle Restrictions",
            "notes": ""
        }
    },
    "Meals and Dietary Restrictions": {
        "template": {
            "long_name": "Enter Meals and Dietary Restrictions",
            "short_name": "Meals and Dietary Restrictions",
            "original_name": "Meals and Dietary Restrictions",
            "optional": false,
            "section_number": "5.5.1",
            "section_title": "Meals and Dietary Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Meals and Dietary Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the restrictions related to participant diet during the trial.",
            "guidance": "If applicable, describe any restrictions on diet (e.g., food and drink restrictions, timing of meals relative to dosing, etc.).",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5.1 Meals and Dietary Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Meals and Dietary Restrictions",
            "notes": ""
        }
    },
    "Caffeine Alcohol Tobacco and Other Restrictions": {
        "template": {
            "long_name": "Enter Caffeine, Alcohol, Tobacco, and Other Restrictions",
            "short_name": "Caffeine Alcohol Tobacco and Other Restrictions",
            "original_name": "Caffeine, Alcohol, Tobacco, and Other Restrictions",
            "optional": false,
            "section_number": "5.5.2",
            "section_title": "Caffeine, Alcohol, Tobacco, and Other Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Caffeine Alcohol Tobacco and Other Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the restrictions related to participant intake of caffeine, alcohol, tobacco, and other habit-forming substances during the trial.",
            "guidance": "If applicable, describe any restrictions on the intake of caffeine, alcohol, tobacco, or other restrictions.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.2.2 Caffeine, Alcohol, Tobacco, and Other Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Physical Activity Restrictions": {
        "template": {
            "long_name": "Enter Physical Activity Restrictions",
            "short_name": "Physical Activity Restrictions",
            "original_name": "Physical Activity Restrictions",
            "optional": false,
            "section_number": "5.5.3",
            "section_title": "Physical Activity Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Physical Activity Restrictions",
            "data_type": "Text",
            "definition": "C17708\nFor review purpose, see definition of the controlled terminology below\nAny form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc.",
            "guidance": "If applicable, describe any restrictions on activity (e.g., in first-in-human trials, activity may be restricted by ensuring participants remain in bed for 4 to 6 hours after dosing).",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5.3 Physical Activity Restrictions\nConcept: C17708",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Physical Activity Restrictions",
            "notes": ""
        }
    },
    "Other Activity Restrictions": {
        "template": {
            "long_name": "Enter Other Activity Restrictions",
            "short_name": "Other Activity Restrictions",
            "original_name": "Other Activity Restrictions",
            "optional": false,
            "section_number": "5.5.4",
            "section_title": "Other Activity Restrictions",
            "instructions": []
        },
        "technical": {
            "name": "Other Activity Restrictions",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn activity that is different than the one(s) previously specified or mentioned.",
            "guidance": "If applicable, describe restrictions on any other activity (e.g., blood or tissue donation, driving, heavy machinery use, or sun exposure).",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "5.5.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.5.4 Other Activity Restrictions\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Other Activity Restrictions",
            "notes": ""
        }
    },
    "Screen Failure": {
        "template": {
            "long_name": "Enter Screen Failure",
            "short_name": "Screen Failure",
            "original_name": "Screen Failure",
            "optional": false,
            "section_number": "5.6",
            "section_title": "Screen Failure and Rescreening",
            "instructions": []
        },
        "technical": {
            "name": "Screen Failure",
            "data_type": "Text",
            "definition": "C49628\nFor review purpose, see definition of the controlled terminology below\nThe potential subject who does not meet eligibility (inclusion/exclusion) criteria during the screening period.",
            "guidance": "Describe screen failure and indicate how screen failure will be handled in the trial, including conditions and criteria upon which rescreening is acceptable. If applicable, indicate the circumstances and time window under which a repeat procedure is allowed for screen failure relating to specific inclusion/exclusion criteria for the trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.6 Screen Failure and Rescreening\nConcept: C49628",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Screen Failure",
            "notes": ""
        }
    },
    "Rescreening": {
        "template": {
            "long_name": "Enter Rescreening",
            "short_name": "Rescreening",
            "original_name": "Rescreening",
            "optional": false,
            "section_number": "5.6",
            "section_title": "Screen Failure and Rescreening",
            "instructions": []
        },
        "technical": {
            "name": "Rescreening",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe process of active consideration of subjects for enrolment in a trial, for those potential subjects who have failed a prior screening attempt.",
            "guidance": "Describe screen failure and indicate how screen failure will be handled in the trial, including conditions and criteria upon which rescreening is acceptable. If applicable, indicate the circumstances and time window under which a repeat procedure is allowed for screen failure relating to specific inclusion/exclusion criteria for the trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "5.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 5.6 Screen Failure and Rescreening\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Rescreening",
            "notes": ""
        }
    },
    "description of the overview of trial interventions or a heading for the optional table below": {
        "template": {
            "long_name": "Enter description of the overview of trial interventions or a heading for the optional table below",
            "short_name": "description of the overview of trial interventions or a heading for the optional table below",
            "original_name": "description of the overview of trial interventions or a heading for the optional table below",
            "optional": false,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Description of the overview of trial interventions or a heading for the optional table below",
            "data_type": "Text",
            "definition": "CNEW",
            "guidance": "Trial interventions are all pre-specified, investigational and non-investigational medicinal products, medical devices or other interventions intended for the participants during the trial. The investigational trial intervention is the product used in the trial as part of trial objectives. Description of investigational trial intervention is provided in Section 6.1. Other trial interventions that are not part of trial objectives (not an investigational role in this trial) are described in Section 6.9 Description of Non-investigational trial interventions. \nAny regional requirements should be noted in the appropriate subsections. \nProvide an overview of investigational and non-investigational trial interventions. Classify the trial intervention as IMP, NIMP/AxMP designations based on study design and local legislation. Consider the optional table below",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6 TRIAL INTERVENTION AND CONCOMITANT THERAPY\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "description of the overview of trial interventions or a heading for the optional table below"
        }
    },
    "Arm Name": {
        "template": {
            "long_name": "Enter Arm Name",
            "short_name": "Arm Name",
            "original_name": "Arm Name",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Arm Name",
            "data_type": "Text",
            "definition": "C93729\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) for the arm.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to many; one to interventions for arm name",
            "relationship": "6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name \nConcept: C93729",
            "repeating": "Yes, repeatable for each arm name and intervention and use combination",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Arm Name",
            "notes": ""
        }
    },
    "Intervention Name": {
        "template": {
            "long_name": "Enter Intervention Name",
            "short_name": "Intervention Name",
            "original_name": "Intervention Name",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Intervention Name",
            "data_type": "Text",
            "definition": "C177930\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) for the study intervention.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to arm name and arm type",
            "relationship": "6",
            "value": "Nonproprietary name or Sponsor Investigational Product Code",
            "business_rules": "Value Allowed: Yes\nRelationship: Arm name and intervention name, Concept: C177930",
            "repeating": "Yes, repeatable for each arm name and arm type",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Intervention Name",
            "notes": ""
        }
    },
    "Dosage Strengths": {
        "template": {
            "long_name": "Enter Dosage Strength(s)",
            "short_name": "Dosage Strengths",
            "original_name": "Dosage Strength(s)",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Dosage Strengths",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe strength of a drug product, which indicates the amount of each active ingredient in a given dosage form, measured in units of volume or concentration.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each dosage formulation",
            "relationship": "Trial Intervention and Concomitant Therapy",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and dose strength, 6 Trial Intervention and Concomitant Therapy\nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention and formulation per arm name and arm type",
            "ct": []
        }
    },
    "Dosage Levels": {
        "template": {
            "long_name": "Enter Dosage Level(s)",
            "short_name": "Dosage Levels",
            "original_name": "Dosage Level(s)",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Dosage Levels",
            "data_type": "Text",
            "definition": "C94394\nFor review purpose, see definition of the controlled terminology below\nSpecified quantity of a medicine, to be taken at one time or at stated intervals. [ISO 11615:2012 Health Informatics]",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention and dosage formulation",
            "relationship": "6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and dose level\nConcept: C94394",
            "repeating": "Yes, repeatable for each intervention, dose formulation, dosage strength and dosage level per arm",
            "ct": []
        }
    },
    "Regimen-Treatment Period-Vaccination Regimen": {
        "template": {
            "long_name": "Enter Regimen/Treatment Period/Vaccination Regimen",
            "short_name": "Regimen-Treatment Period-Vaccination Regimen",
            "original_name": "Regimen/Treatment Period/Vaccination Regimen",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Regimen-Treatment Period-Vaccination regimen",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the schedule and periodicity of a treatment or vaccination regimen.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention, dose formulation, dosage strength per arm",
            "relationship": "6",
            "value": "Regimen/Treatment Period",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and regimen/treatment period/vaccine regimen, Concept: CNEW",
            "repeating": "Yes, repeatable for each arm name",
            "ct": [],
            "short_name": "Regimen-Treatment Period-Vaccination Regimen"
        }
    },
    "Description of Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Description of Investigational Trial Intervention",
            "short_name": "Description of Investigational Trial Intervention",
            "original_name": "Description of Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.1",
            "section_title": "Description of Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Description of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the investigational trial intervention.",
            "guidance": "Describe the investigational trial intervention to be administered in each arm of the trial and for each period of the trial including route and mode of administration, dose, dosage regimen, duration of intervention, use, packaging and labelling. \nRefer to approved regional labelling, as appropriate. \nFor drug/device combination products, include details on the configuration and use of the device and device manufacturer. A device user manual may be referenced in this section.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.1 Description of Investigational Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Description of Investigational Trial Intervention",
            "notes": ""
        }
    },
    "Rationale for Investigational Trial Intervention Dose and Regimen": {
        "template": {
            "long_name": "Enter Rationale for Investigational Trial Intervention Dose and Regimen",
            "short_name": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "original_name": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "optional": false,
            "section_number": "6.2",
            "section_title": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "instructions": []
        },
        "technical": {
            "name": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the trial intervention dose and dose regimen.",
            "guidance": "Provide a rationale for the selection of the dose(s) or dose range, pharmaceutical dose form, the route of administration, and dosing regimen of the investigational trial intervention, as applicable. This rationale should include relevant results from previous nonclinical studies and clinical trials that support selection of the dose and regimen. Discuss impact of differences in study population characteristics (for example, age, sex and/or race) which could lead to differences in pharmacokinetics and pharmacodynamics in this study as compared to previous studies. If applicable, justify any differences in dose regimen or therapeutic use relative to approved labelling. Describe prior trials and other information that support the dose and/or dose regimen of the investigational intervention.\nInclude a rationale for prospective dose adjustments incorporated in the trial, if any.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.2 Rationale for Investigational Trial Intervention Dose and Regimen\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Rationale for Investigational Trial Intervention Dose and Regimen",
            "notes": ""
        }
    },
    "Investigational Trial Intervention Administration": {
        "template": {
            "long_name": "Enter Investigational Trial Intervention Administration",
            "short_name": "Investigational Trial Intervention Administration",
            "original_name": "Investigational Trial Intervention Administration",
            "optional": false,
            "section_number": "6.3",
            "section_title": "Investigational Trial Intervention Administration",
            "instructions": []
        },
        "technical": {
            "name": "Investigational Trial Intervention Administration",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the trial intervention dose and dose regimen.",
            "guidance": "Describe the detailed procedures for administration of each participant\u2019s dose of each investigational trial intervention. This may include the timing of dosing (for example, time of day, interval), the duration (for example, the length of time participants will be administered the investigational trial intervention), and the timing of dosing relative to meals. \nInclude any specific instructions to trial participants about when or how to prepare and take the dose(s) and how delayed or missed doses should be handled. \nDose escalation or cohort expansion as part of the overall design should be covered in Section 4.1 Description of Trial Design.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.3 Investigational Trial Intervention Administration\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Investigational Trial Intervention Administration",
            "notes": ""
        }
    },
    "Investigational Trial Intervention Dose Modification": {
        "template": {
            "long_name": "Enter Investigational Trial Intervention Dose Modification",
            "short_name": "Investigational Trial Intervention Dose Modification",
            "original_name": "Investigational Trial Intervention Dose Modification",
            "optional": false,
            "section_number": "6.4",
            "section_title": "Investigational Trial Intervention Dose Modification",
            "instructions": []
        },
        "technical": {
            "name": "Investigational Trial Intervention Dose Modification",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA change, alteration, or adjustment to the dose of a investigational trial intervention.",
            "guidance": "For each participant, describe any dose modifications allowed, including conditions for such dose modifications, particularly regarding failure to respond or safety concerns. State any minimum period required before a participant\u2019s dose might be raised to the next higher dose or dose range. Include whether it is permissible to start and stop treatment and how dose reductions (if permitted) are to be managed. \nInformation on stopping investigational trial intervention for participants due to safety/other reasons should be detailed in Section 7 Participant Discontinuation of Trial Intervention and Discontinuation or Withdrawal from Trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.4 Investigational Trial Intervention Dose Modification\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Investigational Trial Intervention Dose Modification",
            "notes": ""
        }
    },
    "Management of Investigational Trial Intervention Overdose": {
        "template": {
            "long_name": "Enter Management of Investigational Trial Intervention Overdose",
            "short_name": "Management of Investigational Trial Intervention Overdose",
            "original_name": "Management of Investigational Trial Intervention Overdose",
            "optional": false,
            "section_number": "6.5",
            "section_title": "Management of Investigational Trial Intervention Overdose",
            "instructions": []
        },
        "technical": {
            "name": "Management of Investigational Trial Intervention Overdose",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of how a potential investigational trial intervention overdose will be handled.",
            "guidance": "Describe what is meant by investigational trial intervention overdose. Provide any available information on managing the overdose and ensure it is consistent with the Investigator\u2019s Brochure or product labelling. Cross-references these documents as applicable.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.5 Management of Investigational Trial Intervention Overdose\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Preparation of Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Preparation of Investigational Trial Intervention ",
            "short_name": "Preparation of Investigational Trial Intervention",
            "original_name": "Preparation of Investigational Trial Intervention ",
            "optional": false,
            "section_number": "6.6.1",
            "section_title": "{Preparation of Investigational Trial Intervention}",
            "instructions": []
        },
        "technical": {
            "name": "Preparation of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "C176274\nFor review purpose, see definition of the controlled terminology below\nThe way in which the investigational trial intervention is prepared for use or administration to the study participant.",
            "guidance": "Describe any preparation of the investigational trial intervention, and when necessary, by whom. When applicable, describe the maximum hold time once thawed/mixed before administration. Include thawing, diluting, mixing, and reconstitution/preparation instructions. For drug/device combination products, include any relevant assembly or use instructions and reference the package insert that is provided separately.\u00a0\nIf the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.6.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.6.1 Preparation of Investigational Trial Intervention\nConcept: C176274",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Preparation of Investigational Trial Intervention",
            "notes": ""
        }
    },
    "Storage and Handling of Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Storage and Handling of Investigational Trial Intervention",
            "short_name": "Storage and Handling of Investigational Trial Intervention",
            "original_name": "Storage and Handling of Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.6.2",
            "section_title": "Storage and Handling of Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Storage and Handling of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "C115525\nFor review purpose, see definition of the controlled terminology below\nThe safe handling, storage, distribution, and return of unused investigational trial intervention.",
            "guidance": "Describe storage and handling requirements (for example, protection from light, temperature, humidity) for the investigational trial intervention(s). For trials in which multi-dose vials are utilised, provide additional information regarding stability and expiration time after initial use (for example, the seal is broken).\u00a0\nState how the investigational trial intervention(s) will be provided to the Investigator. If applicable, describe the kits, packaging, or other material of the investigational trial intervention for blinding purposes.\u00a0\nIf the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.6.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.6.2 Storage and Handling of Investigational Trial Intervention\nConcept: C115525",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Storage and Handling of Investigational Trial Intervention",
            "notes": ""
        }
    },
    "Accountability of Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Accountability of Investigational Trial Intervention",
            "short_name": "Accountability of Investigational Trial Intervention",
            "original_name": "Accountability of Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.6.3",
            "section_title": "Accountability of Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Accountability of Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "C176267\nFor review purpose, see definition of the controlled terminology below\nThe act or process for documenting the storage, inventory tracking, and disposition of the investigational trial intervention.",
            "guidance": "Describe the method by which the accountability will be achieved, including trial intervention will be distributed and related details, including:\nhow and by whom the trial intervention will be distributed\nparticipation of a drug repository or pharmacy, if applicable, \nplans for disposal or return of unused product\nif applicable, plans for reconciliation of investigational trial intervention",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.6.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.6.3 Accountability of Trial Intervention\nConcept: C176267",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Accountability of Investigational Trial Intervention",
            "notes": ""
        }
    },
    "Participant Assignment to Investigational Trial Intervention": {
        "template": {
            "long_name": "Enter Participant Assignment to Investigational Trial Intervention",
            "short_name": "Participant Assignment to Investigational Trial Intervention",
            "original_name": "Participant Assignment to Investigational Trial Intervention",
            "optional": false,
            "section_number": "6.7.1",
            "section_title": "Participant Assignment to Investigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Participant Assignment to Investigational Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe technique used to assign trial participants to a trial arm.",
            "guidance": "Describe the method of assigning participants to investigational trial intervention without being so specific that blinding or randomisation might be compromised. If assignment to investigational trial intervention is by randomisation, describe when randomisation occurs relative to screening. State that at enrollment, participant identification codes should be assigned. \nIf adaptive randomisation or other methods of covariate balancing/minimisation are employed, include a cross-reference to the methods of analysis in Section 10 Statistical Considerations. As applicable, details regarding the implementation of procedures to minimise bias should be described.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.7.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.1 Participant Assignment to Investigational Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Participant Assignment to Investigational Trial Intervention",
            "notes": ""
        }
    },
    "Randomisation": {
        "template": {
            "long_name": "Enter Randomisation",
            "short_name": "Randomisation",
            "original_name": "Randomisation",
            "optional": false,
            "section_number": "6.7.2",
            "section_title": "{Randomisation}",
            "instructions": []
        },
        "technical": {
            "name": "Randomisation",
            "data_type": "Text",
            "definition": "C25196\nFor review purpose, see definition of the controlled terminology below\nThe process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. [ICH E6 1.48]",
            "guidance": "Describe the randomisation procedures (for example, central randomisation procedures), the method used to generate the randomisation schedule (for example, computer generated), the source of the randomisation schedule (for example, sponsor, investigator, or other), and whether IxRS will be used. To maintain the integrity of the blinding, do not include the block size.",
            "conformance": "Conditional: when randomised trial",
            "cardinality": "One to one",
            "relationship": "6.7.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.2 Randomisation\nConcept: C25196",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Randomisation",
            "notes": ""
        }
    },
    "Measures to Maintain Blinding": {
        "template": {
            "long_name": "Enter Measures to Maintain Blinding",
            "short_name": "Measures to Maintain Blinding",
            "original_name": "Measures to Maintain Blinding",
            "optional": false,
            "section_number": "6.7.3",
            "section_title": "{Measures to Maintain Blinding}",
            "instructions": []
        },
        "technical": {
            "name": "Measures to Maintain Blinding",
            "data_type": "Text",
            "definition": "C189349\nFor review purpose, see definition of the controlled terminology below\nThe methodology used for enacting trial blinding.",
            "guidance": "Describe efforts to ensure that the investigational trial intervention(s) are as indistinguishable as possible. Plans for the maintenance of randomisation codes and appropriate blinding for the trial should be described. Procedures for planned (e.g. Interim Analysis), and unintentional (e.g. breach of procedure) breaking of randomisation codes should be provided. For unplanned but intentional actions (e.g. safety events), refer to Section 6.7.4 Emergency Unblinding at the Site.\nIf the trial allows for some investigators or other designated staff to remain unblinded (for example, to allow them to adjust investigational trial intervention), the means of maintaining the blinding for other investigators or staff should be explained. Measures to prevent unblinding by laboratory measurements or while performing study assessments, if used, should be described.",
            "conformance": "Conditional: when blind trial",
            "cardinality": "One to one",
            "relationship": "6.7.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.3 Blinding\nConcept: C189349",
            "repeating": "No",
            "ct": []
        }
    },
    "Emergency Unblinding at the Site": {
        "template": {
            "long_name": "Enter Emergency Unblinding at the Site",
            "short_name": "Emergency Unblinding at the Site",
            "original_name": "Emergency Unblinding at the Site",
            "optional": false,
            "section_number": "6.7.4",
            "section_title": "{Emergency Unblinding at the Site}",
            "instructions": []
        },
        "technical": {
            "name": "Emergency Unblinding at the Site",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the methodology used for unblinding of the trial treatment in the case of a sudden unforeseen crisis that requires immediate medical care of the participant.",
            "guidance": "Describe the criteria for breaking the trial blind or participant code. Describe the circumstances in which the blinding would be broken for an individual or for all participants and who has responsibility. Include the procedure for emergency unblinding such as via IxRS or code envelopes as well as documentation of unblinding. Indicate to whom the intentional and unplanned unblinding should be reported.",
            "conformance": "Conditional: when blind trial",
            "cardinality": "One to one",
            "relationship": "6.7.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.7.4 Emergency Unblinding at the Site\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Emergency Unblinding at the Site",
            "notes": ""
        }
    },
    "Investigational Trial Intervention Adherence": {
        "template": {
            "long_name": "Enter Investigational Trial Intervention Adherence",
            "short_name": "Investigational Trial Intervention Adherence",
            "original_name": "Investigational Trial Intervention Adherence",
            "optional": false,
            "section_number": "6.8",
            "section_title": "Investigational Trial Intervention Adherence",
            "instructions": []
        },
        "technical": {
            "name": "Investigational Trial Intervention Adherence",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the measures taken to ensure trial intervention compliance, including mandatory documentation to be filled out and the source data that will be used to document investigational trial intervention compliance.",
            "guidance": "Describe the measures to monitor and document participants\u2019 compliance with investigational intervention (e.g. study intervention accountability records, diary cards, or investigational intervention concentration measurements).\nList what documents are mandatory to complete (for example, participant drug log) and what source data/records will be used to document investigational intervention compliance.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.8",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.8 Investigational Trial Intervention Adherence\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Description of Noninvestigational Trial Intervention": {
        "template": {
            "long_name": "Enter Description of Noninvestigational Trial Intervention",
            "short_name": "Description of Noninvestigational Trial Intervention",
            "original_name": "Description of Noninvestigational Trial Intervention",
            "optional": false,
            "section_number": "6.9",
            "section_title": "Description of Noninvestigational Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Description of Noninvestigational Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the non-investigational trial intervention",
            "guidance": "As stated in Section 6, non-investigational interventions are products used in the trial but are not part of trial objectives and hence, are not investigational trial interventions. \nThe non-investigational trial intervention(s) may be described concisely in a table or in the following sections as applicable.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9 Description of Noninvestigational Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rescue Therapy": {
        "template": {
            "long_name": "Enter Rescue Therapy",
            "short_name": "Rescue Therapy",
            "original_name": "Rescue Therapy",
            "optional": false,
            "section_number": "6.9.2",
            "section_title": "{Rescue Therapy}",
            "instructions": []
        },
        "technical": {
            "name": "Rescue Therapy",
            "data_type": "Text",
            "definition": "C165835\nFor review purpose, see definition of the controlled terminology below\nMedicinal products identified in the protocol as those that may be administered to subjects when the efficacy of the investigational medicinal product (IMP) is not satisfactory, the effect of the IMP is too great and is likely to cause a hazard to the patient, or to manage an emergency situation. [After EU-CTR Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017]",
            "guidance": "List all permitted rescue medications, treatments, and/or procedures, including any relevant instructions about administration and any conditions for use. \nIf administration of rescue therapy leads to the temporary discontinuation of trial intervention or a participant\u2019s withdrawal from the trial, refer to Section 7 Participant Discontinuation of Trial Intervention and Withdrawal from Trial.",
            "conformance": "Conditional: when any rescue therapies are defined",
            "cardinality": "One to one",
            "relationship": "6.9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9.2 Rescue Therapy\nConcept: C165835",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Rescue Therapy",
            "notes": ""
        }
    },
    "Other Noninvestigational Trial Intervention": {
        "template": {
            "long_name": "Enter Other Noninvestigational Trial Intervention",
            "short_name": "Other Noninvestigational Trial Intervention",
            "original_name": "Other Noninvestigational Trial Intervention",
            "optional": false,
            "section_number": "6.9.3",
            "section_title": "{Other Noninvestigational Trial Intervention}",
            "instructions": []
        },
        "technical": {
            "name": "Other Noninvestigational Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA non-investigational trial therapy that is different than the one(s) previously specified or mentioned.",
            "guidance": "If applicable, describe the use of any other non-investigational intervention, for example, challenge agents or diagnostics.",
            "conformance": "Conditional: when any other non-investigational interventions are defined",
            "cardinality": "One to one",
            "relationship": "6.9.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9.3 Other Noninvestigational Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "Other Noninvestigational Trial Intervention"
        }
    },
    "Concomitant Therapy": {
        "template": {
            "long_name": "Enter Concomitant Therapy",
            "short_name": "Concomitant Therapy",
            "original_name": "Concomitant Therapy",
            "optional": false,
            "section_number": "6.10",
            "section_title": "Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Concomitant Therapy",
            "data_type": "Text",
            "definition": "C53630\nFor review purpose, see definition of the controlled terminology below\nAny pharmaceutical agent, other than the trial interventions, that is administered to or used by the subject prior to or during a specified time period.",
            "guidance": "Describe the concomitant medications, supplements, complementary and alternative therapies, treatments, and/or procedures which are prohibited or permitted during the trial and include details about when the information will be collected (for example, screening, all visits). \nThis section should be consistent with the medication restrictions in the inclusion/exclusion criteria. \nWhen appropriate to separate the content, subheadings may be used.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "6.10",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.10 Concomitant Therapy\nConcept: C53630",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Concomitant Therapy",
            "notes": ""
        }
    },
    "Prohibited Concomitant Therapy": {
        "template": {
            "long_name": "Enter Prohibited Concomitant Therapy",
            "short_name": "Prohibited Concomitant Therapy",
            "original_name": "Prohibited Concomitant Therapy",
            "optional": false,
            "section_number": "6.10.1",
            "section_title": "{Prohibited Concomitant Therapy}",
            "instructions": []
        },
        "technical": {
            "name": "Prohibited Concomitant Therapy",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nConcomitant therapy that is banned from use in the trial.",
            "guidance": "If applicable, describe any prohibited concomitant therapy.",
            "conformance": "Conditional: when any prohibited concomitant therapies are defined",
            "cardinality": "One to one",
            "relationship": "6.10.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.10.1 Prohibited Concomitant Therapy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Prohibited Concomitant Therapy",
            "notes": ""
        }
    },
    "Permitted Concomitant Therapy": {
        "template": {
            "long_name": "Enter Permitted Concomitant Therapy",
            "short_name": "Permitted Concomitant Therapy",
            "original_name": "Permitted Concomitant Therapy",
            "optional": false,
            "section_number": "6.10.2",
            "section_title": "{Permitted Concomitant Therapy}",
            "instructions": []
        },
        "technical": {
            "name": "Permitted Concomitant Therapy",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nConcomitant therapy that is approved for use in the trial.",
            "guidance": "If applicable, describe any permitted concomitant therapy.",
            "conformance": "Conditional: when any permitted concomitant therapies are defined",
            "cardinality": "One to one",
            "relationship": "6.10.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.10.2 Permitted Concomitant Therapy\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Permitted Concomitant Therapy",
            "notes": ""
        }
    },
    "Permanent Discontinuation of Trial Intervention": {
        "template": {
            "long_name": "Enter Permanent Discontinuation of Trial Intervention",
            "short_name": "Permanent Discontinuation of Trial Intervention",
            "original_name": "Permanent Discontinuation of Trial Intervention",
            "optional": false,
            "section_number": "7.1.1",
            "section_title": "Permanent Discontinuation of Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Permanent Discontinuation of Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to permanently discontinue the administration of trial intervention.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "7.1.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.1.1 Permanent Discontinuation of Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Temporary Discontinuation of Trial Intervention": {
        "template": {
            "long_name": "Enter Temporary Discontinuation of Trial Intervention",
            "short_name": "Temporary Discontinuation of Trial Intervention",
            "original_name": "Temporary Discontinuation of Trial Intervention",
            "optional": false,
            "section_number": "7.1.2",
            "section_title": "Temporary Discontinuation of Trial Intervention",
            "instructions": []
        },
        "technical": {
            "name": "Temporary Discontinuation of Trial Intervention",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to temporarily discontinue the administration of trial intervention.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "7.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.1.2 Temporary Discontinuation of Trial Intervention\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Rechallenge": {
        "template": {
            "long_name": "Enter Rechallenge",
            "short_name": "Rechallenge",
            "original_name": "Rechallenge",
            "optional": false,
            "section_number": "7.1.3",
            "section_title": "Rechallenge",
            "instructions": []
        },
        "technical": {
            "name": "Rechallenge",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to reintroduce previously withdrawn or temporarily discontinued medical intervention in the same patient.",
            "guidance": "Describe the criteria for rechallenge/restarting trial intervention, how and when to perform rechallenge, number of rechallenges allowed during the trial, and whether all, or specify which, assessments will be performed for the stated duration of the trial.\nIf rechallenge is not allowed, state this.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "7.1.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.1.3 Rechallenge\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Rechallenge",
            "notes": ""
        }
    },
    "Participant Discontinuation or Withdrawal from Trial": {
        "template": {
            "long_name": "Enter Participant Discontinuation or Withdrawal from Trial",
            "short_name": "Participant Discontinuation or Withdrawal from Trial",
            "original_name": "Participant Discontinuation or Withdrawal from Trial",
            "optional": false,
            "section_number": "7.2",
            "section_title": "Participant Discontinuation or Withdrawal from the Trial",
            "instructions": []
        },
        "technical": {
            "name": "Participant Discontinuation or Withdrawal from Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe rationale for why the participant either discontinued or withdrawal from the trial.",
            "guidance": "Describe the criteria for participant discontinuation or withdrawal from the trial.\nDescribe the reason for withdrawal and the type of data to be collected for the final assessments with reference to the schedule of activities for the participant\u2019s end of study visit unless provided in another section. \nIn many cases, the only reason for a participant being considered withdrawn from the trial should be a participant\u2019s withdrawal of consent to continue to participate in the trial. All other participants, including those who discontinue treatment, should remain in the trial and continue to be followed to prevent missing data in important analyses. Refer to Section 10 Statistical Considerations for the data that must be collected for the trial estimands.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "7.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.2 Participants Discontinuation or Withdrawal from the Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Participant Discontinuation or Withdrawal from Trial",
            "notes": ""
        }
    },
    "Management of Loss to Follow-Up": {
        "template": {
            "long_name": "Enter Management of Loss to Follow-Up",
            "short_name": "Management of Loss to Follow-Up",
            "original_name": "Management of Loss to Follow-Up",
            "optional": false,
            "section_number": "7.3",
            "section_title": "Management of Loss to Follow-Up",
            "instructions": []
        },
        "technical": {
            "name": "Management of Loss to Follow-Up",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe mitigation strategies to be employed for the loss or lack of continuation of a participant to follow-up, including the frequency by which follow-up occurs.",
            "guidance": "Describe how the trial will define how participants are lost to follow-up. In general, participants should be considered lost to follow-up only if they cannot be reached despite multiple attempts to contact. Also describe approaches that will be used to minimise loss to follow-up, such as multiple, diverse methods to remain in contact with participants (e.g., telephone calls, texts, and emails to the participant) and how contacts will be recorded.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "7.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 7.3 Management of Loss to Follow-up\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Trial Assessments and Procedures Considerations": {
        "template": {
            "long_name": "Enter Trial Assessments and Procedures Considerations",
            "short_name": "Trial Assessments and Procedures Considerations",
            "original_name": "Trial Assessments and Procedures Considerations",
            "optional": false,
            "section_number": "8.1",
            "section_title": "Trial Assessments and Procedures Considerations",
            "instructions": []
        },
        "technical": {
            "name": "Trial Assessments and Procedures Considerations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of general considerations applicable across trial assessments and procedures.",
            "guidance": "Describe general considerations applicable across trial assessments and procedures.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.1 Trial Assessments and Procedures Considerations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Screening Assessments and Procedures": {
        "template": {
            "long_name": "Enter Screening Assessments and Procedures",
            "short_name": "Screening Assessments and Procedures",
            "original_name": "Screening Assessments and Procedures",
            "optional": false,
            "section_number": "8.2",
            "section_title": "Screening/Baseline Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Screening Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to the screening epoch of the trial.",
            "guidance": "Describe any assessments and procedures that are unique to screening/baseline (e.g., collection of data on participant characteristics, assessments/procedures performed for the purpose of determining eligibility or for stratification) in this section. Describe screening and baseline assessments and procedures separately when screening and baseline are different or performed at different visits.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.2 Screening/Baseline Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Screening Assessments and Procedures",
            "notes": ""
        }
    },
    "Baseline Assessments and Procedures": {
        "template": {
            "long_name": "Enter Baseline Assessments and Procedures",
            "short_name": "Baseline Assessments and Procedures",
            "original_name": "Baseline Assessments and Procedures",
            "optional": false,
            "section_number": "8.2",
            "section_title": "Screening/Baseline Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Baseline Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to the baseline epoch of the trial.",
            "guidance": "Describe any assessments and procedures that are unique to screening/baseline (e.g., collection of data on participant characteristics, assessments/procedures performed for the purpose of determining eligibility or for stratification) in this section. Describe screening and baseline assessments and procedures separately when screening and baseline are different or performed at different visits.",
            "conformance": "Conditional: when the Baseline Assessments and Procedures are different from Screening",
            "cardinality": "One to one",
            "relationship": "8.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.2 Screening/Baseline Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Baseline Assessments and Procedures",
            "notes": ""
        }
    },
    "Efficacy Assessments and Procedures": {
        "template": {
            "long_name": "Enter Efficacy Assessments and Procedures",
            "short_name": "Efficacy Assessments and Procedures",
            "original_name": "Efficacy Assessments and Procedures",
            "optional": false,
            "section_number": "8.3",
            "section_title": "Efficacy Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Efficacy Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to trial intervention efficacy.",
            "guidance": "Describe efficacy assessments and procedures in this section. Cross reference Section 8.7 Immunogenicity Assessments if immunogenicity assessments are used in efficacy determination.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.3 Efficacy Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Efficacy Assessments and Procedures",
            "notes": ""
        }
    },
    "Safety Assessments and Procedures": {
        "template": {
            "long_name": "Enter Safety Assessments and Procedures",
            "short_name": "Safety Assessments and Procedures",
            "original_name": "Safety Assessments and Procedures",
            "optional": false,
            "section_number": "8.4",
            "section_title": "Safety Assessments and Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Safety Assessments and Procedures",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the assessments and procedures related to participant safety within the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4 Safety Assessments and Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Safety Assessments and Procedures",
            "notes": ""
        }
    },
    "Physical Examination": {
        "template": {
            "long_name": "Enter Physical Examination",
            "short_name": "Physical Examination",
            "original_name": "Physical Examination",
            "optional": false,
            "section_number": "8.4.1",
            "section_title": "{Physical Examination}",
            "instructions": []
        },
        "technical": {
            "name": "Physical Examination",
            "data_type": "Text",
            "definition": "C20989\nFor review purpose, see definition of the controlled terminology below\nThe procedures for a systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation.",
            "guidance": "Include any specific instructions for the collection and interpretation of physical examinations.",
            "conformance": "Conditional: when Physical Exams are required",
            "cardinality": "One to one",
            "relationship": "8.4.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.1 Physical Examination\nConcept: C20989",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Physical Examination",
            "notes": ""
        }
    },
    "Vital Signs": {
        "template": {
            "long_name": "Enter Vital Signs",
            "short_name": "Vital Signs",
            "original_name": "Vital Signs",
            "optional": false,
            "section_number": "8.4.2",
            "section_title": "{Vital Signs}",
            "instructions": []
        },
        "technical": {
            "name": "Vital Signs",
            "data_type": "Text",
            "definition": "C154628\nFor review purpose, see definition of the controlled terminology below \nThe procedures for measurements of the body's basic functions that provide insight into the health status of the person.",
            "guidance": "Include any specific instructions for the collection and interpretation of vital signs.",
            "conformance": "Conditional: when Vital Signs are required",
            "cardinality": "One to one",
            "relationship": "8.4.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.2 Vital Signs\nConcept: C154628",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Vital Signs",
            "notes": ""
        }
    },
    "Electrocardiograms": {
        "template": {
            "long_name": "Enter Electrocardiograms",
            "short_name": "Electrocardiograms",
            "original_name": "Electrocardiograms",
            "optional": false,
            "section_number": "8.4.3",
            "section_title": "{Electrocardiograms}",
            "instructions": []
        },
        "technical": {
            "name": "Electrocardiograms",
            "data_type": "Text",
            "definition": "C168186\nFor review purpose, see definition of the controlled terminology below\nThe procedures for the recordings produced by the variations in electrical potential caused by electrical activity of the heart muscle and detected at the body surface, as a method for studying the action of the heart muscle.",
            "guidance": "Include any specific instructions for the collection, interpretation, and archiving of ECGs.",
            "conformance": "Conditional: when Electrocardiograms are required",
            "cardinality": "One to one",
            "relationship": "8.4.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.3 Electrocardiograms\nConcept: C168186",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Electrocardiograms",
            "notes": ""
        }
    },
    "Pregnancy Testing": {
        "template": {
            "long_name": "Enter Pregnancy Testing",
            "short_name": "Pregnancy Testing",
            "original_name": "Pregnancy Testing",
            "optional": false,
            "section_number": "8.4.5",
            "section_title": "{Pregnancy Testing}",
            "instructions": []
        },
        "technical": {
            "name": "Pregnancy Testing",
            "data_type": "Text",
            "definition": "C92949\nFor review purpose, see definition of the controlled terminology below\nAny examination performed to assess if a female is gravid.",
            "guidance": "Include any specific instructions for the collection and interpretation of pregnancy testing.",
            "conformance": "Conditional: when Pregnancy Testing is required",
            "cardinality": "One to one",
            "relationship": "8.4.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.5 Pregnancy Testing\nConcept: C92949",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Pregnancy Testing",
            "notes": ""
        }
    },
    "Suicidal Ideation and Behaviour Risk Monitoring": {
        "template": {
            "long_name": "Enter Suicidal Ideation and Behaviour Risk Monitoring",
            "short_name": "Suicidal Ideation and Behaviour Risk Monitoring",
            "original_name": "Suicidal Ideation and Behaviour Risk Monitoring",
            "optional": false,
            "section_number": "8.4.6",
            "section_title": "{Suicidal Ideation and Behaviour Risk Monitoring}",
            "instructions": []
        },
        "technical": {
            "name": "Suicidal Ideation and Behaviour Risk Monitoring",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of data collection procedures and analysis related to suicidal ideation and behaviour risk monitoring.",
            "guidance": "If the trial meets any of the criteria requiring suicidal ideation and behaviour risk monitoring by the guidance/guideline in each region, include justification for the need for suicidal ideation and behaviour risk monitoring in the study and add any specific instructions for the collection and interpretation of the assessment. In case this is an AESI in the study, justification should also be provided in Section 9.2.4 Adverse Events of Special Interest.",
            "conformance": "Conditional: when Suicidal Ideation and Behaviour Risk Monitoring are required",
            "cardinality": "One to one",
            "relationship": "8.4.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.6 Suicidal Ideation and Behaviour Risk Monitoring\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Suicidal Ideation and Behaviour Risk Monitoring",
            "notes": ""
        }
    },
    "Pharmacokinetics": {
        "template": {
            "long_name": "Enter Pharmacokinetics",
            "short_name": "Pharmacokinetics",
            "original_name": "Pharmacokinetics",
            "optional": false,
            "section_number": "8.5",
            "section_title": "Pharmacokinetics",
            "instructions": []
        },
        "technical": {
            "name": "Pharmacokinetics",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in pharmacokinetic assessments within the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.5 Pharmacokinetics\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Pharmacokinetics",
            "notes": ""
        }
    },
    "Genetics and Pharmacogenomics": {
        "template": {
            "long_name": "Enter Genetics and Pharmacogenomics",
            "short_name": "Genetics and Pharmacogenomics",
            "original_name": "Genetics and Pharmacogenomics",
            "optional": false,
            "section_number": "8.6.1",
            "section_title": "Genetics and Pharmacogenomics",
            "instructions": []
        },
        "technical": {
            "name": "Genetics and Pharmacogenomics",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in genetic and pharmacogenomic biomarker assessments within the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.6.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.6.1 Genetics and Pharmacogenomics\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Genetics and Pharmacogenomics",
            "notes": ""
        }
    },
    "Pharmacodynamic Biomarkers": {
        "template": {
            "long_name": "Enter Pharmacodynamic Biomarkers",
            "short_name": "Pharmacodynamic Biomarkers",
            "original_name": "Pharmacodynamic Biomarkers",
            "optional": false,
            "section_number": "8.6.2",
            "section_title": "Pharmacodynamic Biomarkers",
            "instructions": []
        },
        "technical": {
            "name": "Pharmacodynamic Biomarkers",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in pharmacodynamic biomarker assessments within the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.6.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.6.2 Pharmacodynamic Biomarkers\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Pharmacodynamic Biomarkers",
            "notes": ""
        }
    },
    "Other Biomarkers": {
        "template": {
            "long_name": "Enter Other Biomarkers",
            "short_name": "Other Biomarkers",
            "original_name": "Other Biomarkers",
            "optional": false,
            "section_number": "8.6.3",
            "section_title": "{Other Biomarkers}",
            "instructions": []
        },
        "technical": {
            "name": "Other Biomarkers",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in other biomarker assessments within the trial.",
            "guidance": "",
            "conformance": "Conditional: when Other Biomarkers are required",
            "cardinality": "One to one",
            "relationship": "8.6.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.6.3 Other Biomarkers\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Other Biomarkers",
            "notes": ""
        }
    },
    "Immunogenicity Assessments": {
        "template": {
            "long_name": "Enter Immunogenicity Assessments",
            "short_name": "Immunogenicity Assessments",
            "original_name": "Immunogenicity Assessments",
            "optional": false,
            "section_number": "8.7",
            "section_title": "Immunogenicity Assessments",
            "instructions": []
        },
        "technical": {
            "name": "Immunogenicity Assessments",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in immunogenicity assessments within the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.7",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.7 Immunogenicity Assessments\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Immunogenicity Assessments",
            "notes": ""
        }
    },
    "Medical Resource Utilisation and Health Economics": {
        "template": {
            "long_name": "Enter Medical Resource Utilisation and Health Economics",
            "short_name": "Medical Resource Utilisation and Health Economics",
            "original_name": "Medical Resource Utilisation and Health Economics",
            "optional": false,
            "section_number": "8.8",
            "section_title": "Medical Resource Utilisation and Health Economics",
            "instructions": []
        },
        "technical": {
            "name": "Medical Resource Utilisation and Health Economics",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about medical resource utilization and the health outcome measures, collection method and participant burden.",
            "guidance": "This section does not apply to COAs. Include this section only for any value evidence and outcomes assessments not included in either the efficacy or safety sections.\nDescribe the health outcome measures, collection method (e.g., diary, physician interview), and participant burden.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "8.8",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.8 Medical Resource Utilisation and Health Economics\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Medical Resource Utilisation and Health Economics",
            "notes": ""
        }
    },
    "Definitions of Adverse Events": {
        "template": {
            "long_name": "Enter Definitions of Adverse Events",
            "short_name": "Definitions of Adverse Events",
            "original_name": "Definitions of Adverse Events",
            "optional": false,
            "section_number": "9.1.1",
            "section_title": "Definitions of Adverse Events",
            "instructions": []
        },
        "technical": {
            "name": "Definitions of Adverse Events",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of adverse events within the context of the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.1.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.1.1 Definitions of Adverse Events\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Definitions of Serious Adverse Events": {
        "template": {
            "long_name": "Enter Definitions of Serious Adverse Events",
            "short_name": "Definitions of Serious Adverse Events",
            "original_name": "Definitions of Serious Adverse Events",
            "optional": false,
            "section_number": "9.1.2",
            "section_title": "Definitions of Serious Adverse Events",
            "instructions": []
        },
        "technical": {
            "name": "Definitions of Serious Adverse Events",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of serious adverse events within the context of the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.1.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.1.2 Definitions of Serious Adverse Events\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Definition of Medical Device Product Complaints": {
        "template": {
            "long_name": "Enter Definition of Medical Device Product Complaints",
            "short_name": "Definition of Medical Device Product Complaints",
            "original_name": "Definition of Medical Device Product Complaints",
            "optional": false,
            "section_number": "9.1.3.1",
            "section_title": "{Definition of Medical Device Product Complaints}",
            "instructions": []
        },
        "technical": {
            "name": "Definition of Medical Device Product Complaints",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of medical device product complaints within the context of the trial.",
            "guidance": "N/A",
            "conformance": "Conditional: when there is Medical Device Product Complaints",
            "cardinality": "One to one",
            "relationship": "9.1.3.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.1.3.1 Definition of Medical Device Product Complaints\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Definition of Medical Device Product Complaints",
            "notes": ""
        }
    },
    "Event Type": {
        "template": {
            "long_name": "Event Type",
            "short_name": "Event Type",
            "original_name": "Event Type",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Event Type",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA categorization or classification of trial-related safety events, such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events.",
            "guidance": "N/A",
            "conformance": "Optional if the table is used",
            "cardinality": "One to many",
            "relationship": "9.2",
            "value": "Adverse Event (C41331), Serious Adverse Event(C41335), Trial Intervention Complaint (CNEW), Medical Device Product Complaint (C54026), Pregnancy Event (C25742), Lactation Event (CNEW), Post-Partum Event (CNEW), Reportable Adverse Event of Special Interest (CNEW), Not Reportable Adverse Event of Special Interest (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type \nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Event Type Response",
                    "definition": "A terminology value set relevant to the safety event type responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C41331",
                    "preferred_term": "Adverse Event",
                    "definition": "Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment."
                },
                {
                    "ncit_code": "C41335",
                    "preferred_term": "Serious Adverse Event",
                    "definition": "Any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/ incapacity, or is a congenital anomaly/ birth defect."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Intervention Complaint",
                    "definition": "Any concern about the safety and/or quality of any trial-related interventions."
                },
                {
                    "ncit_code": "C54026",
                    "preferred_term": "Medical Device Product Complaint",
                    "definition": "Any concern about the safety, quality, and/or performance of a trial-related drug-device combination."
                },
                {
                    "ncit_code": "C25742",
                    "preferred_term": "Pregnancy Event",
                    "definition": "Any event that occurs when the participant is pregnant."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Lactation Event",
                    "definition": "Any event that occurs when the participant is lactating."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Post-Partum Event",
                    "definition": "Any event that occurs when the participant is in the stages of recovery post pregnancy and birth event."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Reportable Adverse Event of Special Interest",
                    "definition": "An adverse event of special interest (serious or non-serious) is one of scientific and medical concern specific to the sponsor\u2019s product or programme, for which ongoing monitoring and rapid communication by the investigator to the sponsor could be appropriate, and which is deemed to be reportable to the appropriate regulatory authority."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not Reportable Adverse Event of Special Interest",
                    "definition": "An adverse event of special interest (serious or non-serious) is one of scientific and medical concern specific to the sponsor\u2019s product or programme, for which ongoing monitoring and rapid communication by the investigator to the sponsor could be appropriate, and which is deemed to be not reportable to the appropriate regulatory authority."
                }
            ]
        }
    },
    "Situational Scope": {
        "template": {
            "long_name": "Situational Scope",
            "short_name": "Situational Scope",
            "original_name": "Situational Scope",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Situational Scope",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the specific circumstances and context in which safety events are collected and monitored.",
            "guidance": "N/A",
            "conformance": "Optional if table used",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, Situational Scope\nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type",
            "ct": []
        }
    },
    "Reportable Period Start": {
        "template": {
            "long_name": "Reportable Period Start",
            "short_name": "Reportable Period Start",
            "original_name": "Reportable Period Start",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Reportable Period Start",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date on which reporting will begin for trial related events such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events.",
            "guidance": "N/A",
            "conformance": "Optional if table used",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, Situational Scope\nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type and situational scope",
            "ct": []
        }
    },
    "Reportable Period End": {
        "template": {
            "long_name": "Reportable Period End",
            "short_name": "Reportable Period End",
            "original_name": "Reportable Period End",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Reportable Period End",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date on which reporting will cease for trial related events such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events.",
            "guidance": "N/A",
            "conformance": "Optional if table used",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, Situational Scope, Reportable Period Start\nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type, situation scope, reportable period start",
            "ct": []
        }
    },
    "Method for Reporting": {
        "template": {
            "long_name": "Method for Reporting",
            "short_name": "Method for Reporting",
            "original_name": "Method for Reporting",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Method for Reporting",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the technique by which trial related events, such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events, are reported to the sponsor and/or regulatory authority.",
            "guidance": "N/A",
            "conformance": "Optional if used",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, Situational Scope\nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type and situational scope",
            "ct": []
        }
    },
    "Backup Method for Reporting": {
        "template": {
            "long_name": "Backup Method for Reporting",
            "short_name": "Backup Method for Reporting",
            "original_name": "Backup Method for Reporting",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Back-up Method for Reporting",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of alternative techniques by which trial related events, such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events, are reported to the sponsor and/or regulatory authority.",
            "guidance": "N/A",
            "conformance": "Optional if table is used",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, Situational Scope\nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type and situational scope",
            "ct": [],
            "short_name": "Backup Method for Reporting"
        }
    },
    "Event Collection and Reporting Timing": {
        "template": {
            "long_name": "Enter Event Collection and Reporting Timing",
            "short_name": "Event Collection and Reporting Timing",
            "original_name": "Event Collection and Reporting Timing",
            "optional": false,
            "section_number": "9.2.1",
            "section_title": "Timing",
            "instructions": []
        },
        "technical": {
            "name": "Event Collection and Reporting Timing",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the timing window between trial related events and their reporting to the sponsor or designee.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.1 Timing\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Identification": {
        "template": {
            "long_name": "Enter Identification",
            "short_name": "Identification",
            "original_name": "Identification",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Identification",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA summary of the identification, recording, assessments of severity and causality, and follow-up of adverse events, serious adverse events, pregnancy and postpartum events, and medical device product complaints.",
            "guidance": "Specify how information will be identified (e.g., spontaneous reporting, solicited questions).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Identification and 9.2.2 Collection Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Severity": {
        "template": {
            "long_name": "Enter Severity",
            "short_name": "Severity",
            "original_name": "Severity",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Severity",
            "data_type": "Text",
            "definition": "C25676\nFor review purpose, see definition of the controlled terminology below \nThe evaluation of the intensity (severity) of an event.",
            "guidance": "Specify the intensity rating categories/scale.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Severity and 9.2.2 Collection Procedures\nConcept: C25676",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Severity",
            "notes": ""
        }
    },
    "Causality": {
        "template": {
            "long_name": "Enter Causality",
            "short_name": "Causality",
            "original_name": "Causality",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Causality",
            "data_type": "Text",
            "definition": "C82552\nFor review purpose, see definition of the controlled terminology below\nThe evaluation of the degree of causality (attributability) between a trial intervention and an event.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Causality and 9.2.2 Collection Procedures\nConcept: C82552",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Causality",
            "notes": ""
        }
    },
    "Recording": {
        "template": {
            "long_name": "Enter Recording",
            "short_name": "Recording",
            "original_name": "Recording",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Recording",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description for the procedures used to document an event.",
            "guidance": "Specify procedures for recording.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Recording and 9.2.2 Collection Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Follow-up": {
        "template": {
            "long_name": "Enter Follow-up",
            "short_name": "Follow-up",
            "original_name": "Follow-up",
            "optional": false,
            "section_number": "9.2.2",
            "section_title": "Collection Procedures",
            "instructions": []
        },
        "technical": {
            "name": "Follow-up",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the procedures for follow-up, including the assessment tools that will be used to monitor an event and the duration of follow-up.",
            "guidance": "Specify the procedures for follow-up. Include the assessment tools that will be used to monitor the events and the duration of follow-up after appearance of the events.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Follow-up and 9.2.2 Collection Procedures\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Reporting": {
        "template": {
            "long_name": "Enter Reporting",
            "short_name": "Reporting",
            "original_name": "Reporting",
            "optional": false,
            "section_number": "9.2.3",
            "section_title": "Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Reporting",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the method and timelines for reporting an event to the sponsor.",
            "guidance": "Specify the reporting method (e.g., an electronic data collection tool or a paper CRF), backup reporting method if applicable and reporting timeline to the Sponsor.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.3 Reporting\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Regulatory Reporting Requirements": {
        "template": {
            "long_name": "Enter Regulatory Reporting Requirements",
            "short_name": "Regulatory Reporting Requirements",
            "original_name": "Regulatory Reporting Requirements",
            "optional": false,
            "section_number": "9.2.3.1",
            "section_title": "Regulatory Reporting Requirements",
            "instructions": []
        },
        "technical": {
            "name": "Regulatory Reporting Requirements",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the requirements for the sponsor/designee to report a serious adverse event, including the criteria for reporting, to the relevant regulatory authority.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.3.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.3.1 Regulatory Reporting Requirements\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Adverse Events of Special Interest or state Not applicable": {
        "template": {
            "long_name": "Enter Adverse Events of Special Interest or state \u201cNot applicable\u201d",
            "short_name": "Adverse Events of Special Interest or state Not applicable",
            "original_name": "Adverse Events of Special Interest or state \u201cNot applicable\u201d",
            "optional": false,
            "section_number": "9.2.4",
            "section_title": "Adverse Events of Special Interest",
            "instructions": []
        },
        "technical": {
            "name": "Adverse Events of Special Interest or state Not applicable",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to define, measure, confirm, and report the occurrence of adverse events that are of special interest to the specific trial, or state not applicable.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.4 Adverse Events of Special Interest\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Participants Who Become Pregnant During the Trial": {
        "template": {
            "long_name": "Enter Participants Who Become Pregnant During the Trial",
            "short_name": "Participants Who Become Pregnant During the Trial",
            "original_name": "Participants Who Become Pregnant During the Trial",
            "optional": false,
            "section_number": "9.3.1",
            "section_title": "{Participants Who Become Pregnant During the Trial}",
            "instructions": []
        },
        "technical": {
            "name": "Participants Who Become Pregnant During the Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to collect pregnancy data for a trial participant who becomes pregnant while the participant is in the trial, as well as data collection about the child.",
            "guidance": "",
            "conformance": "Conditional: when collecting pregnancy data for a trial participant who becomes pregnant during the trial.",
            "cardinality": "One to one",
            "relationship": "9.3.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.3.1 Participants Who Become Pregnant During the Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Participants Who Become Pregnant During the Trial",
            "notes": ""
        }
    },
    "Participants Whose Partners Become Pregnant During the Trial": {
        "template": {
            "long_name": "Enter Participants Whose Partners Become Pregnant During the Trial",
            "short_name": "Participants Whose Partners Become Pregnant During the Trial",
            "original_name": "Participants Whose Partners Become Pregnant During the Trial",
            "optional": false,
            "section_number": "9.3.2",
            "section_title": "{Participants Whose Partners Become Pregnant During the Trial}",
            "instructions": []
        },
        "technical": {
            "name": "Participants Whose Partners Become Pregnant During the Trial",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to collect pregnancy data for a trial participant's partner, who becomes pregnant while the participant is in the trial.",
            "guidance": "",
            "conformance": "Conditional: when collecting pregnancy data for the partner of a trial participant who becomes pregnant during the trial.",
            "cardinality": "One to one",
            "relationship": "9.3.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.3.2 Participants Whose Partners Become Pregnant During the Trial\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Special Safety Situations": {
        "template": {
            "long_name": "Enter Special Safety Situations",
            "short_name": "Special Safety Situations",
            "original_name": "Special Safety Situations",
            "optional": false,
            "section_number": "9.4",
            "section_title": "Special Safety Situations",
            "instructions": []
        },
        "technical": {
            "name": "Special Safety Situations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA characterization or classification of those trial specific situations that are associated with the trial intervention(s) and require regulatory reporting, but that do not qualify as an adverse event or serious adverse event for the given trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.4 Special Safety Situations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "General Considerations": {
        "template": {
            "long_name": "Enter General Considerations",
            "short_name": "General Considerations",
            "original_name": "General Considerations",
            "optional": false,
            "section_number": "10.1",
            "section_title": "General Considerations",
            "instructions": []
        },
        "technical": {
            "name": "General Considerations",
            "data_type": "Text",
            "definition": "C164387\nFor review purpose, see definition of the controlled terminology below\nCareful thought or deliberation related to the planned conduct of statistical analyses within the context of the trial.",
            "guidance": "Provide statements relevant to statistical considerations in general. For example, this might include statements indicating whether there is a separate statistical analysis plan, which general summary statistics will be provided, and when the analyses will be conducted (e.g. \u201cThe analysis will be conducted on all participant data at the time the trial ends.\u201d).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.1 General Considerations, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: C164387",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "General Considerations",
            "notes": ""
        }
    },
    "Analysis Sets": {
        "template": {
            "long_name": "Enter Analysis Sets",
            "short_name": "Analysis Sets",
            "original_name": "Analysis Sets",
            "optional": false,
            "section_number": "10.2",
            "section_title": "Analysis Sets",
            "instructions": []
        },
        "technical": {
            "name": "Analysis Sets",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the set of participants whose data are to be included in the analyses.",
            "guidance": "Describe analysis sets to be considered at the trial level, i.e. the set of participants whose data are to be included in the analyses. For each analysis described in Section 10, it should be clear which analysis set should be used.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.2 Analysis Sets, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Analysis Sets",
            "notes": ""
        }
    },
    "Analyses of Demographics and Other Baseline Variables": {
        "template": {
            "long_name": "Enter Analyses of Demographics and Other Baseline Variables",
            "short_name": "Analyses of Demographics and Other Baseline Variables",
            "original_name": "Analyses of Demographics and Other Baseline Variables",
            "optional": false,
            "section_number": "10.3",
            "section_title": "Analyses of Demographics and Other Baseline Variables",
            "instructions": []
        },
        "technical": {
            "name": "Analyses of Demographics and Other Baseline Variables",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of analyses relevant to variables at baseline, for example demographics, related to the trial.",
            "guidance": "Describe the summary statistics that will be used to describe the distribution of demographic and other relevant variables at baseline. Specify the timing of the measurement of the variables (e.g., at inclusion in the trial; before, or at randomisation). Relevant variables include but are not limited to: stratification variables specified in Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding, covariates for the statistical models specified in Section 10.4 Analyses Associated with the Primary Objective(s), other suspected predictive or prognostic variables, and variables used for planned subgroup analyses.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.3 Analyses of Demographics and Other Baseline Variables, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Analyses of Demographics and Other Baseline Variables",
            "notes": ""
        }
    },
    "Statistical Analysis Method": {
        "template": {
            "long_name": "Enter Statistical Analysis Method",
            "short_name": "Statistical Analysis Method",
            "original_name": "Statistical Analysis Method",
            "optional": false,
            "section_number": "10.4.1.1",
            "section_title": "Statistical Analysis Method",
            "instructions": []
        },
        "technical": {
            "name": "Statistical Method of Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical model, hypothesis, and methods of analyses for each objective within the trial.",
            "guidance": "Describe the statistical analysis methods that will be used to evaluate the primary objective(s) and associated estimand(s) in Section 3.1. Ensure that the statistical hypothesis/model/analysis (and corresponding assumptions) is aligned with the primary estimand(s). If there is more than one primary objective, present each objective as a level 3 heading and present each subsequent heading in Section 10.4 as a level 4 heading.\nFor each objective, state the null and alternative hypotheses, including the pre-planned type 1 error rate, or alternative criteria for evaluating whether the objective has been met, and relevant operating characteristics if appropriate. Describe the statistical model used and the factors that will be included (covariates and interactions) and any rules for handling these factors (for example, pooling of centres).\nIf modelling and simulation methods are to be used, please describe the model (inputs and outputs), the underlying assumptions, and the method of model fitting.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.4.X.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.4.X.1 Statistical Analysis Method\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.4.X.1, 10.4.X.2, 10.4.X.3, 10.4.X.4, 10.4.X.5).",
            "ct": [],
            "short_name": "Statistical Analysis Method"
        }
    },
    "Handling of Data in Relation to Primary Estimands": {
        "template": {
            "long_name": "Enter Handling of Data in Relation to Primary Estimand(s)",
            "short_name": "Handling of Data in Relation to Primary Estimands",
            "original_name": "Handling of Data in Relation to Primary Estimand(s)",
            "optional": false,
            "section_number": "10.4.1.2",
            "section_title": "Handling of Data in Relation to Primary Estimand(s)",
            "instructions": []
        },
        "technical": {
            "name": "Handling of Data in Relation to Primary Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how data will be handled for the statistical analysis in line with the primary estimand.",
            "guidance": "For each intercurrent event of the primary estimand(s) (Section 3.1, Estimand(s) for the Primary Objective(s)), explain how data will be handled for the statistical analysis in line with the primary estimand. The handling of intercurrent events in statistical analysis should be aligned with the specific estimand strategies being used.\nThis section should describe with more detail the rationale and handling of the data rather than repeating the guidance from the preceding sections.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.4.X.2 Handling of Data in relation to Primary Estimand(s)",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.4.X.2 Handling of Data in relation to Primary Estimand(s)\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.4.X.1, 10.4.X.2, 10.4.X.3, 10.4.X.4, 10.4.X.5).",
            "ct": []
        }
    },
    "Sensitivity Analysis": {
        "template": {
            "long_name": "Enter Sensitivity Analysis",
            "short_name": "Sensitivity Analysis",
            "original_name": "Sensitivity Analysis",
            "optional": false,
            "section_number": "10.4.1.4",
            "section_title": "{Sensitivity Analysis}",
            "instructions": []
        },
        "technical": {
            "name": "Sensitivity Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the series of analyses conducted to explore the robustness of inferences from the main estimator to deviations from its underlying modelling assumptions and limitations in the data.",
            "guidance": "Describe sensitivity analyses. Sensitivity analyses are a series of analyses conducted with the intent to explore the robustness of inferences from the main estimator to deviations from its underlying modelling assumptions and limitations in the data.",
            "conformance": "Conditional: when there is Sensitivity Analysis for a primary objective",
            "cardinality": "One to many",
            "relationship": "10.4.X.4",
            "value": "Text",
            "business_rules": "Value Allowed Yes\nRelationship: 10.4.X.4 Sensitivity Analysis\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.4.X.1, 10.4.X.2, 10.4.X.3, 10.4.X.4, 10.4.X.5).",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Sensitivity Analysis",
            "notes": ""
        }
    },
    "Supplementary Analysis": {
        "template": {
            "long_name": "Enter Supplementary Analysis",
            "short_name": "Supplementary Analysis",
            "original_name": "Supplementary Analysis",
            "optional": false,
            "section_number": "10.4.1.5",
            "section_title": "{Supplementary Analysis}",
            "instructions": []
        },
        "technical": {
            "name": "Supplementary Analysis",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses that are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "guidance": "Describe any supplementary analysis if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "conformance": "Conditional: when there is Supplementary Analysis for a primary objective",
            "cardinality": "One to one",
            "relationship": "10.4.X.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.4.X.5 Supplementary Analysis\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.4.X.1, 10.4.X.2, 10.4.X.3, 10.4.X.4, 10.4.X.5).",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Supplementary Analysis",
            "notes": ""
        }
    },
    "Handling of Data in Relation to Secondary Estimands": {
        "template": {
            "long_name": "Enter Handling of Data in Relation to Secondary Estimand(s)",
            "short_name": "Handling of Data in Relation to Secondary Estimands",
            "original_name": "Handling of Data in Relation to Secondary Estimand(s)",
            "optional": false,
            "section_number": "10.5.1.2",
            "section_title": "{Handling of Data in Relation to Secondary Estimand(s)}",
            "instructions": []
        },
        "technical": {
            "name": "Handling of Data in Relation to Secondary Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how data will be handled for the statistical analysis in line with the Secondary estimand.",
            "guidance": "For each intercurrent event of the Secondary estimand(s) (Section 3.1, Estimand(s) for the Secondary Objective(s)), explain how data will be handled for the statistical analysis in line with the Secondary estimand. The handling of intercurrent events in statistical analysis should be aligned with the specific estimand strategies being used.\nThis section should describe with more detail the rationale and handling of the data rather than repeating the guidance from the preceding sections.",
            "conformance": "Conditional: when there is Secondary estimand",
            "cardinality": "One to one",
            "relationship": "10.5.X.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:10.5.X.2 Handling of Data in relation to Secondary Estimand(s)\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.5.X.1, 10.5.X.2, 10.5.X.3, 10.5.X.4, 10.5.X.5).",
            "ct": []
        }
    },
    "Handling of Missing Data in Relation to Secondary Estimands": {
        "template": {
            "long_name": "Enter Handling of Missing Data in Relation to Secondary Estimand(s)",
            "short_name": "Handling of Missing Data in Relation to Secondary Estimands",
            "original_name": "Handling of Missing Data in Relation to Secondary Estimand(s)",
            "optional": false,
            "section_number": "10.5.1.3",
            "section_title": "{Handling of Missing Data in Relation to Secondary Estimand(s)}",
            "instructions": []
        },
        "technical": {
            "name": "Handling of Missing Data in Relation to Secondary Estimands",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how missing data associated with the Secondary estimand will be handled, including the rationale for the approach.",
            "guidance": "Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach.",
            "conformance": "Conditional: when there is Secondary estimand",
            "cardinality": "One to one",
            "relationship": "10.5.X.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.5.X.3 Handling of Missing Data in Relation to Secondary Estimand(s)\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.5.X.1, 10.5.X.2, 10.5.X.3, 10.5.X.4, 10.5.X.5).",
            "ct": []
        }
    },
    "Safety Analyses": {
        "template": {
            "long_name": "Enter Safety Analyses",
            "short_name": "Safety Analyses",
            "original_name": "Safety Analyses",
            "optional": false,
            "section_number": "10.7",
            "section_title": "Safety Analyses",
            "instructions": []
        },
        "technical": {
            "name": "Safety Analyses",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses of relevant safety variables, including adverse events of special interest.",
            "guidance": "If safety is a primary and/or secondary objective, describe the corresponding safety analyses in the appropriate section above (Section 10.4 Analyses Associated with the Primary Objective(s) or Section 10.5 Analyses Associated with the Secondary Objective[s]). In this section, describe statistical methods that will be used to analyse relevant safety outcomes, including any AESI. This should typically include specification of a measure to estimate risk within treatment arms, a measure to compare risks across treatment arms, and a measure of statistical uncertainty around the comparison such as a confidence interval.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.7",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.7 Safety Analyses\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Safety Analyses",
            "notes": ""
        }
    },
    "Other Analyses": {
        "template": {
            "long_name": "Enter Other Analyses",
            "short_name": "Other Analyses",
            "original_name": "Other Analyses",
            "optional": false,
            "section_number": "10.8",
            "section_title": "Other Analyses",
            "instructions": []
        },
        "technical": {
            "name": "Other Analyses",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses that are different than the one(s) previously specified or mentioned.",
            "guidance": "Describe other analyses not included in Sections 10.3-10.8, such as subgroup analyses.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.8",
            "value": "Text",
            "business_rules": "Value AllowedYes\nRelationship: 10.8 Other Analyses,Concept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Other Analyses",
            "notes": ""
        }
    },
    "Interim Analyses": {
        "template": {
            "long_name": "Enter Interim Analyses",
            "short_name": "Interim Analyses",
            "original_name": "Interim Analyses",
            "optional": false,
            "section_number": "10.9",
            "section_title": "Interim Analyses",
            "instructions": []
        },
        "technical": {
            "name": "Interim Analyses",
            "data_type": "Text",
            "definition": "C142582\nFor review purpose, see definition of the controlled terminology below\nA textual description of any analysis intended to compare treatment arms with respect to efficacy or safety at any time prior to the formal completion of a trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.9 Interim Analyses\nConcept: C142582",
            "repeating": "Yes, repeatable for each interim",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Interim Analyses",
            "notes": ""
        }
    },
    "Multiplicity Adjustments": {
        "template": {
            "long_name": "Enter Multiplicity Adjustments",
            "short_name": "Multiplicity Adjustments",
            "original_name": "Multiplicity Adjustments",
            "optional": false,
            "section_number": "10.10",
            "section_title": "Multiplicity Adjustments",
            "instructions": []
        },
        "technical": {
            "name": "Multiplicity Adjustments",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical adjustments needed to limit the probability of false positive findings in trials where there are multple simultaneous hypotheses.",
            "guidance": "Multiple testing procedures may be needed to limit the probability of false positive findings in a trial. Reasons for carrying out multiple statistical tests include - but are not restricted to - multiple endpoints, multiple treatment groups, multiple hypotheses, subgroups, different statistical methods, etc.\nDescribe any approaches to multiplicity control for the trial. This description might go beyond the analysis of primary objectives.\nSpecify the statistical approach to control the overall type I error rate as well as the (adjusted) significance levels to test specific hypotheses, as applicable. Clarify whether the tests/confidence intervals are one- or two-sided.\nState the circumstances under which a study will be considered to have met its primary objective(s). For example, in a study with two primary efficacy endpoints, this section should state whether the study would be expected to provide evidence on at least one or on both of the endpoints in order to confirm the efficacy of the treatment.\nFor some statistical approaches it might be helpful to include a graphical depiction, as visualisation will be helpful for understanding, coupled with the clinical translation of the mathematical choices.\nDetails regarding Interim Analyses should be provided in section 10.9.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.10",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship:10.10 Multiplicity Adjustments\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Multiplicity Adjustments",
            "notes": ""
        }
    },
    "Sample Size Determination": {
        "template": {
            "long_name": "Enter Sample Size Determination",
            "short_name": "Sample Size Determination",
            "original_name": "Sample Size Determination",
            "optional": false,
            "section_number": "10.11",
            "section_title": "Sample Size Determination",
            "instructions": []
        },
        "technical": {
            "name": "Sample Size Determination",
            "data_type": "Text",
            "definition": "C115467\nFor review purpose, see definition of the controlled terminology below\nA statistical calculation to determine the number of subjects required for the primary analysis, which should be large enough to provide a reliable answer to the questions addressed and should be determined by the primary objective of the trial. If the sample size is determined on some other basis, then this should be made clear and justified.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.11",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.11 Sample Size Determination,\nConcept: C115467",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Sample Size Determination",
            "notes": ""
        }
    },
    "Regulatory and Ethical Considerations": {
        "template": {
            "long_name": "Enter Regulatory and Ethical Considerations",
            "short_name": "Regulatory and Ethical Considerations",
            "original_name": "Regulatory and Ethical Considerations",
            "optional": false,
            "section_number": "11.1",
            "section_title": "Regulatory and Ethical Considerations",
            "instructions": []
        },
        "technical": {
            "name": "Regulatory and Ethical Considerations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nCareful thought or deliberation related to the regulatory and ethical aspects of the trial.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.1 Regulatory and Ethical Considerations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Regulatory and Ethical Considerations",
            "notes": ""
        }
    },
    "Trial Oversight": {
        "template": {
            "long_name": "Enter Trial Oversight ",
            "short_name": "Trial Oversight",
            "original_name": "Trial Oversight ",
            "optional": false,
            "section_number": "11.2",
            "section_title": "Trial Oversight",
            "instructions": []
        },
        "technical": {
            "name": "Trial Oversight",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the planned processes and procedures to govern and conduct a clinical trial in order to protect the rights, safety and welfare of the trial participants.",
            "guidance": "Concisely summarize the trial oversight listing the investigator and sponsor responsibilities not covered in other sections of the protocol which are essential for the operations of the trial, specifying the ones related to quality assurance.\nif not using below optional subheadings",
            "conformance": "Conditional: if not using the optional subheadings Level 3 (11.2.1, 11.2.2)",
            "cardinality": "One to one",
            "relationship": "11.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.2 Trial Oversight\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Investigator Responsibilities": {
        "template": {
            "long_name": "Enter Investigator Responsibilities",
            "short_name": "Investigator Responsibilities",
            "original_name": "Investigator Responsibilities",
            "optional": false,
            "section_number": "11.2.1",
            "section_title": "Investigator Responsibilities",
            "instructions": []
        },
        "technical": {
            "name": "Investigator Responsibilities",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the investigator with respect to the trial.",
            "guidance": "Describe the investigator duties, including the oversight of duties delegated to a third party that may impact the trial conduct at sites, if applicable and if not addressed elsewhere.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "11.2.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.2.1 Investigator Responsibilities\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Investigator Responsibilities",
            "notes": ""
        }
    },
    "Sponsor Responsibilities": {
        "template": {
            "long_name": "Enter Sponsor Responsibilities",
            "short_name": "Sponsor Responsibilities",
            "original_name": "Sponsor Responsibilities",
            "optional": true,
            "section_number": "11.2.2",
            "section_title": "Sponsor Responsibilities",
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Responsibilities",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the sponsor with respect to the trial.",
            "guidance": "Describe the sponsor duties, including those to be transferred to a third party that may impact the investigators sites, if applicable.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "11.2.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.2.2 Sponsor Responsibilities\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Sponsor Responsibilities",
            "notes": ""
        }
    },
    "Description of Informed Consent Process": {
        "template": {
            "long_name": "Enter Description of Informed Consent Process",
            "short_name": "Description of Informed Consent Process",
            "original_name": "Description of Informed Consent Process",
            "optional": false,
            "section_number": "11.3",
            "section_title": "Informed Consent Process",
            "instructions": []
        },
        "technical": {
            "name": "Description of Informed Consent Process",
            "data_type": "Text",
            "definition": "C184390\nFor review purpose, see definition of the controlled terminology below\nThe procedure by which informed consent is obtained and documented by means of a written, signed, and dated informed consent form. This process may include obtaining assent from participants with legally authorised representatives. (ICH GCP)",
            "guidance": "Specify the key elements of the informed consent process, including any special needs and how these are addressed (e.g., assent, capacity, legally acceptable representative, adolescents who may reach age of majority during the trial, pregnant participants and pregnant partners of participants).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: C184390",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Description of Informed Consent Process",
            "notes": ""
        }
    },
    "Description of Assent Process": {
        "template": {
            "long_name": "Enter Description of Assent Process",
            "short_name": "Description of Assent Process",
            "original_name": "Description of Assent Process",
            "optional": true,
            "section_number": "11.3",
            "section_title": "Informed Consent Process",
            "instructions": [
                "If enrollment in the trial may occur during an emergency in which the participant or their legally acceptable representative is not able or available to give consent, describe the consent process."
            ]
        },
        "technical": {
            "name": "Description of Assent Process",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the assent process for those individuals unable to give informed consent on their own behalf, to participate in the trial.",
            "guidance": "N/A",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "11.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Description of Assent Process",
            "notes": ""
        }
    },
    "Description of Emergency Consent Process": {
        "template": {
            "long_name": "Enter Description of Emergency Consent Process",
            "short_name": "Description of Emergency Consent Process",
            "original_name": "Description of Emergency Consent Process",
            "optional": true,
            "section_number": "11.3",
            "section_title": "Informed Consent Process",
            "instructions": []
        },
        "technical": {
            "name": "Description of Emergency Consent Process",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA type of informed consent process that may occur during an emergency situation in which the participant or their legally authorised representative is not available to give consent.",
            "guidance": "If enrollment in the trial may occur during an emergency in which the participant or their legally acceptable representative is not able or available to give consent, describe the consent process.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "11.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Description of Emergency Consent Process",
            "notes": ""
        }
    },
    "Informed Consent for Rescreening": {
        "template": {
            "long_name": "Enter Informed Consent for Rescreening",
            "short_name": "Informed Consent for Rescreening",
            "original_name": "Informed Consent for Rescreening",
            "optional": false,
            "section_number": "11.3.1",
            "section_title": "{Informed Consent for Rescreening}",
            "instructions": []
        },
        "technical": {
            "name": "Informed Consent for Rescreening",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the consent requirements for participants in the event of screen failure and rescreening.",
            "guidance": "If participants can be rescreened as described in Section 5.6, state whether the participant needs to complete a new consent. Screen failure and rescreening should be clearly defined in the protocol, with cross-reference to those definitions.",
            "conformance": "Conditional",
            "cardinality": "One to one",
            "relationship": "11.3.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3.1 Informed Consent for Rescreening\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Informed Consent for Use of Remaining Samples in Exploratory Research": {
        "template": {
            "long_name": "Enter Informed Consent for Use of Remaining Samples in Exploratory Research",
            "short_name": "Informed Consent for Use of Remaining Samples in Exploratory Research",
            "original_name": "Informed Consent for Use of Remaining Samples in Exploratory Research",
            "optional": false,
            "section_number": "11.3.2",
            "section_title": "{Informed Consent for Use of Remaining Samples in Exploratory Research}",
            "instructions": []
        },
        "technical": {
            "name": "Informed Consent for Use of Remaining Samples in Exploratory Research",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the consent requirements for exploratory research using the remainder of mandatory samples. If applicable, this may include text in the original consent that address the use of remaining samples or additional text.",
            "guidance": "If participants will be asked to consent to optional exploratory research using the remainder of mandatory samples, describe the use of remaining samples for optional exploratory research.\nIf any exploratory research is planned and additional written consent regarding the use of remaining samples for exploratory research will be obtained, describe the consent process.",
            "conformance": "Conditional",
            "cardinality": "One to one",
            "relationship": "11.3.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Committees": {
        "template": {
            "long_name": "Enter Committees",
            "short_name": "Committees",
            "original_name": "Committees",
            "optional": false,
            "section_number": "11.4",
            "section_title": "Committees",
            "instructions": []
        },
        "technical": {
            "name": "Committees",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the type and administrative structure of any committee associated with the trial.",
            "guidance": "Briefly describe the administrative structure of committees that will be reviewing data while the trial is ongoing, and the type of committee (e.g., Dose Escalation Committee, Data Monitoring Committee or Data Safety Monitoring Board). Note that specific details may be required depending on local law or regulation. If applicable, Committee Charters may be cross-referenced. If no committees are applicable, state \u201cNot applicable.\u201d",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.4 Committees\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Committees",
            "notes": ""
        }
    },
    "Insurance and Indemnity": {
        "template": {
            "long_name": "Enter Insurance and Indemnity",
            "short_name": "Insurance and Indemnity",
            "original_name": "Insurance and Indemnity",
            "optional": false,
            "section_number": "11.5",
            "section_title": "Insurance and Indemnity",
            "instructions": []
        },
        "technical": {
            "name": "Insurance and Indemnity",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise summary of the arrangements for participants insurance and indemnity as required by the applicable regulatory body.",
            "guidance": "Concisely summarize the arrangements for participants insurance and indemnity if not addressed in a separate agreement, if required by the applicable regulatory requirements.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.5 Insurance and Indemnity\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Insurance and Indemnity",
            "notes": ""
        }
    },
    "Risk-Based Quality Management": {
        "template": {
            "long_name": "Enter Risk-Based Quality Management",
            "short_name": "Risk-Based Quality Management",
            "original_name": "Risk-Based Quality Management",
            "optional": false,
            "section_number": "11.6",
            "section_title": "Risk-Based Quality Management",
            "instructions": []
        },
        "technical": {
            "name": "Risk-Based Quality Management",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of how potential risks and critical to quality factors associated with the trial will be identified and handled.",
            "guidance": "Describe the identified critical to quality factors, associated risks and risk mitigation strategies in the trial or refer to a separate document where this is described.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.6 Risk-Based Quality Management\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Data Governance": {
        "template": {
            "long_name": "Enter Data Governance",
            "short_name": "Data Governance",
            "original_name": "Data Governance",
            "optional": false,
            "section_number": "11.7",
            "section_title": "Data Governance",
            "instructions": []
        },
        "technical": {
            "name": "Data Governance",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the key processes to ensure data integrity, traceability and security, in order to enable accurate collection, reporting, monitoring, transfer, retention, access and publication.",
            "guidance": "Describe the key processes for critical trial integrity, traceability and security including a summary of the monitoring approaches enabling accurate collection, reporting, monitoring, transfer, retention, and access if not addressed in separate agreement(s).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.7",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.7 Data Governance\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Data Governance",
            "notes": ""
        }
    },
    "Data Protection": {
        "template": {
            "long_name": "Enter Data Protection",
            "short_name": "Data Protection",
            "original_name": "Data Protection",
            "optional": false,
            "section_number": "11.8",
            "section_title": "Data Protection",
            "instructions": []
        },
        "technical": {
            "name": "Data Protection",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the measures taken to protect the privacy and confidentiality of person information of trial participants in accordance with applicable regulatory requirements on personal data protection and any measures that should be taken in case of a data security breach.",
            "guidance": "Describe the measures to protect the privacy and confidentiality of personal information of trial participants in accordance with applicable regulatory requirements on personal data protection and any measures that should be taken in case of a data security breach.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.8",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.8 Data Protection\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Source Data Introduction": {
        "template": {
            "long_name": "Enter Source Data Introduction",
            "short_name": "Source Data Introduction",
            "original_name": "Source Data Introduction",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "technical": {
            "name": "Source Data Introduction",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of trial-related source data including the importance of source data maintenance and expectations for data traceability.",
            "guidance": "Establish the importance of source data and expectation for traceability of transcribed information back to source. Delineate expectations for investigators (e.g., maintain source data at the site, ensure availability of current records) and trial monitors (e.g., verify CRF data relative to source, ensure that safety of participants is being protected and that conduct is in accordance with GCP). Identify what constitutes source data and its origin or provide a reference to the location of this information, if contained in a separate document, such as a monitoring guideline or source data acknowledgement).\nDescribe the provision for direct access to source data and documents enabling clinical trial-related monitoring, audits and regulatory inspections, if not included in separate agreement(s).",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.9 Source Data\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Source Data Introduction",
            "notes": ""
        }
    },
    "Investigator Expectations for Source Data": {
        "template": {
            "long_name": "Enter Investigator Expectations for Source Data",
            "short_name": "Investigator Expectations for Source Data",
            "original_name": "Investigator Expectations for Source Data",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "technical": {
            "name": "Investigator Expectations for Source Data",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the investigator with respect to maintaining and ensuring availability of the source data.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.9 Source Data\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Investigator Expectations for Source Data",
            "notes": ""
        }
    },
    "Trial Monitor Expectations for Source Data": {
        "template": {
            "long_name": "Enter Trial Monitor Expectations for Source Data",
            "short_name": "Trial Monitor Expectations for Source Data",
            "original_name": "Trial Monitor Expectations for Source Data",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "technical": {
            "name": "Trial Monitor Expectations for Source Data",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the trial monitor with respect to maintaining and ensuring availability of the source data.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.9 Source Data\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Trial Monitor Expectations for Source Data",
            "notes": ""
        }
    },
    "Identification of Source Data": {
        "template": {
            "long_name": "Enter Identification of Source Data",
            "short_name": "Identification of Source Data",
            "original_name": "Identification of Source Data",
            "optional": false,
            "section_number": "11.9",
            "section_title": "Source Data",
            "instructions": []
        },
        "technical": {
            "name": "Identification of Source Data",
            "data_type": "Text",
            "definition": "C125442\nFor review purpose, see definition of the controlled terminology below\nA description of how trial-related source data will be identified.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.9",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.9 Source Data\nConcept: C125442",
            "repeating": "No",
            "ct": []
        }
    },
    "Protocol Deviations": {
        "template": {
            "long_name": "Enter Protocol Deviations",
            "short_name": "Protocol Deviations",
            "original_name": "Protocol Deviations",
            "optional": false,
            "section_number": "11.10",
            "section_title": "Protocol Deviations",
            "instructions": []
        },
        "technical": {
            "name": "Protocol Deviations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of plans for detecting, reviewing, and reporting any deviations from the protocol.",
            "guidance": "Describe plans for detecting, reviewing, and reporting any deviations from the protocol or include reference to a separate document.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.10",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.10 Protocol Deviations\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Decision Rights for Site Closure": {
        "template": {
            "long_name": "Enter Decision Rights for Site Closure",
            "short_name": "Decision Rights for Site Closure",
            "original_name": "Decision Rights for Site Closure",
            "optional": false,
            "section_number": "11.11",
            "section_title": "Early Site Closure",
            "instructions": []
        },
        "technical": {
            "name": "Decision Rights for Site Closure",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the legal principles of entitlement for the sponsor to close a trial site, or for the investigator to initiate the closure of a trial site.",
            "guidance": "List the sponsor\u2019s rights to close a site early. Likewise, list the investigator\u2019s rights to initiate early site closure.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.11",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.11 Early Site Closure\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Decision Rights for Site Closure",
            "notes": ""
        }
    },
    "Criteria for Early Closure": {
        "template": {
            "long_name": "Enter Criteria for Early Closure",
            "short_name": "Criteria for Early Closure",
            "original_name": "Criteria for Early Closure",
            "optional": false,
            "section_number": "11.11",
            "section_title": "Early Site Closure",
            "instructions": []
        },
        "technical": {
            "name": "Criteria for Early Closure",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to close a trial site prematurely.",
            "guidance": "List the criteria for early closure of a site by the sponsor or investigator.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.11",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.11 Early Site Closure\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Criteria for Early Closure",
            "notes": ""
        }
    },
    "Responsibilities Following Early Site Closure": {
        "template": {
            "long_name": "Enter Responsibilities Following Early Site Closure",
            "short_name": "Responsibilities Following Early Site Closure",
            "original_name": "Responsibilities Following Early Site Closure",
            "optional": false,
            "section_number": "11.11",
            "section_title": "Early Site Closure",
            "instructions": []
        },
        "technical": {
            "name": "Responsibilities Following Early Site Closure",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe responsibilities of the sponsor and/or investigator following an unplanned early termination or suspension of the trial at an individual site.",
            "guidance": "List the responsibilities of the sponsor and investigator following early site closure, such as informing the ethics committee(s), and prompt notification of the participant and their transition to appropriate therapy and/or follow-up.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.11",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.11 Early Site Closure\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Data Dissemination": {
        "template": {
            "long_name": "Enter Data Dissemination",
            "short_name": "Data Dissemination",
            "original_name": "Data Dissemination",
            "optional": false,
            "section_number": "11.12",
            "section_title": "Data Dissemination",
            "instructions": []
        },
        "technical": {
            "name": "Data Dissemination",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of whether and which public databases the clinical trial, and results if applicable, will be registered.",
            "guidance": "Describe whether the clinical trial will be registered in public databases, including reporting of results, if applicable.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "11.12",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 11.12 Data Dissemination\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Clinical Laboratory Tests": {
        "template": {
            "long_name": "Enter Clinical Laboratory Tests",
            "short_name": "Clinical Laboratory Tests",
            "original_name": "Clinical Laboratory Tests",
            "optional": false,
            "section_number": "12.1",
            "section_title": "Clinical Laboratory Tests",
            "instructions": []
        },
        "technical": {
            "name": "Clinical Laboratory Tests",
            "data_type": "Text",
            "definition": "C25294\nFor review purpose, see definition of the controlled terminology below\nAny procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.",
            "guidance": "Specify which laboratory parameters should be included in each clinical laboratory assessment panel (e.g., for haematology, chemistry, urinalysis). A tabular presentation for such information is common. If applicable, include equations and references for locally calculated laboratory results. \nIf not applicable, retain heading and enter \u201cNot applicable.\u201d",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "12.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.1 Clinical Laboratory Tests\nConcept: C25294",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Clinical Laboratory Tests",
            "notes": ""
        }
    },
    "Country-Region Identifier": {
        "template": {
            "long_name": "Country/Region Identifier",
            "short_name": "Country-Region Identifier",
            "original_name": "Country/Region Identifier",
            "optional": true,
            "section_number": "12.2",
            "section_title": "Country/Region-Specific Differences",
            "instructions": []
        },
        "technical": {
            "name": "Country-Region Identifier",
            "data_type": "Valid Value",
            "definition": "C20108 or CNEW\nFor review purpose, see definition of the controlled terminology below\nCountry: A sequence of characters used to identify and/or name the country.\nRegion: A sequence of characters used to identify and/or name the region.",
            "guidance": "Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (e.g., document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (e.g., by country/region-specific amendments or addenda).\nAn alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies.\nIf not applicable, retain the heading and enter \u201cNot applicable.\u201d",
            "conformance": "Optional: if there is Country/Region-specific differences",
            "cardinality": "One to many",
            "relationship": "12.2",
            "value": "Country Data element ISO 3166 Alpha 2, Region Data element ISO 3166 Alpha 2\nor\nNot applicable",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country/Region-Specific Differences\nConcept: C20108, CNEW, Heading, Identifier, ISO 3166 Country Codes, Alpha 2; ISO 3166 Region Codes, Alpha 2",
            "repeating": "Yes, repeatable for each Country/Region",
            "ct": []
        }
    },
    "Country-Region Specific Requirements": {
        "template": {
            "long_name": "Enter Country/Region Specific Requirements",
            "short_name": "Country-Region Specific Requirements",
            "original_name": "Country/Region Specific Requirements",
            "optional": true,
            "section_number": "12.2",
            "section_title": "Country/Region-Specific Differences",
            "instructions": []
        },
        "technical": {
            "name": "Country-Region-Specific Requirements",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of any country or region-specific requirements related to the trial but not related to individual items in the protocol.",
            "guidance": "Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (e.g., document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (e.g., by country/region-specific amendments or addenda).\nAn alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies.",
            "conformance": "Optional If there is Country/Region-specific differences",
            "cardinality": "One to many",
            "relationship": "12.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country /Region Identifier ;Country/Region-Specific Differences\nConcept: CNEW",
            "repeating": "Yes, repeatable for each Country/Region",
            "ct": [],
            "short_name": "Country-Region Specific Requirements"
        }
    },
    "Country-Region Specific Protocol Clarifications": {
        "template": {
            "long_name": "Enter Country/Region Specific Protocol Clarifications",
            "short_name": "Country-Region Specific Protocol Clarifications",
            "original_name": "Country/Region Specific Protocol Clarifications",
            "optional": true,
            "section_number": "12.2",
            "section_title": "Country/Region-Specific Differences",
            "instructions": []
        },
        "technical": {
            "name": "Country-Region-specific Protocol Clarifications",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of any country or region-specific clarifications related to a protocol item.",
            "guidance": "Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (e.g., document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (e.g., by country/region-specific amendments or addenda).\nAn alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies.",
            "conformance": "Optional if there is Country/Region-specific differences",
            "cardinality": "One to many",
            "relationship": "12.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country /Region Identifier Country/Region-Specific Differences\nConcept: CNEW",
            "repeating": "Yes, repeatable for each country/region",
            "ct": [],
            "short_name": "Country-Region Specific Protocol Clarifications"
        }
    },
    "Sponsor Approval Date": {
        "template": {
            "long_name": "Enter Sponsor Approval Date",
            "short_name": "Sponsor Approval Date",
            "original_name": "Sponsor Approval Date",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Approval Date",
            "data_type": "Date",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date that the sponsor approved the version of the protocol,",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Date",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading \u201cDocument\u201d; \u201cSponsor Approval Date\u201d \nConcept: CNEW",
            "repeating": "Yes, reuse from the title page",
            "ct": []
        }
    },
    "specify alternative location": {
        "template": {
            "long_name": "specify alternative location",
            "short_name": "specify alternative location",
            "original_name": "specify alternative location",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": [
                "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first)."
            ]
        },
        "technical": {
            "name": "specify alternative location",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nthe physical or virtual location of the date on which the sponsor approved the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: when a specify alternative location is selected",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Text Location where information can be found",
            "business_rules": "Value Allowed: Yes\nRelationship: Location for previous amendments\nConcept: CNEW",
            "repeating": "Yes, reuse from the title page.",
            "ct": []
        }
    },
    "Glossary of Terms and Abbreviations": {
        "template": {
            "long_name": "Enter Glossary of Terms and Abbreviations",
            "short_name": "Glossary of Terms and Abbreviations",
            "original_name": "Glossary of Terms and Abbreviations",
            "optional": false,
            "section_number": "13",
            "section_title": "Appendix: Glossary of Terms and Abbreviations",
            "instructions": []
        },
        "technical": {
            "name": "Glossary of Terms and Abbreviations",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA collection of abbreviations (a shortened form of a word or phrase) and definitions (a concise explanation of the meaning of a word or phrase or symbol).",
            "guidance": "Define abbreviations and other terms used in the protocol. A tabular presentation is common and may serve as the definition at first use.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "13",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Glossary of Terms and Abbreviations",
            "notes": ""
        }
    },
    "References": {
        "template": {
            "long_name": "Enter References",
            "short_name": "References",
            "original_name": "References",
            "optional": false,
            "section_number": "14",
            "section_title": "Appendix: References",
            "instructions": []
        },
        "technical": {
            "name": "References",
            "data_type": "Text",
            "definition": "C184397\nFor review purpose, see definition of the controlled terminology below\nThe curated list of sources that are cited within the reference section of the document.",
            "guidance": "References should be listed in a common format that includes all relevant information to identify the source and date published. If not published, this should be clearly indicated.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "14",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 14 APPENDIX: REFERENCES\nConcept: C184397",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "References",
            "notes": ""
        }
    },
    "IMP or NIMP": {
        "template": {
            "long_name": "Select IMP or NIMP",
            "short_name": "IMP or NIMP",
            "original_name": "Select IMP or NIMP",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "IMP-NIMP",
            "data_type": "Valid value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the investigational intervention is an investigational medicinal product or an auxiliary medicinal product.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention",
            "relationship": "6",
            "value": "IMP(CNEW), NIMP(C156473)",
            "business_rules": "Value Allowed: Yes\nRelationship: One per each intervention \nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention per arm",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Investigational Medicinal Product Indicator Response",
                    "definition": "A terminology value set relevant to the investigational medicinal product indicator responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "IMP",
                    "definition": "A medicinal product which is being tested or used as a reference, including as a placebo, in a clinical trial."
                },
                {
                    "ncit_code": "C156473",
                    "preferred_term": "NIMP (AxMP)",
                    "definition": "A medicinal product that is related to the specific needs of the clinical trial as described in the protocol, but not as an investigational medicinal product."
                }
            ],
            "short_name": "IMP or NIMP"
        }
    },
    "Control Type": {
        "template": {
            "long_name": "Control type",
            "short_name": "Control Type",
            "original_name": "Control type",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Control Type",
            "data_type": "Valid Value",
            "definition": "C49647\nFor review purpose, see definition of the controlled terminology below\nA characterisation or classification of the comparator against which the study intervention is evaluated.",
            "guidance": "Control method (for example, placebo, active comparator, low dose, historical, standard of care, sham procedure, or none [uncontrolled])",
            "conformance": "Required",
            "cardinality": "One to one; One to Heading; One to Sponsor Protocol Identifier",
            "relationship": "1.1.2",
            "value": "Placebo (C49648), active comparator(C49649), Dose Response(C120841); Different Dose or Regimen (CNEW), External (CNEW), sham procedure(C184727), or No Control(C28280)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title; Sponsor Protocol Identifier\nConcept: C49647",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66785",
                    "preferred_term": "TCNTRL",
                    "definition": "A terminology codelist relevant to a comparator against which the study treatment is evaluated."
                },
                {
                    "ncit_code": "C49649",
                    "preferred_term": "Active Comparator",
                    "definition": "A type of control, which has a demonstrated effect, administered as a comparator to subjects in a clinical trial."
                },
                {
                    "ncit_code": "C120841",
                    "preferred_term": "Dose Response",
                    "definition": "A type of control using different doses or regimens of the same treatment across the treatment arms."
                },
                {
                    "ncit_code": "C28280",
                    "preferred_term": "No Control",
                    "definition": "A clinical study that lacks a comparison (i.e., a control) group."
                },
                {
                    "ncit_code": "C49648",
                    "preferred_term": "Placebo",
                    "definition": "An inactive, identical-appearing drug or treatment that does not contain the test product."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Different Dose or Regimen",
                    "definition": "A type of control that comprises a different dose or dosage regimen in comparison to the investigational intervention dose or dosage regimen."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "External",
                    "definition": "The use of external control data as a control arm for those studies where ethical concerns and/or underserved disease indications may make it difficult to enroll subjects/participants."
                },
                {
                    "ncit_code": "C184727",
                    "preferred_term": "Sham Procedure",
                    "definition": "A type of negative control in which a procedure is performed that mimics the procedure under study but does not include investigational processes or components."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "type",
                    "klass": "StudyArm",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@arms/StudyArm/@type"
                }
            ],
            "map_status": "Mapped",
            "name": "Control Type",
            "notes": ""
        }
    },
    "Minimum Age": {
        "template": {
            "long_name": "minimum age",
            "short_name": "Minimum Age",
            "original_name": "minimum age",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Minimum age",
            "data_type": "Number",
            "definition": "C49693\nFor review purpose, see definition of the controlled terminology below\nThe anticipated minimum age of the participants to be entered in a clinical trial.",
            "guidance": "Population age range - For trials in which multiple age ranges may be eligible (for example, a younger cohort and an older cohort), indicate the minimum and maximum ages for the trial overall, with an additional comment for any excluded age ranges.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "Integer",
            "business_rules": "Value Allowed: Yes\nRelationship: population age, Minimum; minimum unit of age\nConcept:C49693",
            "repeating": "No",
            "ct": [],
            "short_name": "Minimum Age"
        },
        "usdm": {
            "items": [
                {
                    "attribute": "plannedAge",
                    "klass": "StudyDesignPopulation",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@plannedAge"
                },
                {
                    "attribute": "plannedAge",
                    "klass": "StudyCohort",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@cohorts/StudyCohort/@plannedAge"
                },
                {
                    "attribute": "minValue",
                    "klass": "Range",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@plannedAge/Range/@minValue"
                }
            ],
            "map_status": "Mapped",
            "name": "Minimum Age",
            "notes": ""
        }
    },
    "Blinded Roles": {
        "template": {
            "long_name": "blinded roles",
            "short_name": "Blinded Roles",
            "original_name": "blinded roles",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Blinded roles",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn identifying designation assigned to a blinded individual within a clinical trial that corresponds with their function",
            "guidance": "\u201cNot applicable (No blinding)\u201d indicates an open label trial.",
            "conformance": "Required",
            "cardinality": "One to many",
            "relationship": "1.1.2",
            "value": "Participant (C142710), Care Provider (C17445), Investigator (C25936), Outcomes Assessor (CNEW), Sponsor (C70793) Not Applicable (C48660)",
            "business_rules": "Value Allowed: Yes, Multiple roles can be selected\nRelationship: Blinded Roles; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Blinding Role",
                    "definition": "A terminology value set relevant to the trial blinding roles within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C142710",
                    "preferred_term": "Participant",
                    "definition": "A member of the clinical study population from whom data are being collected."
                },
                {
                    "ncit_code": "C17445",
                    "preferred_term": "Care Provider",
                    "definition": "The primary person in charge of the care of a patient, usually a family member or a designated health care professional."
                },
                {
                    "ncit_code": "C25936",
                    "preferred_term": "Investigator",
                    "definition": "A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at the trial site, the investigator is the responsible leader of the team and may be called the principal investigator."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Outcomes Assessor",
                    "definition": "The individual who evaluates the outcome(s) of interest."
                },
                {
                    "ncit_code": "C70793",
                    "preferred_term": "Sponsor",
                    "definition": "An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical study."
                },
                {
                    "ncit_code": "C48660",
                    "preferred_term": "Not Applicable",
                    "definition": "Determination of a value is not relevant in the current context."
                }
            ],
            "short_name": "Blinded Roles"
        },
        "usdm": {
            "items": [
                {
                    "attribute": "maskingRoles",
                    "klass": "StudyDesign",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@maskingRoles"
                }
            ],
            "map_status": "Mapped",
            "name": "Blinded Roles",
            "notes": ""
        }
    },
    "Arm Type": {
        "template": {
            "long_name": "Select Arm Type",
            "short_name": "Arm Type",
            "original_name": "Select Arm Type",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Arm Type",
            "data_type": "Valid Value",
            "definition": "C172457\nFor review purpose, see definition of the controlled terminology below\nA characterization or classification of the study arm.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each arm name",
            "relationship": "6",
            "value": "Experimental Arm(C174266), Active Comparator Arm(C174267), Placebo Comparator Arm (C174268, Sham Comparator Arm (C174269), No Intervention Arm (C174270), Control Arm(C174226)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and arm type\nConcept: C172457",
            "repeating": "Yes, repeatable for each arm name",
            "ct": [
                {
                    "ncit_code": "C174222",
                    "preferred_term": "Study Arm Type Value Set Terminology",
                    "definition": "The terminology relevant to the identification of the kind of arm."
                },
                {
                    "ncit_code": "C174267",
                    "preferred_term": "Active Comparator Arm",
                    "definition": "An arm describing the active comparator."
                },
                {
                    "ncit_code": "C174226",
                    "preferred_term": "Control Arm",
                    "definition": "An arm describing the intervention or treatment plan for a group of participants in the study receiving a control. The control may comprise a non-investigational product (active control) or regimen, placebo, or no treatment."
                },
                {
                    "ncit_code": "C174266",
                    "preferred_term": "Experimental Arm",
                    "definition": "An arm describing the intervention or treatment plan for a group of participants in the study receiving test product(s)."
                },
                {
                    "ncit_code": "C174270",
                    "preferred_term": "No Intervention Arm",
                    "definition": "A study arm without an intervention or treatment."
                },
                {
                    "ncit_code": "C174268",
                    "preferred_term": "Placebo Comparator Arm",
                    "definition": "An arm describing the placebo comparator."
                },
                {
                    "ncit_code": "C174269",
                    "preferred_term": "Sham Comparator Arm",
                    "definition": "An arm describing the sham comparator."
                }
            ]
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Arm Type",
            "notes": ""
        }
    },
    "Intervention Type": {
        "template": {
            "long_name": "Select Intervention Type",
            "short_name": "Intervention Type",
            "original_name": "Select Intervention Type",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Intervention Type",
            "data_type": "Valid Value",
            "definition": "C98747\nFor review purpose, see definition of the controlled terminology below\nThe kind of product or procedure studied in a trial.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention name",
            "relationship": "6",
            "value": "Drug (C1909), Device (C16830), Biologic (C307), Vaccine (C923), Non-Surgical Procedure (CNEW), Surgery (C15329), Radiation (C15313), Behavioral (C15184), Genetic (C15238), Dietary Supplement (C1505), Combination Product (C54696), Diagnostic Test (C18020)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name, arm type and Intervention name, Concept: C98747",
            "repeating": "Yes, repeatable for each arm name and arm type combination",
            "ct": [
                {
                    "ncit_code": "C99078",
                    "preferred_term": "INTTYPE",
                    "definition": "A terminology codelist relevant to the kind of product or procedure studied in a trial."
                },
                {
                    "ncit_code": "C15184",
                    "preferred_term": "Behavioral",
                    "definition": "A technique used to change the behavior of a subject (e.g., psychotherapy, lifestyle counseling, or hypnosis)."
                },
                {
                    "ncit_code": "C307",
                    "preferred_term": "Biologic",
                    "definition": "A product of biological origin applicable to the prevention, treatment, or cure of a disease or condition, for example: virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product."
                },
                {
                    "ncit_code": "C923",
                    "preferred_term": "Vaccine",
                    "definition": "A medicinal product inducing immunity against disease, most often to prevent occurrence of a disease, (e.g., a preventative vaccine against infectious disease), but also to treat a disease, (e.g., a therapeutic vaccine against cancer)."
                },
                {
                    "ncit_code": "C54696",
                    "preferred_term": "Combination Product",
                    "definition": "A product composed of two or more different types of medical products (i.e., a combination of a drug, device, and/or biological product with one another and are referred to as \"constituent parts\" of the combination product)."
                },
                {
                    "ncit_code": "C16830",
                    "preferred_term": "Device",
                    "definition": "Any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, intended by the manufacturer to be used, alone or in combination for, one or more specific medical purpose(s)."
                },
                {
                    "ncit_code": "C1505",
                    "preferred_term": "Dietary Supplement",
                    "definition": "Preparations containing ingredient(s) intended to supplement the diet."
                },
                {
                    "ncit_code": "C1909",
                    "preferred_term": "Drug",
                    "definition": "An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient."
                },
                {
                    "ncit_code": "C15238",
                    "preferred_term": "Genetic",
                    "definition": "Introduction of genetic material into cells in order to correct or treat an inherited or acquired disease."
                },
                {
                    "ncit_code": "C15329",
                    "preferred_term": "Surgery",
                    "definition": "A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Non-Surgical Procedure",
                    "definition": "A medical procedure that produces an effect, or that is intended to alter the course of a disease in a patient or population, which is not considered a surgical procedure."
                },
                {
                    "ncit_code": "C15313",
                    "preferred_term": "Radiation",
                    "definition": "Use of targeted or whole body radiation to treat a disease."
                },
                {
                    "ncit_code": "C18020",
                    "preferred_term": "Diagnostic Test",
                    "definition": "Any procedure or test to diagnose a disease or disorder."
                }
            ]
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Intervention Type",
            "notes": ""
        }
    },
    "Pharmaceutical Dose Formulation": {
        "template": {
            "long_name": "Select Pharmaceutical Dose Form",
            "short_name": "Pharmaceutical Dose Formulation",
            "original_name": "Select Pharmaceutical Dose Form",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Pharmaceutical Dose Formulation",
            "data_type": "Valid Value",
            "definition": "C42636\nFor review purpose, see definition of the controlled terminology below\nPhysical characteristics of a drug product, (e.g. tablet, capsule, or solution) that contains a drug substance, generally-but not necessarily-in association with one or more other ingredients",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each arm name, arm type and intervention combination",
            "relationship": "6",
            "value": "Use IDMP (e.g., EDQM, CDISC)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and dosage formulation\nConcept: C42636",
            "repeating": "Yes, repeatable for each intervention and dosage formulation",
            "ct": []
        }
    },
    "Background Trial Intervention": {
        "template": {
            "long_name": "Enter Background Trial Interventions",
            "short_name": "Background Trial Intervention",
            "original_name": "Background Trial Interventions",
            "optional": false,
            "section_number": "6.9.1",
            "section_title": "{Background Trial Intervention}",
            "instructions": []
        },
        "technical": {
            "name": "Background Trial Intervention",
            "data_type": "Text",
            "definition": "C165822\nFor review purpose, see definition of the controlled terminology below\nMedicinal products that are administered to each clinical trial subject, regardless of randomization group, a) to treat the indication which is the object of the study, or b) required in the protocol as part of standard care for a condition that is not the indication under investigation, and is relevant for the clinical trial design. [After Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017]",
            "guidance": "Describe permitted background intervention(s), including administration and any conditions for use.",
            "conformance": "Conditional: when any background interventions are defined",
            "cardinality": "One to one",
            "relationship": "6.9.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 6.9.1 Background Trial Intervention\nConcept: C165822",
            "repeating": "No",
            "ct": []
        }
    },
    "Handling of Missing Data in Relation to Primary Estimand": {
        "template": {
            "long_name": "Enter Handling of Missing Data in Relation to Primary Estimand(s)",
            "short_name": "Handling of Missing Data in Relation to Primary Estimand",
            "original_name": "Handling of Missing Data in Relation to Primary Estimand(s)",
            "optional": false,
            "section_number": "10.4.1.3",
            "section_title": "Handling of Missing Data in Relation to Primary Estimand(s)",
            "instructions": []
        },
        "technical": {
            "name": "Handling of Missing Data in Relation to Primary Estimand",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how missing data associated with the primary estimand will be handled, including the rationale for the approach.",
            "guidance": "Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.4.X.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.4.X.3 Handling of Missing Data\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.4.X.1, 10.4.X.2, 10.4.X.3, 10.4.X.4, 10.4.X.5).",
            "ct": []
        }
    },
    "Analysis Associated with Exploratory Objectives": {
        "template": {
            "long_name": "Enter Analyses Associated with the Exploratory Objective(s)",
            "short_name": "Analysis Associated with Exploratory Objectives",
            "original_name": "Analyses Associated with the Exploratory Objective(s)",
            "optional": false,
            "section_number": "10.6",
            "section_title": "Analyses Associated with the Exploratory Objective(s)",
            "instructions": []
        },
        "technical": {
            "name": "Analysis Associated with Exploratory Objectivess",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical model, hypothesis, and methods of analyses for each exploratory objective within the trial.",
            "guidance": "Describe any exploratory analyses, if applicable. Additional subsections could be created to describe the analyses, as needed. If there is no exploratory objective, indicate \u201cnot applicable\u201d",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "10.6",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.6 Analysis Associated with the Exploratory Objective(s),\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "Analysis Associated with Exploratory Objectives"
        }
    },
    "Intervention Model": {
        "template": {
            "long_name": "Intervention model",
            "short_name": "Intervention Model",
            "original_name": "Intervention model",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Intervention Model",
            "data_type": "Valid Value",
            "definition": "C98746\nFor review purpose, see definition of the controlled terminology below\nThe overall design configuration for assigning intervention to participants.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one; One to Heading One to Sponsor Protocol Identifier",
            "relationship": "1.1.2",
            "value": "Single group (C82640), parallel group (C82639), cross-over (C82637), factorial(C82638), sequential (C142568), other(C17649)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title; Sponsor Protocol Identifier\nConcept: C98746",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C99076",
                    "preferred_term": "INTMODEL",
                    "definition": "A terminology codelist relevant to the trial design developed to compare treatment groups."
                },
                {
                    "ncit_code": "C82637",
                    "preferred_term": "Cross-over",
                    "definition": "Participants receive one of two or more alternative intervention(s) during the initial epoch of the study and receive other intervention(s) during the subsequent epoch(s) of the study."
                },
                {
                    "ncit_code": "C82638",
                    "preferred_term": "Factorial",
                    "definition": "Two or more interventions, each alone or in combination, are evaluated in parallel against a control group. This study design allows for the comparison of active drug to placebo, presence of drug-drug interactions, and comparison of active drugs against each other."
                },
                {
                    "ncit_code": "C82639",
                    "preferred_term": "Parallel Group",
                    "definition": "Participants are assigned to one of two or more treatment groups in parallel for the duration of the study."
                },
                {
                    "ncit_code": "C142568",
                    "preferred_term": "Sequential",
                    "definition": "Groups of participants are assigned to receive interventions based on prior milestones being reached in the study."
                },
                {
                    "ncit_code": "C82640",
                    "preferred_term": "Single Group",
                    "definition": "All trial participants are assigned to a single treatment group for the duration of the study."
                },
                {
                    "ncit_code": "C17649",
                    "preferred_term": "Other",
                    "definition": "Different than the one(s) previously specified or mentioned."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "interventionModel",
                    "klass": "StudyDesign",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@interventionModel"
                }
            ],
            "map_status": "Mapped",
            "name": "Intervention Model",
            "notes": ""
        }
    },
    "Population Level Summary": {
        "template": {
            "long_name": "Enter Population-level Summary",
            "short_name": "Population Level Summary",
            "original_name": "Population-level Summary",
            "optional": false,
            "section_number": "3.1.1",
            "section_title": "Primary Objective <#>",
            "instructions": []
        },
        "technical": {
            "name": "Population-Level Summary",
            "data_type": "Text",
            "definition": "C188853\nFor review purpose, see definition of the controlled terminology below\nThe variable to be obtained for each patient that is required to address the clinical question. The specification of the variable might include whether the patient experiences an intercurrent event",
            "guidance": "Description of the population-level summary (e.g., mean difference, relative risk)",
            "conformance": "Conditional: If there is a population-level summary as estimand",
            "cardinality": "One to Row Heading, One to Primary Objective Table, Project Identifier",
            "relationship": "3.1.X",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description\nConcept: C188853",
            "repeating": "Yes, repeatable for each numbered primary objective",
            "ct": [],
            "short_name": "Population Level Summary"
        }
    },
    "Population Type": {
        "template": {
            "long_name": "Population type",
            "short_name": "Population Type",
            "original_name": "Population type",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Population Type",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA characterisation or classification of the trial population.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one; One to Heading; One to Sponsor Protocol Identifier",
            "relationship": "1.1.2",
            "value": "With Disease (CNEW); Without Disease (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Population Type Response",
                    "definition": "A terminology value set relevant to the study population type responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "With Disease",
                    "definition": "An indication that the individual or group of individuals has been diagnosed with the disease of interest or under study."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Without Disease",
                    "definition": "An indication that the individual or group of individuals has not been diagnosed with the disease of interest or under study."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "includesHealthySubjects",
                    "klass": "StudyDesignPopulation",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@includesHealthySubjects"
                },
                {
                    "attribute": "includesHealthySubjects",
                    "klass": "StudyCohort",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@population/StudyDesignPopulation/@cohorts/StudyCohort/@includesHealthySubjects"
                }
            ],
            "map_status": "Mapped",
            "name": "Population Type",
            "notes": ""
        }
    },
    "Intervention Assignment Method": {
        "template": {
            "long_name": "Intervention assignment method",
            "short_name": "Intervention Assignment Method",
            "original_name": "Intervention assignment method",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Intervention Assignment Method",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe process used to assign trial participants to a trial intervention or trial arm.",
            "guidance": "Intervention assignment method - Do NOT state block size.",
            "conformance": "Required",
            "cardinality": "One to one: One toSponsor Protocol Identifier",
            "relationship": "1.1.2",
            "value": "Randomisation (C25196), Stratification (C25689), Stratified Randomisation (CNEW), Other (C17649) or Not Applicable (C48660)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row title identifier; Sponsor Protocol Identifiers\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Intervention Assignment Method Response",
                    "definition": "A terminology value set relevant to the trial intervention assignment method responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C25196",
                    "preferred_term": "Randomisation",
                    "definition": "The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group."
                },
                {
                    "ncit_code": "C25689",
                    "preferred_term": "Stratification",
                    "definition": "Grouping defined by important prognostic factors measured at baseline."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Stratified Randomisation",
                    "definition": "The process of grouping trial participants into strata according to important prognostic factors and then assigning participants within each stratum to different treatment or control groups using an element of chance and in order to reduce bias."
                }
            ]
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Intervention Assignment Method",
            "notes": ""
        }
    },
    "Disease Related Events or Outcomes Not Qualifying as AEs or SAEs": {
        "template": {
            "long_name": "Enter Disease-related Events or Outcomes not Qualifying as AEs or SAEs",
            "short_name": "Disease Related Events or Outcomes Not Qualifying as AEs or SAEs",
            "original_name": "Disease-related Events or Outcomes not Qualifying as AEs or SAEs",
            "optional": false,
            "section_number": "9.2.5",
            "section_title": "Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
            "instructions": []
        },
        "technical": {
            "name": "Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of events or outcomes related to the trial disease indication but not qualifying as adverse events or serious adverse events within the trial, or state not applicable.",
            "guidance": "Specify any DREs, DROs, or both that will not be reported as AEs or SAEs (e.g., seizures in anticonvulsant trials) or state \u201cNot applicable.\u201d",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.2.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.2.5 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "Disease Related Events or Outcomes Not Qualifying as AEs or SAEs"
        }
    },
    "Describe Method": {
        "template": {
            "long_name": "describe method",
            "short_name": "Describe Method",
            "original_name": "describe method",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "describe method",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA block of text containing the name and signature of the sponsor's signatory, along with a signature date, or a statement on behalf of the sponsor that describes the method of protocol approval.",
            "guidance": "Include either the Sponsor signature or the statement below.",
            "conformance": "Optional",
            "cardinality": "One to one",
            "relationship": "Title Page",
            "value": "Sponsor Signature Block (CNEW)\n OR \nSponsor Protocol Approval Statement (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Sponsor Signatory Response",
                    "definition": "A terminology value set relevant to the sponsor signatory responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Sponsor Signature Block",
                    "definition": "A block of text containing the name and signature of the sponsor's signatory, along with the signature date."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Sponsor Protocol Approval Statement",
                    "definition": "A statement that the protocol was approved by a method as described. This protocol was approved via <describe method>"
                }
            ],
            "short_name": "Describe Method"
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Describe Method",
            "notes": "USDM has avoided handling the issue of signatures. Align with the FHIR work during Phase 4"
        }
    },
    "State location where Information can be found": {
        "template": {
            "long_name": "State location where information can be found",
            "short_name": "State location where Information can be found",
            "original_name": "State location where information can be found",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "All versions should be uniquely identifiable. "
            ]
        },
        "technical": {
            "name": "State location where Information can be found",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below \nThe date that the sponsor approved the current version of the protocol, or the physical or virtual location of the date on which the sponsor approved the current version of the protocol.",
            "guidance": "All versions should be uniquely identifiable.",
            "conformance": "Required",
            "cardinality": "One to one; One to Sponsor Protocol Identifier; One to Original Protocol One to Amendment Identifier",
            "relationship": "Title Page",
            "value": "Sponsor Approval Date (C132352)\nLocation of Sponsor Approval Date (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Protocol Identifier, Protocol Amendment\nConcept: CNEW",
            "repeating": "Yes, reuse to approval date in Section 12.3",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Sponsor Approval Response",
                    "definition": "A terminology value set relevant to the sponsor approval responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C132352",
                    "preferred_term": "Sponsor Approval Date",
                    "definition": "The date that the sponsor approved the current version of the protocol."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Location of Sponsor Approval Date",
                    "definition": "The physical or virtual location of the date on which the sponsor approved the current version of the protocol."
                }
            ]
        }
    },
    "Use": {
        "template": {
            "long_name": "Select Use",
            "short_name": "Use",
            "original_name": "Select Use",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Use",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe reason or intention for the use of the trial intervention within the trial arm.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention",
            "relationship": "6",
            "value": "Experimental Intervention(C41161), Placebo(C753), Rescue Medicine(C165835), Background treatment(C165822), Challenge Agent(C158128), Diagnostic(C18020), Additional Required treatment (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and use, \nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention per arm",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Intervention Use Response",
                    "definition": "A terminology value set relevant to the intervention use responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "C41161",
                    "preferred_term": "Experimental Intervention",
                    "definition": "The drug, device, therapy, procedure, or process under investigation in a clinical study that is believed to have an effect on outcomes of interest in a study (e.g., health-related quality of life, efficacy, safety, pharmacoeconomics"
                },
                {
                    "ncit_code": "C753",
                    "preferred_term": "Placebo",
                    "definition": "A pharmaceutical preparation that does not contain the investigational agent and is generally prepared to be physically indistinguishable from the preparation containing the investigational product."
                },
                {
                    "ncit_code": "C165835",
                    "preferred_term": "Rescue Medicine",
                    "definition": "Medicinal products identified in the protocol as those that may be administered to subjects when the efficacy of the investigational medicinal product (IMP) is not satisfactory, the effect of the IMP is too great and is likely to cause a hazard to the patient, or to manage an emergency situation."
                },
                {
                    "ncit_code": "C165822",
                    "preferred_term": "Background Treatment",
                    "definition": "Medicinal products that are administered to each clinical trial subject, regardless of randomization group, a) to treat the indication which is the object of the study, or b) required in the protocol as part of standard care for a condition that is not the indication under investigation, and is relevant for the clinical trial design."
                },
                {
                    "ncit_code": "C158128",
                    "preferred_term": "Challenge Agent",
                    "definition": "A non-investigational medicinal product (NIMP) given to trial subjects to produce a physiological response that is necessary before the pharmacological action of the investigational medicinal product can be assessed."
                },
                {
                    "ncit_code": "C18020",
                    "preferred_term": "Diagnostic",
                    "definition": "Any procedure or test to diagnose a disease or disorder."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Additional Required Treatment",
                    "definition": "A medicinal product that must be administered along with the experimental treatment (e.g., drug studies wherein opioid blockers are administered to prevent overdose)."
                }
            ]
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Use",
            "notes": ""
        }
    },
    "Sourcing": {
        "template": {
            "long_name": "Select Sourcing",
            "short_name": "Sourcing",
            "original_name": "Select Sourcing",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Sourcing",
            "data_type": "Valid Value",
            "definition": "CNEW\nCNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the investigational intervention is sourced from a local or central vendor.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to many",
            "relationship": "6",
            "value": "Centrally Sourced (CNEW); Locally Sourced (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: One per each Intervention\nConcept: CNEW",
            "repeating": "Yes, repeatable for each intervention per arm name",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Investigational Intervention Sourcing Response",
                    "definition": "A terminology value set relevant to the investigational intervention source responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Centrally Sourced",
                    "definition": "An indication that the entity is obtained from a central vendor."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Locally Sourced",
                    "definition": "An indication that the entity is obtained from a local vendor."
                }
            ]
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Sourcing",
            "notes": ""
        }
    },
    "Route of Administration": {
        "template": {
            "long_name": "Select Route of Administration",
            "short_name": "Route of Administration",
            "original_name": "Select Route of Administration",
            "optional": true,
            "section_number": "6",
            "section_title": "Trial Intervention And Concomitant Therapy",
            "instructions": []
        },
        "technical": {
            "name": "Route of Administration",
            "data_type": "Valid Value",
            "definition": "C38114\nFor review purpose, see definition of the controlled terminology below\nPath by which the pharmaceutical product is taken into or makes contact with the body.",
            "guidance": "N/A",
            "conformance": "Optional: if the table used",
            "cardinality": "One to each intervention and dosage formulation",
            "relationship": "6",
            "value": "Use IDMP (e.g. EDQM, CDISC)",
            "business_rules": "Value Allowed: Yes\nRelationship: arm name and route of administration\nConcept: C38114",
            "repeating": "Yes, repeatable for each intervention. Dose formulation, per arm name",
            "ct": []
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Route of Administration",
            "notes": ""
        }
    },
    "Site Distribution": {
        "template": {
            "long_name": "Site distribution",
            "short_name": "Site Distribution",
            "original_name": "Site distribution",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Site Distribution",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the occurrence applies to a single or multiple trial sites.",
            "guidance": "N/A",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "1.1.2",
            "value": "single-centre (CNEW), multi-centre(CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title heading; Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Trial Site Distribution Response",
                    "definition": "A terminology value set relevant to the trial site distribution responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Single-Centre",
                    "definition": "A clinical study that is conducted at a single study site."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Multicentre",
                    "definition": "A clinical trial conducted according to a single protocol but at more than one site, and therefore, carried out by more than one investigator."
                }
            ]
        },
        "usdm": {
            "items": [
                {
                    "attribute": "name",
                    "klass": "StudySite",
                    "notes": "If count is greater then one then multi-center",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@organizations/ResearchOrganization/@manages/@name"
                }
            ],
            "map_status": "Mapped",
            "name": "Site Distribution",
            "notes": ""
        }
    },
    "Current Amendment Enrollment": {
        "template": {
            "long_name": "#/%",
            "short_name": "Current Amendment Enrollment",
            "original_name": "#/%",
            "optional": true,
            "section_number": null,
            "section_title": null,
            "instructions": [
                "Enter the approximate number or percentage of participants enrolled as a percentage of the expected total. If the number of expected participants is changing as a result of the current amendment, use the updated number of expected participants to estimate the current percent of enrollment. Estimates are adequate, as precise enrollment figures will likely be changing while an amendment is being prepared.",
                "For a country/regional amendment, provide the estimated local or regional enrollment at the time the Sponsor approved the amendment."
            ]
        },
        "technical": {
            "name": "---",
            "data_type": "Text",
            "definition": "C68846\nCNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
            "guidance": "",
            "conformance": "Optional",
            "cardinality": "One to one; One to amendment number",
            "relationship": "Amendment Details",
            "value": "Approximate <#/%> enrolled <Globally/Locally/by Cohort>",
            "business_rules": "Value Allowed: Yes\nRelationship: Statement\nConcept: C68846, CNEW",
            "repeating": "Yes, reuse to Section 12.3",
            "ct": [],
            "short_name": "Current Amendment Enrollment"
        }
    },
    "Substantial Impact Safety": {
        "template": {
            "long_name": "Yes/No",
            "short_name": "Substantial Impact Safety",
            "original_name": "Yes/No",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Yes-No",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the amendment likely to have a substantial impact on the safety or rights of the participants.",
            "guidance": "N/A",
            "conformance": "Conditional If there is an amendment",
            "cardinality": "One to one; One to Amendment Identifier; One to Sponsor Protocol Identifier",
            "relationship": "Amendment Details",
            "value": "Yes (C49488), No (C49487)",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Amendment Identifier, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66742",
                    "preferred_term": "NY",
                    "definition": "A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable."
                },
                {
                    "ncit_code": "C49487",
                    "preferred_term": "No",
                    "definition": "The non-affirmative response to a question."
                },
                {
                    "ncit_code": "C49488",
                    "preferred_term": "Yes",
                    "definition": "The affirmative response to a question."
                }
            ],
            "short_name": "Substantial Impact Safety"
        }
    },
    "Substantial Impact Data": {
        "template": {
            "long_name": "Yes/No",
            "short_name": "Substantial Impact Data",
            "original_name": "Yes/No",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Yes-No 2",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the amendment likely to have a substantial impact on the reliability and robustness of the data generated in the clinical trial.",
            "guidance": "N/A",
            "conformance": "Conditional : if there is an amendment",
            "cardinality": "One to one; One to Amendment Identifier; One to Sponsor Protocol Identifier",
            "relationship": "Amendment Details",
            "value": "Yes (C49488), No (C49487)",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Amendment Identifier, Sponsor Protocol Identifier\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "C66742",
                    "preferred_term": "NY",
                    "definition": "A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable."
                },
                {
                    "ncit_code": "C49487",
                    "preferred_term": "No",
                    "definition": "The non-affirmative response to a question."
                },
                {
                    "ncit_code": "C49488",
                    "preferred_term": "Yes",
                    "definition": "The affirmative response to a question."
                }
            ],
            "short_name": "Substantial Impact Data"
        }
    },
    "Population Diagnosis or Condition": {
        "template": {
            "long_name": "Population diagnosis or condition",
            "short_name": "Population Diagnosis or Condition",
            "original_name": "Population diagnosis or condition",
            "optional": false,
            "section_number": "1.1.2",
            "section_title": "Overall Design",
            "instructions": []
        },
        "technical": {
            "name": "Population Diagnosis or Condition",
            "data_type": "Valid Value or Text",
            "definition": "C112038\nFor review purpose, see definition of the controlled terminology below\nA textual description of the condition, disease or disorder that the clinical trial is intended to investigate or address.",
            "guidance": "MedDRA Preferred Term(s) or indicate \u201cother\u201d and describe.",
            "conformance": "Required",
            "cardinality": "One to one; One to Heading; One to Sponsor Protocol Identifier",
            "relationship": "1.1.2",
            "value": "Use examples MedDRA PT or SNOMED\nCT: \u201cacute lung injury,\u201d or a specific biomarker profile); indicate \u201cN/A \u2013 Healthy\u201d for studies in healthy volunteers",
            "business_rules": "Value Allowed: Yes\nRelationship: Row Title Heading; Sponsor Protocol Identifier\nConcept: C112038",
            "repeating": "Yes, repeatable for each population diagnosis or condition",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "codes",
                    "klass": "Indication",
                    "notes": "",
                    "path": "StudyVersion/@studyDesigns/StudyDesign/@indications/Indication/@codes"
                }
            ],
            "map_status": "Mapped",
            "name": "Population Diagnosis or Condition",
            "notes": ""
        }
    },
    "Clinical Safety Laboratory Assessments": {
        "template": {
            "long_name": "Enter Clinical Laboratory Assessments",
            "short_name": "Clinical Safety Laboratory Assessments",
            "original_name": "Clinical Laboratory Assessments",
            "optional": false,
            "section_number": "8.4.4",
            "section_title": "{Clinical Laboratory Assessments}",
            "instructions": []
        },
        "technical": {
            "name": "Clinical Safety Laboratory Assessments",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial-related laboratory assessments and procedures related to participant safety.",
            "guidance": "",
            "conformance": "Conditional: when Clinical Laboratory Assessments are required",
            "cardinality": "One to one",
            "relationship": "8.4.4",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 8.4.4 Clinical Laboratory Assessments\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        },
        "usdm": {
            "items": [
                {
                    "attribute": "text",
                    "klass": "NarrativeContent",
                    "notes": "",
                    "path": "StudyVersion/@documentVersion/StudyProtocolDocumentVersion/@contents/NarrativeContent/@text"
                }
            ],
            "map_status": "Mapped",
            "name": "Clinical Safety Laboratory Assessments",
            "notes": ""
        }
    },
    "Definition of Product Complaints": {
        "template": {
            "long_name": "Enter Definitions of Product Complaints",
            "short_name": "Definition of Product Complaints",
            "original_name": "Definitions of Product Complaints",
            "optional": false,
            "section_number": "9.1.3",
            "section_title": "Definitions of Product Complaints",
            "instructions": []
        },
        "technical": {
            "name": "Definition of Product Complaints",
            "data_type": "Text",
            "definition": "",
            "guidance": "Specify the definition of product complaints in the context of the trial.",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "9.1.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 9.1.3 Definition of Product Complaints\nConcept: CNEW",
            "repeating": "No",
            "ct": []
        }
    },
    "Timing for Reporting to Sponsor or Designee": {
        "template": {
            "long_name": "Timing for reporting to Sponsor or Designee",
            "short_name": "Timing for Reporting to Sponsor or Designee",
            "original_name": "Timing for reporting to Sponsor or Designee",
            "optional": true,
            "section_number": "9.2",
            "section_title": "Timing and Procedures for Collection and Reporting",
            "instructions": []
        },
        "technical": {
            "name": "Timing for Reporting to Sponsor or Designee",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the timing window between trial related events and their reporting to the sponsor or designee.",
            "guidance": "N/A",
            "conformance": "Optional if table used",
            "cardinality": "One to one",
            "relationship": "9.2",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Event Type, Situational Scope\nConcept: CNEW",
            "repeating": "Yes, repeatable for each event type and situational scope",
            "ct": []
        }
    },
    "Secondary Objectives Statistical Analysis Method": {
        "template": {
            "long_name": "Enter Statistical Analysis Method",
            "short_name": "Secondary Objectives Statistical Analysis Method",
            "original_name": "Statistical Analysis Method",
            "optional": false,
            "section_number": "10.5.1.1",
            "section_title": "{Statistical Analysis Method}",
            "instructions": []
        },
        "technical": {
            "name": "Statistical Method of Analysis 17",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical model, hypothesis, and methods of analyses for each objective within the trial.",
            "guidance": "Describe the statistical analysis methods that will be used to evaluate the Secondary objective(s) and associated estimand(s) in Section 3.2. Ensure that the statistical hypothesis/model/analysis (and corresponding assumptions) is aligned with the Secondary estimand(s). If there is more than one Secondary objective, present each objective as a level 3 heading and present each subsequent heading in Section 10.5 as a level 4 heading.\nFor each objective, state the null and alternative hypotheses, including the pre-planned type 1 error rate, or alternative criteria for evaluating whether the objective has been met, and relevant operating characteristics if appropriate. Describe the statistical model used and the factors that will be included (covariates and interactions) and any rules for handling these factors (for example, pooling of centres).\nIf modelling and simulation methods are to be used, please describe the model (inputs and outputs), the underlying assumptions, and the method of model fitting.",
            "conformance": "Conditional: when there is Secondary estimand",
            "cardinality": "One to one",
            "relationship": "10.5.X.1",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.5.X.1 Statistical Analysis Method\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.5.X.1, 10.5.X.2, 10.5.X.3, 10.5.X.4, 10.5.X.5).",
            "ct": [],
            "short_name": "Secondary Objectives Statistical Analysis Method"
        }
    },
    "Secondary Objectives Sensitivity Analysis": {
        "template": {
            "long_name": "Enter Sensitivity Analysis",
            "short_name": "Secondary Objectives Sensitivity Analysis",
            "original_name": "Sensitivity Analysis",
            "optional": false,
            "section_number": "10.5.1.4",
            "section_title": "{Sensitivity Analysis}",
            "instructions": []
        },
        "technical": {
            "name": "Sensitivity Analysis 18",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the series of analyses conducted to explore the robustness of inferences from the main estimator to deviations from its underlying modelling assumptions and limitations in the data.",
            "guidance": "Describe any supplementary analysis, if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "conformance": "Conditional: when there is Seconday Objective and sensitivity Analysis for a Secondary objective",
            "cardinality": "One to one",
            "relationship": "10.5.X.4",
            "value": "Text",
            "business_rules": "Value Allowed Yes\nRelationship: 10.5.X.4 Sensitivity Analysis\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.5.X.1, 10.5.X.2, 10.5.X.3, 10.5.X.4, 10.5.X.5).",
            "ct": [],
            "short_name": "Secondary Objectives Sensitivity Analysis"
        }
    },
    "Secondary Objectives Supplementary Analysis": {
        "template": {
            "long_name": "Enter Supplementary Analysis",
            "short_name": "Secondary Objectives Supplementary Analysis",
            "original_name": "Supplementary Analysis",
            "optional": false,
            "section_number": "10.5.1.5",
            "section_title": "{Supplementary Analysis}",
            "instructions": []
        },
        "technical": {
            "name": "Supplementary Analysis 19",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses that are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "guidance": "Describe any supplementary analysis if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
            "conformance": "Conditional: when there Supplementary Analysis for a Secondary objective",
            "cardinality": "One to one",
            "relationship": "10.5.X.5",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: 10.5.X.5 Supplementary Analysis\nConcept: CNEW",
            "repeating": "Yes, repeatable for each objective as a series of level 4 sections (10.5.X.1, 10.5.X.2, 10.5.X.3, 10.5.X.4, 10.5.X.5).",
            "ct": [],
            "short_name": "Secondary Objectives Supplementary Analysis"
        }
    },
    "Prior Amendment Identifier": {
        "template": {
            "long_name": "Enter Amendment Identifier",
            "short_name": "Prior Amendment Identifier",
            "original_name": "Amendment Identifier",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Amendment Identifier 21",
            "data_type": "Text or Universal Text \u201cOriginal Protocol\u201d",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to uniquely identify a protocol amendment.",
            "guidance": "",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Text or Universal Text \u201cOriginal Protocol\u201d",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading \u201cDocument\u201d\nConcept: CNEW",
            "repeating": "Yes, reuse from the title page",
            "ct": [],
            "short_name": "Prior Amendment Identifier"
        }
    },
    "Previous Amendment Overview Description of Change": {
        "template": {
            "long_name": "Enter Description of Change",
            "short_name": "Previous Amendment Overview Description of Change",
            "original_name": "Description of Change",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Description of Change 24",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: if there is a previous amendment. Table optional",
            "cardinality": "Column Heading \nRow Content",
            "relationship": "12.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading \u201cDescription of Change\u201d and 12.3 Prior Protocol Amendment(s) \nConcept: CNEW",
            "repeating": "Yes, repeatable for every description of change",
            "ct": [],
            "short_name": "Previous Amendment Overview Description of Change"
        }
    },
    "Previous Amendment Overview Brief Rationale for Change": {
        "template": {
            "long_name": "Enter Brief Rationale for Change",
            "short_name": "Previous Amendment Overview Brief Rationale for Change",
            "original_name": "Brief Rationale for Change",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Brief Rationale for Change 25",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe brief reason for the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: if there is a previous amendment. Table optional",
            "cardinality": "One to Column Heading\nRow description of change \nSection# and Name",
            "relationship": "12.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading {Brief Rationale for Change} and description of change <Description of Change> \nConcept: CNEW",
            "repeating": "Yes, repeatable for every description of change",
            "ct": [],
            "short_name": "Previous Amendment Overview Brief Rationale for Change"
        }
    },
    "Previous Amendment Overview Section": {
        "template": {
            "long_name": "Enter Section # and Name of Change",
            "short_name": "Previous Amendment Overview Section",
            "original_name": "Section # and Name of Change",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Section - and Name of Change 26",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe protocol section number and name containing the change introduced in the current version of the protocol.",
            "guidance": "N/A",
            "conformance": "Conditional: if there is a previous amendment. Table optional",
            "cardinality": "One to Column Heading\nRow description of change \nDescription of Change, Rational for Amendment Change",
            "relationship": "12.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Description of Change Concept: CNEW",
            "repeating": "Yes, repeatable for every Description of Change",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Protocol Number and Name Response",
                    "definition": "A terminology value set relevant to the protocol number and name responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1 PROTOCOL SUMMARY",
                    "definition": "Section 1 of the ICH M11 Protocol standard, PROTOCOL SUMMARY."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.1 Protocol Synopsis",
                    "definition": "Section 1.1 of the ICH M11 Protocol standard, Protocol Synopsis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.1.1 Primary and Secondary Objectives and Estimands",
                    "definition": "Section 1.1.1 of the ICH M11 Protocol standard, Primary and Secondary Objectives and Estimands."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.1.2 Overall Design",
                    "definition": "Section 1.1.2 of the ICH M11 Protocol standard, Overall Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.2 Trial Schema",
                    "definition": "Section 1.2 of the ICH M11 Protocol standard, Trial Schema."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "1.3 Schedule of Activities",
                    "definition": "Section 1.3 of the ICH M11 Protocol standard, Schedule of Activities."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2 INTRODUCTION",
                    "definition": "Section 2 of the ICH M11 Protocol standard, INTRODUCTION."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.1 Purpose of Trial",
                    "definition": "Section 2.1 of the ICH M11 Protocol standard, Purpose of Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.2 Assessment of Risks and Benefits",
                    "definition": "Section 2.2 of the ICH M11 Protocol standard, Summary of Benefits and Risks."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.2.1  Risk Summary and Mitigation Strategy",
                    "definition": "Section 2.2.1 of the ICH M11 Protocol standard,  Risk Summary and Mitigation Strategy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.2.2 Benefit Summary",
                    "definition": "Section 2.2.2 of the ICH M11 Protocol standard, Benefit Summary."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "2.2.3 Overall Risk-Benefit Assessment",
                    "definition": "Section 2.2.3 of the ICH M11 Protocol standard, Overall Risk-Benefit Assessment."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3 TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS",
                    "definition": "Section 3 of the ICH M11 Protocol standard, TRIAL OBJECTIVES AND ASSOCIATED ESTIMANDS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.1 Primary Objective(s) and Associated Estimand(s)",
                    "definition": "Section 3.1 of the ICH M11 Protocol standard, Primary Objective(s) and Associated Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.1.1 Primary  Objective",
                    "definition": "Section 3.1.1 of the ICH M11 Protocol standard, Primary  Objective."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.2 Secondary Objective(s) and Associated Estimand(s)",
                    "definition": "Section 3.2 of the ICH M11 Protocol standard, Secondary Objective(s) and Associated Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "3.3 Exploratory Objective(s)",
                    "definition": "Section 3.3 of the ICH M11 Protocol standard, Exploratory Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4 TRIAL DESIGN",
                    "definition": "Section 4 of the ICH M11 Protocol standard, TRIAL DESIGN."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.1 Description of Trial Design",
                    "definition": "Section 4.1 of the ICH M11 Protocol standard, Description of Trial Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.1.1 Stakeholder Input into Design",
                    "definition": "Section 4.1.1 of the ICH M11 Protocol standard, Stakeholder Input into Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2 Rationale for Trial Design",
                    "definition": "Section 4.2 of the ICH M11 Protocol standard, Rationale for Trial Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.1 Rationale for Intervention Model",
                    "definition": "Section 4.2.1 of the ICH M11 Protocol standard, Rationale for Intervention Model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.2 Rationale for Duration",
                    "definition": "Section 4.2.2 of the ICH M11 Protocol standard, Rationale for Duration."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.3 Rationale for Estimands",
                    "definition": "Section 4.2.3 of the ICH M11 Protocol standard, Rationale for Estimands."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.4 Rationale for Interim Analysis",
                    "definition": "Section 4.2.4 of the ICH M11 Protocol standard, Rationale for Interim Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.5 Rationale for Control Type",
                    "definition": "Section 4.2.5 of the ICH M11 Protocol standard, Rationale for Control Type."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.6 Rationale for Adaptive or Novel Trial Design",
                    "definition": "Section 4.2.6 of the ICH M11 Protocol standard, Rationale for Adaptive or Novel Trial Design."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.2.7 Rationale for Other Trial Design Aspects",
                    "definition": "Section 4.2.7 of the ICH M11 Protocol standard, Rationale for Other Trial Design Aspects."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.3 Trial Stopping Rules",
                    "definition": "Section 4.3 of the ICH M11 Protocol standard, Trial Stopping Rules."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.4 Start of Trial and End of Trial",
                    "definition": "Section 4.4 of the ICH M11 Protocol standard, Start of Trial and End of Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "4.5 Access to Trial Intervention After End of Trial",
                    "definition": "Section 4.5 of the ICH M11 Protocol standard, Access to Trial Intervention After End of Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5 TRIAL POPULATION",
                    "definition": "Section 5 of the ICH M11 Protocol standard, TRIAL POPULATION."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.1 Description of Trial Population and Rationale",
                    "definition": "Section 5.1 of the ICH M11 Protocol standard, Description of Trial Population and Rationale."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.2 Inclusion Criteria",
                    "definition": "Section 5.2 of the ICH M11 Protocol standard, Inclusion Criteria."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.3 Exclusion Criteria",
                    "definition": "Section 5.3 of the ICH M11 Protocol standard, Exclusion Criteria."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.4 Contraception",
                    "definition": "Section 5.4 of the ICH M11 Protocol standard, Contraception."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.4.1 Definitions Related to Childbearing Potential",
                    "definition": "Section 5.4.1 of the ICH M11 Protocol standard, Definitions Related to Childbearing Potential."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.4.2 Contraception Requirements",
                    "definition": "Section 5.4.2 of the ICH M11 Protocol standard, Contraception Requirements."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5 Lifestyle Restrictions",
                    "definition": "Section 5.5 of the ICH M11 Protocol standard, Lifestyle Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.1 Meals and Dietary Restrictions",
                    "definition": "Section 5.5.1 of the ICH M11 Protocol standard, Contraception Requirements."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.2 Caffeine, Alcohol, Tobacco, and Other Restrictions",
                    "definition": "Section 5.5.2 of the ICH M11 Protocol standard, Caffeine, Alcohol, Tobacco, and Other Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.3 Physical Activity Restrictions",
                    "definition": "Section 5.5.3 of the ICH M11 Protocol standard, Physical Activity Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.5.4 Other Activity Restrictions",
                    "definition": "Section 5.5.4 of the ICH M11 Protocol standard, Other Activity Restrictions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "5.6 Screen Failure and Rescreening",
                    "definition": "Section 5.6 of the ICH M11 Protocol standard, Screen Failure and Rescreening."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6 TRIAL INTERVENTION AND CONCOMITANT THERAPY",
                    "definition": "Section 6 of the ICH M11 Protocol standard, TRIAL INTERVENTION AND CONCOMITANT THERAPY."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.1 Description of Investigational Trial Intervention",
                    "definition": "Section 6.1 of the ICH M11 Protocol standard, Overview of Trial Interventions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.2 Description of Investigational Trial Intervention",
                    "definition": "Section 6.2 of the ICH M11 Protocol standard, Description of Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.3 Rationale for Investigation Trial Intervention Dose and Regimen",
                    "definition": "Section 6.3 of the ICH M11 Protocol standard, Rationale for Investigation Trial Intervention Dose and Regimen."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.4 Investigational Trial Intervention Administration",
                    "definition": "Section 6.4 of the ICH M11 Protocol standard, Investigational Trial Intervention Administration."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.5 Investigational Trial Intervention Dose Modification",
                    "definition": "Section 6.5 of the ICH M11 Protocol standard, Investigational Trial Intervention Dose Modification."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.6 Management of Investigational Trial Intervention Overdose",
                    "definition": "Section 6.6 of the ICH M11 Protocol standard, Management of Investigational Trial Intervention Overdose."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7 Preparation, Storage, Handling and Accountability of Investigational Trial Intervention(s)",
                    "definition": "Section 6.7 of the ICH M11 Protocol standard, Preparation, Storage, Handling and Accountability of Investigational Trial Intervention(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7.1 Preparation of Investigational Trial Intervention(s)",
                    "definition": "Section 6.7.1 of the ICH M11 Protocol standard, Preparation of Investigational Trial Intervention(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7.2 Storage and Handling of Investigational Trial Intervention",
                    "definition": "Section 6.7.2 of the ICH M11 Protocol standard, Storage and Handling of Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.7.3 Accountability of Investigational Trial Intervention",
                    "definition": "Section 6.7.3 of the ICH M11 Protocol standard, Accountability of Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8 Investigational Trial Intervention Assignment, Randomisation and Blinding",
                    "definition": "Section 6.8 of the ICH M11 Protocol standard, Investigational Trial Intervention Assignment, Randomisation and Blinding."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.1 Participant Assignment to Investigational Trial Intervention",
                    "definition": "Section 6.8.1 of the ICH M11 Protocol standard, Participant Assignment to Investigational Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.2 Randomisation",
                    "definition": "Section 6.8.2 of the ICH M11 Protocol standard, Randomisation."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.3 Blinding",
                    "definition": "Section 6.8.3 of the ICH M11 Protocol standard, Blinding."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.8.4 Emergency Unblinding at the Site",
                    "definition": "Section 6.8.4 of the ICH M11 Protocol standard, Emergency Unblinding at the Site."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.9 Investigational Trial Intervention Compliance",
                    "definition": "Section 6.9 of the ICH M11 Protocol standard, Investigational Trial Intervention Compliance."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10 Description of Non-Investigational Trial Intervention(s)",
                    "definition": "Section 6.1 of the ICH M11 Protocol standard, Description of Non-Investigational Trial Intervention(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10.1 Background Intervention",
                    "definition": "Section 6.10.1 of the ICH M11 Protocol standard, Background Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10.2 Rescue Therapy",
                    "definition": "Section 6.10.2 of the ICH M11 Protocol standard, Rescue Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.10.3 Other Non-investigational Intervention",
                    "definition": "Section 6.10.3 of the ICH M11 Protocol standard, Other Non-investigational Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.11 Concomitant Therapy",
                    "definition": "Section 6.11 of the ICH M11 Protocol standard, Concomitant Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.11.1 Prohibited Concomitant Therapy",
                    "definition": "Section 6.11.1 of the ICH M11 Protocol standard, Prohibited Concomitant Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "6.11.2 Permitted Concomitant Therapy",
                    "definition": "Section 6.11.2 of the ICH M11 Protocol standard, Permitted Concomitant Therapy."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7 PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL",
                    "definition": "Section 7 of the ICH M11 Protocol standard, PARTICIPANT DISCONTINUATION OF TRIAL INTERVENTION AND DISCONTINUATION OR WITHDRAWAL FROM TRIAL."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1 Discontinuation of Trial Intervention for Individual Participants",
                    "definition": "Section 7.1 of the ICH M11 Protocol standard, Discontinuation of Trial Intervention for Individual Participants."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1.1 Permanent Discontinuation of Trial Intervention",
                    "definition": "Section 7.1.1 of the ICH M11 Protocol standard, Permanent Discontinuation of Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1.2 Temporary Discontinuation of Trial Intervention",
                    "definition": "Section 7.1.2 of the ICH M11 Protocol standard, Temporary Discontinuation of Trial Intervention."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.1.3 Rechallenge",
                    "definition": "Section 7.1.3 of the ICH M11 Protocol standard, Rechallenge."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.2 Discontinuation or Withdrawal from the Trial",
                    "definition": "Section 7.2 of the ICH M11 Protocol standard, Discontinuation or Withdrawal from the Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "7.3 Lost to Follow-Up",
                    "definition": "Section 7.3 of the ICH M11 Protocol standard, Lost to Follow-Up."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8 TRIAL ASSESSMENTS AND PROCEDURES",
                    "definition": "Section 8 of the ICH M11 Protocol standard, TRIAL ASSESSMENTS AND PROCEDURES."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.1 Trial Assessments and Procedures Considerations",
                    "definition": "Section 8.1 of the ICH M11 Protocol standard, Trial Assessments and Procedures Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.2 Screening/Baseline Assessments and Procedures",
                    "definition": "Section 8.2 of the ICH M11 Protocol standard, Screening/Baseline Assessments and Procedures."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.3 Efficacy Assessments and Procedures",
                    "definition": "Section 8.3 of the ICH M11 Protocol standard, Efficacy Assessments and Procedures."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4 Safety Assessments and Procedures",
                    "definition": "Section 8.4 of the ICH M11 Protocol standard, Safety Assessments and Procedures."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.1 Physical Examination",
                    "definition": "Section 8.4.1 of the ICH M11 Protocol standard, Physical Examination."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.2 Vital Signs",
                    "definition": "Section 8.4.2 of the ICH M11 Protocol standard, Vital Signs."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.3 Electrocardiograms",
                    "definition": "Section 8.4.3 of the ICH M11 Protocol standard, Electrocardiograms."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.4 Clinical Laboratory Assessments",
                    "definition": "Section 8.4.4 of the ICH M11 Protocol standard, Clinical Laboratory Assessments."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.5 Pregnancy Testing",
                    "definition": "Section 8.4.5 of the ICH M11 Protocol standard, Pregnancy Testing."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.4.6 Suicidal Ideation and Behaviour Risk Monitoring",
                    "definition": "Section 8.4.6 of the ICH M11 Protocol standard, Suicidal Ideation and Behaviour Risk Monitoring."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.5 Pharmacokinetics",
                    "definition": "Section 8.5 of the ICH M11 Protocol standard, Pharmacokinetics."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6 Biomarkers",
                    "definition": "Section 8.6 of the ICH M11 Protocol standard, Biomarkers."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6.1 Genetics and Pharmacogenomics",
                    "definition": "Section 8.6.1 of the ICH M11 Protocol standard, Genetics and Pharmacogenomics."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6.2 Pharmacodynamic Biomarkers",
                    "definition": "Section 8.6.2 of the ICH M11 Protocol standard, Pharmacodynamic Biomarkers."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.6.3 Other Biomarkers",
                    "definition": "Section 8.6.3 of the ICH M11 Protocol standard, Other Biomarkers."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.7 Immunogenicity Assessments",
                    "definition": "Section 8.7 of the ICH M11 Protocol standard, Immunogenicity Assessments."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "8.8 Medical Resource Utilisation and Health Economics",
                    "definition": "Section 8.8 of the ICH M11 Protocol standard, Medical Resource Utilisation and Health Economics."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9 ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION",
                    "definition": "Section 9 of the ICH M11 Protocol standard, ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, PRODUCT COMPLAINTS, PREGNANCY AND POSTPARTUM INFORMATION."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1 Definitions",
                    "definition": "Section 9.1 of the ICH M11 Protocol standard, Definitions."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1.1 Definitions of Adverse Events",
                    "definition": "Section 9.1.1 of the ICH M11 Protocol standard, Definitions of Adverse Events."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1.2 Definitions of Serious Adverse Events",
                    "definition": "Section 9.1.2 of the ICH M11 Protocol standard, Definitions of Serious Adverse Events."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.1.3 Definition of Medical Device Product Complaints",
                    "definition": "Section 9.1.3 of the ICH M11 Protocol standard, Definition of Medical Device Product Complaints."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.2 Timing and Mechanism for Collection and Reporting",
                    "definition": "Section 9.2 of the ICH M11 Protocol standard, Timing and Mechanism for Collection and Reporting."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3 Identification, Recording and Follow-Up",
                    "definition": "Section 9.3 of the ICH M11 Protocol standard, Identification, Recording and Follow-Up."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.1 Identification",
                    "definition": "Section 9.3.1 of the ICH M11 Protocol standard, Identification."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.2 Severity",
                    "definition": "Section 9.3.2 of the ICH M11 Protocol standard, Severity."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.3 Causality",
                    "definition": "Section 9.3.3 of the ICH M11 Protocol standard, Causality."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.3.4 Follow-up",
                    "definition": "Section 9.3.4 of the ICH M11 Protocol standard, Follow-up."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4 Reporting",
                    "definition": "Section 9.4 of the ICH M11 Protocol standard, Reporting."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4.1 Regulatory Reporting Requirements",
                    "definition": "Section 9.4.1 of the ICH M11 Protocol standard, Regulatory Reporting Requirements."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4.2 Adverse Events of Special Interest",
                    "definition": "Section 9.4.2 of the ICH M11 Protocol standard, Adverse Events of Special Interest."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.4.3 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs",
                    "definition": "Section 9.4.3 of the ICH M11 Protocol standard, Disease-related Events or Outcomes Not Qualifying as AEs or SAEs."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.5 Pregnancy and Postpartum Information",
                    "definition": "Section 9.5 of the ICH M11 Protocol standard, Pregnancy and Postpartum Information."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.5.1 Participants Who Become Pregnant During the Trial",
                    "definition": "Section 9.5.1 of the ICH M11 Protocol standard, Participants Who Become Pregnant During the Trial."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "9.5.2 Participants Whose Partners Become Pregnant",
                    "definition": "Section 9.5.2 of the ICH M11 Protocol standard, Participants Whose Partners Become Pregnant."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10 Statistical Considerations",
                    "definition": "Section 10 of the ICH M11 Protocol standard, Statistical Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.1 General Considerations",
                    "definition": "Section 10.1 of the ICH M11 Protocol standard, General Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.2 Analysis Sets",
                    "definition": "Section 10.2 of the ICH M11 Protocol standard, Analysis Sets."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.3 Analyses of Demographics and Other Baseline Variables",
                    "definition": "Section 10.3 of the ICH M11 Protocol standard, Analyses of Demographics and Other Baseline Variables."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4 Analyses Associated with the Primary Objective(s)",
                    "definition": "Section 10.4 of the ICH M11 Protocol standard, Analyses Associated with the Primary Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.1 Statistical Method of Analysis",
                    "definition": "Section 10.4.1 of the ICH M11 Protocol standard, Statistical Method of Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.2 Handling of Data in Relation to Primary Estimand(s)",
                    "definition": "Section 10.4.2 of the ICH M11 Protocol standard, Handling of Data in Relation to Primary Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.3 Handling of Missing Data",
                    "definition": "Section 10.4.3 of the ICH M11 Protocol standard, Handling of Missing Data."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.4 Sensitivity Analysis",
                    "definition": "Section 10.4.4 of the ICH M11 Protocol standard, Sensitivity Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.4.5 Supplementary Analysis",
                    "definition": "Section 10.4.5 of the ICH M11 Protocol standard, Supplementary Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5 Analysis Associated with the Secondary Objective(s)",
                    "definition": "Section 10.5 of the ICH M11 Protocol standard, Analysis Associated with the Secondary Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.1 Statistical Method of Analysis",
                    "definition": "Section 10.5.1 of the ICH M11 Protocol standard, Statistical Method of Analysis."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.2 Handling of Data in Relation to Secondary Estimand(s)",
                    "definition": "Section 10.5.2 of the ICH M11 Protocol standard, Handling of Data in Relation to Secondary Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.3 Handling of Missing Data in Relation to Secondary Estimand(s)",
                    "definition": "Section 10.5.3 of the ICH M11 Protocol standard, Handling of Missing Data in Relation to Secondary Estimand(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.4 Sensitivity Analyses",
                    "definition": "Section 10.5.4 of the ICH M11 Protocol standard, Sensitivity Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.5.5 Supplementary Analyses",
                    "definition": "Section 10.5.5 of the ICH M11 Protocol standard, Supplementary Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.6 Analysis Associated with the Exploratory Objective(s)",
                    "definition": "Section 10.6 of the ICH M11 Protocol standard, Analysis Associated with the Exploratory Objective(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.7 Safety Analyses",
                    "definition": "Section 10.7 of the ICH M11 Protocol standard, Safety Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.8 Other Analyses",
                    "definition": "Section 10.8 of the ICH M11 Protocol standard, Other Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.9 Interim Analyses",
                    "definition": "Section 10.9 of the ICH M11 Protocol standard, Interim Analyses."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.10 Multiplicity Adjustments",
                    "definition": "Section 10.1 of the ICH M11 Protocol standard, Multiplicity Adjustments."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "10.11 Sample Size Determination",
                    "definition": "Section 10.11 of the ICH M11 Protocol standard, Sample Size Determination."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11 TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS",
                    "definition": "Section 11 of the ICH M11 Protocol standard, TRIAL OVERSIGHT AND OTHER GENERAL CONSIDERATIONS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.1 Regulatory and Ethical Considerations",
                    "definition": "Section 11.1 of the ICH M11 Protocol standard, Regulatory and Ethical Considerations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.2 Trial Oversight",
                    "definition": "Section 11.2 of the ICH M11 Protocol standard, Trial Oversight."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.2.1 Investigator Responsibilities",
                    "definition": "Section 11.2.1 of the ICH M11 Protocol standard, Investigator Responsibilities."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.2.2 Sponsor Responsibilities",
                    "definition": "Section 11.2.2 of the ICH M11 Protocol standard, Sponsor Responsibilities."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.3 Informed Consent Process",
                    "definition": "Section 11.3 of the ICH M11 Protocol standard, Informed Consent Process."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.3.1 Informed Consent for Rescreening",
                    "definition": "Section 11.3.1 of the ICH M11 Protocol standard, Informed Consent for Rescreening."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research",
                    "definition": "Section 11.3.2 of the ICH M11 Protocol standard, Informed Consent for Use of Remaining Samples in Exploratory Research."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.4 Committees",
                    "definition": "Section 11.4 of the ICH M11 Protocol standard, Committees."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.5 Insurance and Indemnity",
                    "definition": "Section 11.5 of the ICH M11 Protocol standard, Insurance and Indemnity."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.6 Risk-Based Quality Management",
                    "definition": "Section 11.5 of the ICH M11 Protocol standard, Risk Management."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.7 Data Governance",
                    "definition": "Section 11.7 of the ICH M11 Protocol standard, Data Governance."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.8 Data Protection",
                    "definition": "Section 11.8 of the ICH M11 Protocol standard, Data Protection"
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.9 Source Data",
                    "definition": "Section 11.9 of the ICH M11 Protocol standard, Source Data."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.10 Protocol Deviations",
                    "definition": "Section 11.10 of the ICH M11 Protocol standard, Protocol Deviations."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "11.11 Early Site Closure",
                    "definition": "Section 11.1 of the ICH M11 Protocol standard, Early Site Closure."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12 APPENDIX: SUPPORTING DETAILS",
                    "definition": "Section 12 of the ICH M11 Protocol standard, APPENDIX: SUPPORTING DETAILS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12.1 Clinical Laboratory Tests",
                    "definition": "Section 12.1 of the ICH M11 Protocol standard, Clinical Laboratory Tests."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12.2 Country/Region-Specific Differences",
                    "definition": "Section 12.2 of the ICH M11 Protocol standard, Country/Region-Specific Differences."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "12.3 Prior Protocol Amendment(s)",
                    "definition": "Section 12.3 of the ICH M11 Protocol standard, Prior Protocol Amendment(s)."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS",
                    "definition": "Section 13 of the ICH M11 Protocol standard, APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "14 APPENDIX: REFERENCES",
                    "definition": "Section 14 of the ICH M11 Protocol standard, APPENDIX: REFERENCES."
                }
            ],
            "short_name": "Previous Amendment Overview Section"
        }
    },
    "Previous Amendment Number": {
        "template": {
            "long_name": "enter amendment number",
            "short_name": "Previous Amendment Number",
            "original_name": "enter amendment number",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "amendment number",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to uniquely identify a protocol amendment",
            "guidance": "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first).",
            "conformance": "Conditional: if amendment",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: {The Overview of Changes from each prior protocol amendment is {provided below} or <specify alternative location>}.\nConcept: CNEW",
            "repeating": "Yes, repeatable one table per amendment",
            "ct": [],
            "short_name": "Previous Amendment Number"
        }
    },
    "Previous Amendment Date": {
        "template": {
            "long_name": "enter date",
            "short_name": "Previous Amendment Date",
            "original_name": "enter date",
            "optional": false,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "Sponsor Approval Date 23",
            "data_type": "Date",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date that the sponsor approved the version of the protocol,",
            "guidance": "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first).",
            "conformance": "Conditional: if amendment",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Date",
            "business_rules": "Value Allowed: Yes\nRelationship: {The Overview of Changes from each prior protocol amendment is {provided below} or <specify alternative location>}.\nConcept: CNEW",
            "repeating": "Yes, repeatable one table per amendment",
            "ct": [],
            "short_name": "Previous Amendment Date"
        }
    },
    "Previous Amendment Enrollment": {
        "template": {
            "long_name": "Enter # or % enrolled globally/locally/per cohort",
            "short_name": "Previous Amendment Enrollment",
            "original_name": "# or % enrolled globally/locally/per cohort",
            "optional": true,
            "section_number": "12.3",
            "section_title": "Prior Protocol Amendment(s)",
            "instructions": []
        },
        "technical": {
            "name": "- or -",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage. The numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage.",
            "guidance": "",
            "conformance": "Optional: when there is an amendment and sponsor chooses",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "<# or %> enrolled <globally/locally/per cohort>",
            "business_rules": "Value Allowed: Yes\nRelationship: Document, Sponsor Approval Date\nConcept: CNEW",
            "repeating": "Yes, reuse from the title page",
            "ct": [],
            "short_name": "Previous Amendment Enrollment"
        }
    },
    "Amendment Details": {
        "template": {
            "long_name": "Amendment Details",
            "short_name": "Amendment Details",
            "original_name": "Amendment Details",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Amendment Details",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA written message within the study protocol that describes the amendment details, especially as to whether the protocol has been amended previously.",
            "guidance": "Choose the applicable statement below. For an original protocol that has not been amended, retain the first sentence below and delete the remainder of this entire section.\n{Not applicable. This protocol has not been amended.}\nOr include the below as applicable.\n{This protocol has been amended previously. Details of prior amendments are presented in Section 12.3 Prior Protocol Amendment(s).}",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "Amendment Details",
            "value": "Not applicable. This protocol has not been amended. (CNEW)Or\nThis is the first protocol amendment (CNEW)\nOR\nThis protocol has been amended previously. Details of prior amendments are presented in Section 12.3 Prior Protocol Amendment(s). (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Amendment Details Statement Response",
                    "definition": "A terminology value set relevant to the amendment details statement responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not applicable. This protocol has not been amended.",
                    "definition": "Not applicable. This protocol has not been amended."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "This protocol has been amended previously. Details of prior amendments are presented in Prior Protocol Amendment(s).",
                    "definition": "This protocol has been amended previously. Details of prior amendments are presented in Prior Protocol Amendment(s)."
                }
            ]
        }
    },
    "Primary Reason Other": {
        "template": {
            "long_name": "Primary Reason Other",
            "short_name": "Primary Reason Other",
            "original_name": "Primary Reason Other",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Other description",
            "data_type": "Text",
            "definition": "C17649\nFor review purpose, see definition of the controlled terminology below\nDifferent than the one(s) previously specified or mentioned.",
            "guidance": "Choose from the available categories the primary reason and secondary reason(s) for the amendment. Select the closest match among the choices. Changes to primary estimand, endpoints, or related measures should be listed as a change of strategy. If none of the choices apply, choose \u201cother\u201d and provide a description. If no secondary reason, indicate \u201cNot applicable\u201d for the secondary reason.",
            "conformance": "Conditional : if Other is selected as a Valid Value",
            "cardinality": "One to one",
            "relationship": "Amendment Details",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Primary reason, Sponsor Protocol Identifier, Protocol Amendment\nConcept:C17649",
            "repeating": "No",
            "ct": [],
            "short_name": "Primary Reason Other"
        }
    },
    "Secondary Reason Other": {
        "template": {
            "long_name": "Secondary Reason Other",
            "short_name": "Secondary Reason Other",
            "original_name": "Secondary Reason Other",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Other description 1",
            "data_type": "Text",
            "definition": "C17649\nFor review purpose, see definition of the controlled terminology below\nDifferent than the one(s) previously specified or mentioned.",
            "guidance": "Choose from the available categories as the primary reason and secondary reason(s) for the amendment. Select the closest match among the choices. Changes to primary estimand, endpoints, or related measures should be listed as a change of strategy. If none of the choices apply, choose \u201cother\u201d and provide a description. If no secondary reason, indicate \u201cnot applicable\u201d for the secondary reason.",
            "conformance": "Conditional if Other is selected as a Valid Value",
            "cardinality": "One to one",
            "relationship": "Amendment Details",
            "value": "Text",
            "business_rules": "Value Allowed: Yes\nRelationship: Heading, Secondary reason, Protocol Identifier, Protocol Amendment\nConcept:C17649",
            "repeating": "No",
            "ct": [],
            "short_name": "Secondary Reason Other"
        }
    },
    "Briefly Explain Substantial Impact On Safety": {
        "template": {
            "long_name": "Briefly Explain Substantial Impact On Safety",
            "short_name": "Briefly Explain Substantial Impact On Safety",
            "original_name": "Briefly Explain Substantial Impact On Safety",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "If yes briefly explain",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short descriptive account of any substantial impacts on the safety or rights of the participants due to the protocol amendment.",
            "guidance": "Briefly Explain Substantial Impact On Safety",
            "conformance": "Conditional: if there is an amendment and If the \"Is this amendment likely to have a substantial impact on the safety or rights of the participants? \" is yes",
            "cardinality": "One to one Amendment Identifier,\nIs this amendment likely to have a substantial impact on the safety or rights of the participants? Response when Yes",
            "relationship": "Amendment Details",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Amendment Identifier, Sponsor Protocol Identifier\nWhen the value is yes there is a text response for explanation\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "Briefly Explain Substantial Impact On Safety"
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Briefly Explain Substantial Impact On Safety",
            "notes": ""
        }
    },
    "Briefly Explain Substantial Impact on Data": {
        "template": {
            "long_name": "Briefly Explain Substantial Impact on Data",
            "short_name": "Briefly Explain Substantial Impact on Data",
            "original_name": "Briefly Explain Substantial Impact on Data",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "If yes briefly explain 3",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short descriptive account of any substantial impacts on the reliability and robustness of the data generated in the clinical trial due to the protocol amendment.",
            "guidance": "Briefly Explain Substantial Impact on Data",
            "conformance": "Conditional: if there is an amendment and if the answer to \"Is this amendment likely to have a substantial impact on the reliability and robustness of the data generated in the clinical trial?\" is yes",
            "cardinality": "One to amendment identifier",
            "relationship": "Amendment Details",
            "value": "",
            "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Amendment Identifier, Sponsor Protocol Identifier\nWhen the value is yes there is a text response for explanation\nConcept: CNEW",
            "repeating": "No",
            "ct": [],
            "short_name": "Briefly Explain Substantial Impact on Data"
        },
        "usdm": {
            "items": [],
            "map_status": "To Be Mapped",
            "name": "Briefly Explain Substantial Impact on Data",
            "notes": ""
        }
    },
    "Previous Amendment Enrollment Scope": {
        "template": {
            "long_name": "Previous Amendment Enrollment Scope",
            "short_name": "Previous Amendment Enrollment Scope",
            "original_name": "Previous Amendment Enrollment Scope",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "globally-locally-per cohort",
            "data_type": "Text",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage. The numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage.",
            "guidance": "",
            "conformance": "Optional: when there is an amendment and sponsor chooses",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "<# or %> enrolled <globally/locally/per cohort>",
            "business_rules": "Value Allowed: Yes\nRelationship: Document, Sponsor Approval Date\nConcept: CNEW",
            "repeating": "Yes, reuse from the title page",
            "ct": [],
            "short_name": "Previous Amendment Enrollment Scope"
        }
    },
    "Prior Protocol Amendments": {
        "template": {
            "long_name": "Prior Protocol Amendments",
            "short_name": "Prior Protocol Amendments",
            "original_name": "Prior Protocol Amendments",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Prior Protocol Amendments",
            "data_type": "Valid Value",
            "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn indication as to whether the protocol has not been amended, is the first protocol amendment, or a statement that the protocol has been amended previously.",
            "guidance": "Choose the applicable statement below. For an original protocol that has not been amended, retain the first sentence below and delete the remainder of this entire section. \n{Not applicable. This protocol has not been amended.} \nOr\n{Not applicable. This is the first protocol amendment.} \nOr include the below as applicable.\n{This protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent.}",
            "conformance": "Required",
            "cardinality": "One to one",
            "relationship": "12.3",
            "value": "Not applicable. This protocol has not been amended. (CNEW)\nOr\nNot applicable. This is the first protocol amendment. (CNEW) \nOr \nThis protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent. (CNEW)",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.3 Prior Protocol Amendment(s)\nConcept: CNEW",
            "repeating": "No",
            "ct": [
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "ICH M11 Amendment Details Statement Response",
                    "definition": "A terminology value set relevant to the amendment details statement responses within the ICH M11 Protocol model."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not applicable. This protocol has not been amended.",
                    "definition": "Not applicable. This protocol has not been amended."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "Not applicable. This is the first protocol amendment.",
                    "definition": "Not applicable. This is the first protocol amendment."
                },
                {
                    "ncit_code": "CNEW",
                    "preferred_term": "{This protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent.}",
                    "definition": "{This protocol has been amended previously. The Protocol Amendment Summary of Changes for the current amendment is located directly before the Table of Contents. Prior amendment(s) to this protocol are listed in the table below, beginning with the most recent.}"
                }
            ]
        }
    },
    "Country Region Not Applicable": {
        "template": {
            "long_name": "Country Region Not Applicable",
            "short_name": "Country Region Not Applicable",
            "original_name": "Country Region Not Applicable",
            "optional": false,
            "section_number": null,
            "section_title": null,
            "instructions": []
        },
        "technical": {
            "name": "Not applicable 20",
            "data_type": "Universal Text",
            "definition": "",
            "guidance": "N/A",
            "conformance": "Optional: if there are no Country/Region Specific Differences",
            "cardinality": "One to one",
            "relationship": "12.2",
            "value": "Not applicable",
            "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country/Region-Specific Differences\nConcept: Universal Text",
            "repeating": "No",
            "ct": [],
            "short_name": "Country Region Not Applicable"
        }
    }
}